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ABSTRACT
Virological techniques have previously been used to investigate mumps virus (MuV) 
replication in vitro and have led to a rapid expansion of our understanding of this virus. 
The cell line of choice has been Vero cells, however, recent studies have concluded that 
variants of the original MuV are selected upon passage in Vero cells. The aim of this 
thesis is to describe the effect of cell substrate on MuVs through genotypic and phenotypic 
analysis after growth of MuVs in different host cells.
Data is presented which demonstrates that MuVs passaged in B95a or HeLa cells are of 
greater fitness than the parental Vero cell-grown viruses, when assayed to determine the 
titre o f infectious virus produced. No adaptation period was required for growth of MuVs 
in B95a cells with the exception of one variant of the JL vaccine. An adaptation period 
was required for growth in HeLa cells. Only one of the viruses studied, a variant derived 
from Urabe vaccine, grew to a high inactivity titre in MRC-5 cells. Growth occurred after 
an initial adaptation period, suggesting a narrow bottleneck for virus growth in these cells 
and amino acid 431 in the HN protein is implicated in the adaptation to these cells. 
Sequence analysis of the two envelope glycoproteins implicates amino acids 92, 205, 255, 
347, 392 and 526 in the HN protein of B95a and HeLa derived viruses as being responsible 
for phenotypic changes in plaque morphology and antigenicity but do not solely account 
for host cell tropism.
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CHAPTER I 
INTRODUCTION
12
1.1 GENERAL HISTORY OF MUMPS
Mumps, as an illness, has been recognised since the 5th century BC when Hippocrates 
described epidemics of diseases with symptoms characteristic of mumps, as we now know 
it. A characteristic symptom of mumps is parotitis, or swelling of the parotid gland. In 
1790, a physician, Robert Hamilton, described an illness, "called mumps by the common 
people of England", which he called angina maxillaris. Hamilton was the first to 
document the symptoms of the disease and to associate the involvement of the central 
nervous system (CNS) (Hamilton., 1790). The agent responsible for this disease was not 
identified until 1935 when Johnson and Goodpasture demonstrated that mumps was the 
result of a viral infection (Johnson et at., 1935). Saliva, collected from a human with 
parotitis, was inoculated into the parotid glands of Macacus rhesus monkeys by way of the 
Stensons’ duct. The animals were sacrificed after bilateral parotid swellings were observed 
and a homogenate of the infected glands produced. This emulsion was used to inoculate 
animals for further passage. After eleven passages in the monkey, an emulsion of parotid 
glands, collected from the infected monkeys, was inoculated into humans by way of the 
oral cavity. Six o f the human patients manifested typical clinical mumps. Johnson and 
Goodpasture concluded that mumps was due to a filterable virus present in saliva, at least 
in early stages of the disease, which was capable of inducing parotitis in M. rhesus 
monkeys when inoculated directly into the Stenson’s ducts. The authors also concluded 
that mumps could be contracted by contact with the virus through saliva.
Isolation of the virus causing mumps led to an understanding of the physical and molecular 
properties o f the virus, its epidemiology and pathogenesis and to the production of a 
vaccine, which was introduced in the U.S.A. in 1967 and then in the rest of the world 
leading to a steady decline in the cases of mumps where the vaccine is used appropriately.
13
1.2 THE MUMPS VIRUS
1.2.1 CLASSIFICATION
The negative sense, single-strand RNA genome of mumps virus (MuV) is characteristic of 
viruses within the virus super-family Mononegavirales, which comprises four families; 
Rhabdoviridae, Paramyxoviridae, Bomaviridae and Filoviridae (Pringle and Easton, 
1997). Originally, MuV was classified alongside influenza virus in a Myxoviridae family, 
due to the ability of both viruses to cause haemagglutination and other similar 
characteristics. However, MuV is currently classified in the Rubulavirus genus (Figure 
1.1), within the Paramyxovirinae subfamily of the Paramyxoviridae family of viruses 
(Rima et a l, 1995). The name paramxyo comes from the Greek, para meaning close to 
(referring to the viruses relationship with other myxoviruses) and myxa meaning mucous 
(referring to the site of infection of the virus). The Paramyxoviridae family consists of two 
subfamilies, the Paramyxovirinae and the Pneumovirinae. The Paramyxovirinae contains 
three genera. Paramyxovirus, Rubulavirus and Morbillivirus. The Pneumovirinae 
subfamily contains only one genus, the Pneumovirus. This classification system is based 
on several features including genome organisation, morphological characteristics, activities 
of the expressed proteins and sequence relationships of the encoded proteins.
The rubulavirus genus contains Newcastle disease virus (NDV) which is quite distinct, and 
it has recently been suggested through sequence analysis that it be placed in a separate 
genus (de Leeuw et a l,  1999). Other reasons given were that NDV edits its 
phosphoprotein (?) gene mRNA from P to a V protein, as do measles virus (MV) and 
Sendai Virus (SeV), rather than from the V protein mRNA to the P, as does MuV and other 
rubulaviruses (Steward et a l, 1993). Secondly, paramyxovirus genomes are replicated 
only when they are a multiple of 6  nucleotides in length, termed the ‘rule of six’ (Calain 
and Roux, 1993). NDV conforms strictly to the ‘rule of six’ whereas the replication of
14
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other rubulaviruses are enhanced by this rule but not dependent on it (Murphy., 1997). 
Thirdly, the mRNA start sites for NDV are clustered over four subunit hexamer phasing 
positions (Kolakofsky et a l, 1998), whereas mRNA start sites of other rubulaviruses 
cluster over only three positions. Fourthly, anti-human parainfluenza virus 2 (hPIV2) 
monoclonal antibodies (MAb) react with simian virus 5 (SV5) and MuV but never with 
NDV (Tsurudome et a l, 1989). Finally, the NDV nucleoprotein (NP) does not require the 
P protein to bind the RNA, unlike SeV {Paramyxovirus genus) and hPIV2 {Rubulavirus 
genus) (de Leeuw et a l, 1999). Hence, NDV appears to have evolved separately from 
other rubulaviruses, possibly due to a difference in host, which is avian rather than 
mammalian.
1.2.2 STRUCTURE
Mumps virions are pleomorphic in shape but usually seen as rough spherical particles 
under the electron microscope, although filamentous forms can also be observed. The 
virions are 150nm or more in diameter and are composed of a negative sense RNA helical 
nucleocapsid associated with the nucleoprotein (NP), a phosphoprotein (P) and a large 
protein (L). This nucleocapsid complex is associated with the matrix protein (M), which is 
membrane associated. The virus envelope is derived from the host cell plasma membrane. 
Protruding from this envelope are two glycoproteins of approximately 8-12nm in length, 
known as the haemagglutinin-neuraminidase (HN) glycoprotein and the fusion (F) 
glycoprotein. Some rubulaviruses, of which MuV is one, also contain a small hydrophobic 
(SH) protein, thought to be membrane associated. The SH protein has only been detected 
in MuV-infected cells (Takeuchi et a l, 1996). Figure 1.2 depicts the structure of a MuV 
virion. Two mRNA species are transcribed from the MuV P gene; one directing the 
synthesis of the V protein and one directing the synthesis of the P protein (see section
16
Figure 1.2: Diagram of a member virus of the subfamily Paramyxovirinae. N: 
Nucleocapsid; V: V protein; P: Phosphoprotein; L: Large protein; M: Matrix protein; 
H(N): Haemagglutinin (Neuraminidase) protein; F: Fusion protein (Rima et a/.,1995).
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1.3.2). The V protein has been detected in MuV-infected cells and in virions (Takeuchi et 
al., 1990) but has been shown to be unstable and is gradually degraded in virus infected 
cells (Hu et al., 1993).
1.2.3 GENOME ORGANISATION
MuVs are single-stranded, non-segmented, negative sense RNA viruses. The relative 
positions of the different genes on the viral RNA, encoding the different MuV proteins is 
as follows:
3' . NP - P - M - F - SH - HN - L - 5’
The genome consists of a non-transcribed leader sequence of fifty-five nucleotides and a 
trailer sequence of twenty-four nucleotides. The intragenic start and stop sequences are 
separated by intergenic sequences of one to seven nucleotides. The gene lengths, both in 
nucleotides and amino acids and their respective molecular weight are as shown in Table 
1.1.
Table 1.1: The MuV protein lengths, in nucleotides and amino acids and their respective 
molecular weights (Wolinsky and Waxham, 1990). The nucleotide lengths include non­
coding regions.
PROTEIN NUCLEOTIDE
LENGTH
AMINO ACID 
LENGTH
MOLECULAR 
WEIGHT (Kd)
NP 1,845 549 691
P 1,312 391 451
M 1,253 375 401
F 1,721 538 651
SH 310 57 6.72
HN 1,887 582 oo
L 6,925 2261 H-k OO °u
.
1 Merz et al., 1983
2 Elango et al., 1989
3 Rima et al., 1980
18
1.3 THE MUMPS VIRUS PROTEINS
1.3.1 THE NUCLEOPROTEIN
The nucleoprotein (NP) is responsible for the encapsidation of genomic RNA into an 
RNAse-resistant nucleocapsid of which it is the main component. The NP also associates 
with the P and L proteins during transcription and replication and probably interacts with 
the M protein during virus assembly. The intracellular concentration of unassembled NP is 
thought to be the major factor controlling rates of transcription and replication.
The sequences of many paramyxovirus NP genes have been determined (Morgan et a l, 
1984; Rozenblatt et a l, 1985; Ishida et a l,  1986 & Elango et a l, 1989), and this sequence 
data, along with protease digestion data, suggests that the NP protein is composed of two 
domains. The N-terminal 80% of the NP is relatively well conserved among 
paramyxoviruses within the same genus. The N-terminal body of the NP is thought to be a 
globular domain, which has an overall positive charge that increases the affinity of the N- 
terminal domain for RNA binding. Hence, the N-terminal domain is responsible for RNA 
binding and protection. Deletion mutant analysis of the N-terminal domain of sendai virus 
(SeV), a paramyxovirus, showed that this region was required for nucleocapsid assembly 
(Buchholz et a l, 1993). The N-terminal also possesses NP:NP binding activity, 
presumably essential for ribonucleoprotein (RNP) formation (Liston et a l, 1997).
The C-terminal appears to extend as a tail structure from the globular N-terminal. The C-
terminal 20% is not well conserved and has a highly negative charge. This tail structure
contains most of the protein’s phosphorylation sites and antigenic sites (Hsu and
Kingsbury, 1982). The function of this tail appears to be concerned with the mediation of
P protein binding to nucleocapsids as monoclonal antibodies directed against the C-
terminal domain, released P protein units, which are usually tightly bound within the
nucleocapsid structure (Ryan and Portner, 1990). In addition, the C-terminal domain was
determined to be unnecessary for producing an encapsidated, complementary copy of the
19
template during transcription, as deletions in the C-terminal domain had no effect on this 
process whereas deletions in the N-terminal domain eliminated this activity. However, 
templates assembled with C-terminal deleted NPs were unable to act as templates for new 
rounds of genome replication. Therefore the C-terminal tail appears to be essential for this 
function. After cleavage and removal of the C terminal domain, no difference was 
observed in RNA binding or protection (Heggeness et al., 1981), suggesting that the non­
conserved C-terminal domain is not responsible for RNA binding or for protection of the 
RNA from degradation.
The NP, along with the P and L proteins, combine together to form the nucleocapsid 
complex, a single stranded, left handed helical structure o f  about 1 pm length. The exact 
arrangement of the three proteins in the nucleocapsid is unknown. They are flexible 
structures and can be coiled within the virus particles. The function of the nucleocapsids is 
to protect genomic RNA and they are the sites of viral RNA synthesis.
1.3.2 THE PHOSPHOPROTEIN
The phosphoprotein (P) is, as its name suggests, highly phosphorylated. It plays a central 
role in MuV RNA synthesis and with the L protein, it forms the viral polymerase (P-L) and 
with the unassembled NP, it forms a complex which is possibly the active form in RNA 
encapsidation (Horikami et al., 1992). The P gene is variable in length within the 
Paramyxoviridae family and within the rubulavirus genus the P gene consists of 245 to 397 
amino acid residues.
Transcription of the P gene, except for that expressed within the pneumovirus genus, gives 
rise to more than one gene product by means of overlapping reading frames and by a 
process of transcription known as RNA editing, the consequence of which is a reading 
frame shift. The use of overlapping reading frames is a simple and efficient way for 
negative strand viruses to extend their genetic information without extending their genome
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size. The MuV P gene encodes two proteins, V and P. The unedited version of the P 
mRNA encodes the V protein and, in rubulaviruses, at the RNA editing site one or two 
non-coded G nucleotides are co-transcriptionally inserted into the mRNA resulting in a 
frame shift to yield the P mRNA (Figure 1.3a). The P protein is a fusion of the N-terminal 
portion of the V reading frame with the second open reading frame. The P and V proteins 
therefore share the same N-terminal amino acid sequence upstream of the G insertion site. 
The action of this editing mechanism is unknown but it is thought to occur by polymerase 
stuttering (Matsumura et a/., 1999). This editing mechanism has been observed for other 
paramyxoviruses such as Sendai virus and is directed by a template stutter site located 
upstream of the insertion site (Hausmann et al., 1999). The stuttering model proposes that 
the polymerase pauses at the editing site and nascent RNA slips, causing insertion of extra 
G nucleotides (Vidal et al., 1990). The V protein is present in rubulavirus virions but its 
function is unknown. For the paramyxovirus genus, morbillivirus genus and NDV, the V 
protein is produced from the co-transcriptionally edited P mRNA. Therefore, upon 
translation the N-terminal half of the P protein sequences are fused to the highly conserved, 
cysteine rich domain, expressed from the V protein open reading frame (Figure 1.3b). 
Therefore, RNA editing is not necessary for P protein production.
V  virus constructs of SeV were observed to replicate as efficiently as the wild type in cell 
culture and eggs, indicating that the V protein is non-essential (Kato et al., 1997). 
However, the mutant virus displayed greatly increased gene expression combined with 
severe cytopathogenicity in some cell lines. This suggests the interaction of the V protein 
with cellular factors. In mice, the V  virus produced greatly reduced pathogenicity 
observed as a normal increase in body weight with minimal lesions in the lungs; the target 
organ (Kato et al., 1997). These results suggested different in vivo and in vitro functions of 
the V protein.
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Figure 1.3: The mRNA of the P gene of paramyxoviruses, showing the method by which 
the P gene is edited to give rise to more than one gene product. In MuV and SV5 the P 
protein is a fusion of the N-terminal portion of the V protein with the second ORF, 
whereas, for MV and SeV RNA editing is not required for P protein production.
a) P/V mRNA of MuV and SV5 2 x G insertion site
i
b) P/V mRNA of SeV and MV
G insertion site
I
Studies on SeV (Didcock et al., 1999) indicated that, although SeV does not naturally 
infect humans, it blocks the interferon (IFN) response in human cells; SV5 was also 
observed to block the EFN response in human cells. The authors also noted that SeV but 
not SV5 inhibited interferon response in murine cells. Studies on simian virus 5 (SV5) 
have concluded that this virus inhibits IFN signalling by targeting components of the 
transcription complexes that activate IFN (STAT1) (Didcock et al., 1999). Expression of 
the SV5 V protein, in the absence of other proteins, inhibited EFN signalling and induced 
the degradation of STAT1. The authors concluded that the V protein inhibits interferon 
signalling thus allowing the virus to replicate in vivo.
The N-terminal portion of the SeV P protein contains regions responsible for binding the L 
protein and the C-terminal domain contains regions responsible for binding of the NP 
(Curran et al., 1991). The N-terminal of the P protein contains most of the sites at which 
the protein is phosphorylated (Vidal et al., 1988) and the immediate N-terminal domain
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contains a region essential for RNA synthesis although the mechanism is unclear. This 
domain also contains a unique region required for RNA encapsidation (Curran et a l, 
1994). The regions for L and NP binding within the P protein of SeV have been 
differentiated (Curran, 1998).
The P genes of the morbillivirus and paramyxovirus genera can be edited to give rise to a 
third protein product known as the C protein. Rubulaviruses do not express this protein. It 
is a small protein the function of which is unknown. Using antibodies directed against 
both P and C proteins of morbillivirus MV it was observed that both proteins were 
expressed in virally infected cells (Bellini et al., 1985). The C protein localised in the 
nucleus, suggesting that MV may have an obligate nuclear phase in replication. The P 
protein localised with cytoplasmic inclusions.
1.3.3 THE MATRIX PROTEIN
The M protein is the most abundant protein in the virion. The nucleotide sequences of 
many paramyxovirus M genes have been determined (Blumberg et a l, 1984, Chambers et 
a l, 1986, Elango et a l, 1989, Afzal et a l, 1994). The M protein is a basic protein with 
hydrophobic domains but none large enough to span a lipid bilayer, hence, it is thought to 
be only peripherally associated with the membrane. The M protein is synthesised in free 
ribosomes and is located underneath the viral lipid bilayer within the virion.
The main function of this protein is thought to be in the organisation of the virion structure, 
in preparation for virus budding through the plasma membrane of the infected cell 
(Yoshida et a l, 1976; Matsumoto., 1982). The M protein is thought to associate with the 
cytoplasmic tails of the envelope glycoproteins, the lipid bilayer and the nucleocapsids. 
The nucleocapsids have an overall acidic nature whereas the M protein is basic; this may 
support ionic bonding when the two units associate. The M protein can also associate with 
itself and this association is thought to be essential for the formation of a budding virus
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particle. Analysis of SeV mutants with deletions in the hydrophobic region, resulting in an 
overall negative charge of the putative amphipathic helix, prevented M protein self- 
association. In contrast, SeV mutants with deletions in the hydrophobic region, resulting in 
an overall positive control increased virion formation (Mottet et al., 1996). The M protein 
of many paramyxoviruses is phosphorylated but the function of this is unknown.
Studies on proteins from other negative sense RNA viruses have provided some insight 
into the structure of paramyxovirus proteins. For example, the vesicular stomatitis virus 
(VSV), a member of the rhabdoviridae, M protein consists of at least two distinct domains 
(Coulon et al., 1990). One domain is responsible for structural interactions between the 
RNP and the lipid bilayer, as well as for the regulation of transcription. The second 
domain is thought to be responsible for the shut-off of cellular RNA synthesis and for the 
recognition of a cellular factor required for efficient viral RNA synthesis. It is possible that 
the MuV M protein shows similarities, in structure and function, to the VSV M protein.
In persistent virus infections, such as SSPE, the MV M protein is produced at normal rates. 
However, it is unstable and virus budding fails to occur, hence allowing the infection to 
remain persistent (Hirano et al., 1992). The M protein of a MV strain which caused acute 
measles associated with the intracellular viral nucleocapsids and the plasma membrane, 
whereas the M protein of a virus which caused SSPE localised mainly in the cytosol and 
could not bind viral nucleocapsids. The M protein of the acute measles strain could bind 
SSPE nucleocapsids. The M proteins of MV strains that cause SSPE exhibit a defect in 
nucleocapsid-binding function (Hirano et al., 1993).
1.3.4 THE FUSION PROTEIN
The fusion (F) protein is the major viral glycoprotein involved in virus to cell and cell to 
cell fusion (Bratt and Gallaher et al., 1969). The F protein is a type I integral membrane 
protein (its N-terminus is external to the virion), which spans the membrane once. It has a
three domain structure consisting of a large, relatively hydrophilic domain external to the 
virion, a second domain of approximately twenty uncharged amino acid residues that 
anchor the protein to the membrane and a second hydrophilic domain on the inner side of 
the virion envelope. At the N-terminus of the F protein is a cleavable signal sequence 
which targets the polypeptide to the membrane of the endoplasmic reticulum (ER) during 
translation. At the C-terminus of the F protein is a hydrophobic domain that acts as the 
stop transfer domain and is a transmembrane domain, anchoring the protein in the 
membrane. Figure 1.4 shows a schematic diagram of the F protein.
The F protein is synthesised as an inactive precursor, Fo, which is cleaved by a host cell 
protease, forming a biologically active protein consisting of two sub-units F% and F2 linked 
via a disulphide bond (Scheid and Choppin, 1977). The cleavage of the Fo is vital for 
infectivity and pathogenicity. Cleavage of the F protein occurs intracellularly during 
translocation of the protein through the trans Golgi network. Furin, a host cell protease, is 
located in the trans Golgi network and it is believed to be responsible for the cleavage of Fo 
to Fi and F2 (Ortmann et a/., 1994). Furin is also responsible for processing a number of 
blood clotting factor and growth factors and has been shown the cleave rat proinsulin in the 
production of insulin (Smeekens et a l, 1992). Strains of NDV that contain multibasic 
residues at the cleavage site are virulent for their host whereas strains that have only a 
single basic residue are avirulent (Nagai et al., 1976, Glickman et al., 1988). Cleavage of 
F proteins with single basic residues does not usually occur in cell culture unless an 
exogenous protease is added.
Sequencing studies on paramyxovirus F proteins have shown that the N-terminal twenty 
amino acid residues of Fi are hydrophobic and highly conserved. These are termed the 
fusion peptide. The fusion peptide is usually hidden within the protein, but during the 
fusion process, a conformational change allows the fusion peptide to interact with the cell 
membrane, initiating fusion. It is believed that the active form of the fusion peptide is an
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a-helix within which the conserved hydrophobic residues are located on one face of the 
helix. The F protein also contains two heptad repeat regions. Heptad repeat region A 
(HRA) is located to the carboxyl-side of the fusion peptide and heptad repeat B (HRB) is 
located to the amino-side of the transmembrane domain. Heptad repeat regions can form 
coiled coil structures of a-helices. The a-helical structure consists of seven residue repeats 
in a sequence a, b, c, d, e, f  and g where residues a and d are large and hydrophobic 
(Chambers et al., 1990). HRB consists of leucine or isoleucine residues lined up on one 
face of the helix, at positions a and d, for three or four turns of that helix and is therefore 
known as a leucine zipper motif (Buckland and Wild, 1989).
The heptad repeat regions of the NDV F protein consist of the following amino acids 
(Chambers et al., 1986):
HRA: AkqNaanllrLkesIaaTneaVheVtdgLsqLavaVgkMqqfVndQfhkT 
HRB (leucine zipper motif): LgnVnnsIsnAldkLeeSnskLdkVnvk
These heptad repeat regions may change from one form, in a stable state, to another in a 
more fusogenic state, thus allowing the fusion peptide to interact with the cell membrane.
This is also the case for fusion proteins of other RNA viruses, such as the influenza HA 
fusion protein (Chan et al., 1997), the human immunodeficiency virus (HIV) gp41 fusion 
protein (Joshi et al., 1998) and the Ebola virus gp2 fusion protein (Russell et al., 1994). 
These fusion proteins all share similarities; they are all homotrimers (Russell et al., 1994; 
Chan et al., 1997) containing a heptad repeat region adjacent to the fusion peptide and a 
second heptad repeat region in close proximity to the transmembrane domain (Chambers et 
a l, 1990) and undergo a conformational change to become fusion active, Recently, 
synthetic peptides have been synthesised of the heptad repeat regions of rubulavirus SV5 to 
help determine the role of these regions in membrane fusion (Joshi et a l, 1998). The 
synthetic peptides were observed to form a stable six helical structure, thought to be active
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in membrane fusion and the author suggested the F proteins present the fusion peptides to 
host cells atop a central three stranded coiled coil. Figure 1.5 depicts the structure of the 
influenza HA fusion protein and the proposed structure of the SV5 F protein. The results of 
this study by Joshi et al (1998) suggest that the F protein of paramyxoviruses can form a 
similar structure to the influenza HA and the HTV gp41 fusion proteins. This structure of 
the fusion protein is therefore conserved amongst widely different viruses (Hughson, 
1997).
Three-dimensional (3D) models have been suggested, based on low-resolution cryo- 
electron microscopy for the fusogenic state of HA. Bôttcher et al (1999) three 
dimensionally reconstructed intact HA in two distinct conformations, in its native and 
fusogenic states. Detailed changes were detected in the fusogenic state of HA, the main 
change being the formation of a continuous central cavity through the trimer. Other data 
also suggests relationship of a 3-state model to the mechanism of virus fusion by HA (Puri 
et al., 1990). Here, the HA undergoes a proton driven shift from a tense state at neutral pH, 
to a metastable state (the fusogenic state). This is followed by a shift to a desensitised 
state. Bôttcher et al (1999) concluded that the 3D fusogenic state of their HA resembled 
the metastable state of the 3-state model.
The F protein of MuV has similarities with the influenza virus HA protein, about which 
considerable information has been gathered. The HA protein of influenza is a membrane 
bound glycoprotein, synthesised in the rough endoplasmic reticulum (RER) within an 
infected cell and transported to the cell surface, where it becomes incorporated into the 
newly synthesised virions. The HA protein exists as a trimer consisting of identical 
monomers of HA, the structure of which has been determined by x-ray crystallography 
(Wilson et a l, 1981; Weis et al., 1988), in which HA has the appearance of an elongated 
cylinder and is triangular in cross-section. Each HA monomer is composed of two 
structurally distinct regions, a triple stranded coiled coil of a-hehces and a globular region
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Figure 1.5: The proposed structure of the trimeric coiled coils found in the 
fusion proteins of A) influenza HA (Carr et al., 1993); the native state of HA2 
is depicted on the left as a stem of three helical hairpins (red, yellow and pink) 
fastened by the N-terminal fusion peptide (blue) which was buried in the core 
of the coiled coil. The fusogenic state of HA2 is depicted on the right where 
the fusion peptide was released from the interior HA1 subunits were not 
shown. B) SV5 F protein (Joshi et al., 1998); the F protein was depicted in its 
fusogenic state where the fusion peptide (red) was exposed. The a-helices 
formed by HRA are green and those formed by HRB are blue. The remainder 
of the FI subunit is shown as a loop in black. The F2 subunit was not shown.
B)
of fi-pleated sheets containing the receptor binding site (KBS) and variable antigenic 
determinants. Each HA monomer is initially synthesised as a single polypeptide chain of 
550 amino acids, known as HAO. After translation of the polypeptide four types of 
processing occur. Firstly carbohydrate side chains are added, the number and position of 
which vary with the virus strain (Wiley and Skehel, 1987), next proteolytic cleavage occurs 
by which the amino-terminal hydrophobic signal sequence is removed from the newly 
synthesised HA. Thirdly, the glycoprotein undergoes fatty acid acylation during which 
palmitic acid is added to cysteine residues near to the carboxy-terminus. Lastly, a specific 
cleavage by a host cell protease (Klenk et al., 1975) cleaves HAO into HA1 and HA2 by 
the removal of arginine at position 329. The two chains are covalently linked by 
disulphide bonds. This cleavage stage occurs late in the maturation of the glycoprotein and 
is essential for virus infectivity.
A comparison of the amino acid sequences of Paramyxoviridae F proteins does not show 
much overall homology, but there is similar positioning of glycine and proline residues and 
the overall hydrophobicity suggests that the structure of the F proteins are similar. 
Cysteine residues are conserved within the F protein suggesting that the folding of the 
protein is critical for its function. Which of the cysteine residues act to bond the two 
subunits together is unknown. The F protein of paramyxoviruses is subjected to 
glycosylation (Morrison and Simpson, 1980, Lambert et al., 1988) and in MuV there are 
six to seven possible sites for N-linked glycosylation but as yet there is no evidence as to 
which of these sites are used. The FI subunit contains both complex and high mannose 
oligosaccharides whereas the F2 subunit only contains high mannose oligosaccharides 
(Herrler and Compans, 1983).
For MuVs, syncytium formation only occurs when both HN and F proteins are expressed 
(Tanabayashi et al., 1992), suggesting some interaction between the F and HN proteins for 
syncytium formation. This was also observed for NDV (Morrison et al., 1991), bovine
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parainfluenza virus 3 (bPIV-3) (Sakai and Shibuta, 1989) and hPIV-3 (Ebata et al., 1991). 
However, studies on MV and SV5 showed that the HN, or H protein for MV, had no effect 
on the fusion ability.
It has been suggested that amino acid at position 195 within the F protein plays a critical 
role in determining the extent of cell fusion induced by MuV (Tanabayashi et al., 1994). 
Replacement of Ser 195 by aromatic amino acids, Tyr, Tip or Phe, significantly reduced 
the fusion ability of the otherwise fusion competent RW strain of MuV. Replacement of 
Ser 195 by charged amino acids without aromatic side chains did not alter the fusion ability 
o f a virus. The mutant F proteins with Phe, Asp or Arg at position 195 remained 
uncleaved. Cleavage of the F protein occurs in the Golgi network; hence, die authors 
predicted that the mutant F proteins were incorrectly folded, disturbing protein transport 
from the ER to the golgi and so preventing cleavage. It is unknown how the fusion protein 
interacts with the cell membrane to cause cell fusion but it has been suggested that amino 
acid at position 195 could have an essential role in establishing a possible interaction with 
the HN protein (Tanabayashi et al., 1994).
1.3.5 THE SMALL HYDROPHOBIC PROTEIN
The gene encoding the small hydrophobic (SH) protein is located between the genes 
encoding the F and HN proteins on the RNA of rubulaviruses, MuV and SV5. The SH 
protein of MuV is a hydrophobic integral membrane protein, expressed at the plasma 
membrane with the orientation of a type II protein (Takeuchi et al., 1996). The function of 
this protein is unknown, however, when the SH gene was deleted from an infectious cDNA 
clone of SV5 infectious virus could be recovered, indicating that this protein was not 
necessary for virus viability in tissue culture. No change was observed in the phenotype of 
the SH-deleted mutant (He et al., 1998).
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The nucleotide sequences of SH genes are highly variable between strains of MuV and are 
useful for epidemiological studies. Sequence data of the SH gene for many MuV strains 
have been analysed (Yeo ef a/., 1993; Strohle et al.t 1996; Afzal et al.t 1997; Orvell et al., 
1997), and results from computer analysis of the sequence data suggest that MuV isolates 
form six clusters or genotypes, A to F (Wu et al., 1998; Tecle et al., 1998). Table 1.2 
shows the main isolates from each of the six clusters. Antigenic differences have been 
observed between viruses isolated from these genotypes, where genotype A appears to 
show the most pronounced difference in neutralising epitopes and genotypes B, C and D 
share a number of neutralising epitopes (Yates et al., 1996 & Tecle et al., 1998).
Table 1.2: Mumps virus strains are split into six genotypes according to the sequence of 
their SH genes.
GENOTYPE ISOLATES
A SBL-1, JL, RUB INI, ENDERS, CANADIAN AND USA isolates
B JAPANESE isolates
C EUROPEAN AND CANADIAN isolates
D EUROPEAN and CANADIAN isolates
E UK isolates
F CHINESE isolates
The sequence data of the SH gene show a highly conserved region of fifty nucleotides, 
which precede the initiation codon, whereas the open reading frame is highly variable. A 
high proportion of variability was observed for the first or second base of the codon of the 
open reading frame (ORF).
1.3.6 THE HAEMAGGLUTININ-NEURAMINIDASE PROTEIN
The HN glycoprotein is a type H membrane protein (its N-terminus is located internally to
the virion) which spans the membrane once. It contains a single hydrophobic domain
which acts as a signal sequence to translocate the protein across the ER membrane and as a
stop transfer sequence to anchor the protein in the cell membrane (Figure 1.6).
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Figure 1.6: Schematic diagram of the HN protein showing the transmembrane domain/stop 
transfer signal at the N-terminus, the position of the HR domain and the position of the 
putative neuraminidase active sites.
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The HN protein is responsible for binding of the virus to the host cell and has an undefined
(Markwell and Paulson, 1980), such as glycoproteins or glycolipids, on the cell surface. In 
certain paramyxoviruses, this binding is of sufficiently high affinity that these viruses can 
agglutinate red blood cells of certain m ammalian and avian species to cause 
haemagglutination. As its name suggests, the HN protein also has neuraminidase activity 
to prevent self-aggregation of the virus particles upon virus budding from the cell and to 
prevent re-adsorption of newly synthesised virions to the infected cell. The neuraminidase 
has an acidic optimum pH suggesting that it acts in the acidic trans Golgi network to cleave 
sialic acid residues from the HN and F chains. There is a lack of understanding about the 
role of the neuraminidase protein in the entry pathway of viruses. It is thought to catalyse 
the cleavage of the terminal sialic acid residues at a-2,3- linkages and o2,6-linkages from 
adjacent sugar residues o f glycoproteins and glycolipids to allow the virus to move through 
the mucous rich areas (Corfield et al., 1981; Paulson et al., 1982).
The paramyxovirus HN protein has some similarities to the influenza NA protein. The 
influenza NA glycoprotein is also a type II protein and is a tetramer consisting of identical 
subunits held together by disulphide bridges with a mushroom-shaped appearance under 
the electron microscope and a box shaped head on the top of a thin stalk (Varghese et al..
role in cell fusion. The HN protein is assumed to bind to sialic acid containing molecules
33
1983). This stalk is anchored in the viral membrane by the hydrophobic N-terminal region, 
which acts as the signal for transportation to the cell membrane. The NA protein is 
glycosylated, having N-linked oligosaccharides attached to asparagine residues. Four 
catalytic sites have been identified on the surface of the head. The structures of two 
serotypes of neuraminidase from influenza A have been determined (N2, Varghese et al., 
1983; N9, Baker et al., 1987) and consist of a propeller-like arrangement of six strongly 
twisted 4-stranded p sheets, this six-fold topology being a novel finding. Two distinct 
calcium binding sites are located in the tetramer, on the four fold axis between a cluster of 
eight acidic groups and these appear to aid the stability of the glycoprotein.
As discussed for the influenza NA protein, the MuV HN is an oligomer consisting of 
disulphide linked homodimers forming non-covalently linked tetramers. It is unknown 
where the sites for receptor binding, or for neuraminidase activity are and whether the sites 
are combined or isolated. A hexapeptide, at position 241 to 246, with amino acid sequence 
NRKSCS, within the globular head of the HN protein is completely conserved among all 
paramyxoviruses. This region has some homology with the influenza NA protein active 
binding site which suggests that it may form part of the neuraminidase active site 
(Jorgensen et a l, 1987). A second region, at positions 93 to 110, within the HR domain of 
the HN protein has also been implicated in neuraminidase activity (Wang and lorio, 1999). 
It is assumed that the hexapeptide is more relevant for neuraminidase function due to its 
homology with the influenza NA protein active site and its sequence conservation amongst 
the paramxyoviruses. Mutations have been introduced into this region of rubulavirus NDV 
resulting in decreased fusogenicity, suggesting that the globular head is involved in the 
interaction with the F protein to induce fusion (Mirza et a l, 1994).
The HN protein has two HR domains, between amino acids 93 and 125, which are thought 
to form a-helical structures that can possibly interact with the HR domains of the F protein 
(Stone-Hulslander and Morrison, 1999). Mutations in these HN HR domains were
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observed to adversely affect fusion. It was hypothesised that when the HN glycoprotein 
attaches to its receptor it undergoes a conformational change, which induces a 
corresponding change in the associated F protein, releasing the hydrophobic fusion peptide 
into the target membrane and initiating fusion (Stone-Hulslander and Morrison, 1997, 
Tong and Compans, 1999).
Not only is the HN glycoprotein multifunctional but it is also the major antigenic 
determinant; the protein against which most neutralising antibodies are raised. Monoclonal 
antibodies are very useful for investigating the characteristics of viral proteins, and several 
studies have attempted to determine the antigenic sites within the HN protein by selecting 
and analysing monoclonal antibody resistant (MAR) mutants; A study of the Urabe strain 
identified amino acid residues 359 (Arg in the mutant, Gin in the wild type) and 335 (Lys 
in the mutant, Glu in the wild type) as part of an antigenic site within the HN glycoprotein 
(Yates et al., 1996). A previous study of MAR mutants of the KH strain of MuV identified 
a region encompassing amino acid residues 352 to 360 to be a putative epitope for the 
selecting MAb (Kovamees et al., 1990).
The morbilliviruses do not encode an HN protein. Instead, they encode an H protein, 
which has no detectable neuraminidase activity. MV, a morbillivirus, uses CD46 on cell 
surfaces as the receptor and hence the need for neuraminidase to prevent self-aggregation 
might not be essential. Pneumoviruses do not contain an HN protein either; instead they 
encode a G attachment protein. This G protein is also the main antigenic determinant. 
Epidemiological studies of hRSV and bRSV have focused on the G protein because it 
shows the highest degree of antigenic and genetic diversity among all the pneumovirus 
proteins (Martinez et a l,  1999; Elvander et a l, 1998). The cellular receptor for the 
pneumoviruses is as yet unknown.
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1.3.7 THE LARGE PROTEIN
The L protein is the largest and least abundant viral protein encoded by the L gene close to 
the 5' end of the viral RNA. It is assumed that the L protein, due to its low abundance, 
large size and localisation to the transcriptionally active viral core, is the viral RNA- 
dependent RNA polymerase.
The nucleotide and amino acid sequence of many L proteins of the paramyxovirus family 
have been analysed (Kawano et al., 1991; Blumberg et al., 1988; Higuchi et al., 1992). 
They are all of a similar length, approximately 2,200 amino acids, but there is little overall 
homology outside of the subfamilies. However, there are five short regions of homology in 
close proximity to the centre of the protein, and these regions are also conserved in other 
RNA-dependent polymerases of other virus families (Poch et al., 1990). These regions are 
thought to be crucial for the enzymatic function of the protein.
The P and L proteins form a complex (P-L), and both components are required for 
polymerase activity with the NP:RNA template (Hamaguchi et al., 1988). 
Transcriptionally active nucleocapsids contain 5 to 10 P proteins per L protein. It is also 
assumed that the L protein is involved in the addition of the poly A tail to the 3’end and of 
caps to the 5’end of the mRNA. The methyl-G cap, added to post-transcriptional mRNAs, 
is assumed to be added by the L protein because transcription and replication occur in the 
cytoplasm, whereas cellular mRNAs are capped by enzymes located in the nucleus. The 
large size of this L protein is consistent with its ability to perform these enzymatic 
functions (Chinchar and Portner, 1981).
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1.4 VIRUS REPLICATION
The first step in the infection cycle is entry to the target cell. To gain entry to the cell, the 
virus must first attach to the cell via an interaction between the viral envelope 
glycoprotein/s and a host cell receptor/s. A virus receptor may be defined as a 
macromolecule or complex of macromolecules naturally occurring on the host cell surface 
which specifically binds the virus and through this binding, starts the infectious cycle of 
the virus (Markwell et al., 1984). Most paramyxoviruses bind cells via sialic acid residues 
situated on cell surface glycoconjugates. Sialic acid is the group name for an acyl 
derivative of neuramic acid and approximately twenty different types of sialic acid have 
been identified. A sialidase enzyme from the bacterium Vibrio cholerae destroys the 
sialoglycoconjugate receptor and protects the host cell from infection by SeV (Markwell et 
al., 1980). Hence, the host cell receptor for paramyxoviruses is presumed to be a sialic 
acid containing molecule, either a glycoprotein or a glycolipid. Sialic acid-containing 
proteins or lipids are common to most cells, allowing the virus to enter a number of cell 
types. Respiratory syncytial virus (RSV) is an exception to the above and binds to cellular 
heparin sulphate, a glycosaminoglycan (GAG) (Feldman et al., 2000). The role of cell 
surface GAGs in RSV infection is assumed to involve a specific GAG structural 
configuration (Hallak et al., 2000) and the RSV-GAG interaction facilitates virus 
attachment and entry.
In contrast, MV is different to other paramyxoviruses as it uses a protein and not sialic acid 
as a receptor. A MAb, developed against a specific human cell surface protein, was found 
to inhibit MV infection (Naniche et al., 1992) and precipitated a protein, identified as 
CD46 (Naniche et al., 1993). CD46 is a type 1 integral membrane glycoprotein found on 
nearly all nucleated human tissues and cells. CD46 proteins are expressed in the brain 
strengthening the hypothesis that MV can spread in the brain of SSPE and MTBE patients 
(Cattaneo and Rose, 1993; Billeter et al., 1994).
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As discussed above, influenza viruses also use sialic acid residues for attachment to the cell 
surface. In humans, the site of infection by influenza A is the respiratory epithelium lining 
the trachea, and the virus preferentially binds to and infects the ciliated cells of the 
epithelium rather than the mucous-secreting goblet cells (Edwards et al, 1986), which 
contain sialic acid with an <x2,3 linkage. Epithelial cells contain a sialic acid with an a-2,6- 
linkage, which is less susceptible to the NA (Schulman and Palese, 1977; Sugiura and 
Ueda, 1980). The receptor binding site (RBS) on the HA protein is a depression on the 
globular head, which contains several conserved amino-acid residues and is surrounded by 
variable immunogenically important amino acids forming epitopes. There is a second, but 
weaker, sialic acid binding site located at the base of the globular head at the interface 
between HA1 and HA2.
After MuV has attached to the cellular receptor, the viral membrane fuses directly with the 
host cell plasma membrane at a neutral pH. This fusion event occurs through the 
interaction of the viral F protein with the cell plasma membrane, leading to release of the 
viral nucleocapsids into the cell cytoplasm. It is thought that the F protein has to undergo a 
conformational change to become activated and cause fusion allowing the usually hidden 
fusion peptide to interact with the cell membrane. For those paramyxoviruses, which 
require both HN and F proteins for fusion, such as MuV, this conformational change is 
speculated to occur through interaction of the HN protein with the F protein.
The mechanism through which membrane fusion occurs has been studied in detail for 
influenza virus (Klenk et al., 1975). After influenza virus attachment to sialic acid residues 
on the cell surface, it is internalised by receptor mediated endocytosis in clathrin coated 
pits, rather than by membrane fusion at the cell surface, as for paramyxoviruses. Surface 
bound influenza virus is quickly endocytosed, with a half-life of 10-15 minutes and 
transported to lysosomes where the acid pH causes fusion after an irreversible 
conformational change in the HA. Only HA which has been cleaved from HAO to HA1
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and HA2 can partake in this fusion event. The influenza virus entry pathway is of 
considerable interest as a target for antiviral drugs. One such drug, amantadine, at 
concentrations >0.1 mM, indirectly inhibits the activation of the membrane fusion activity 
of influenza virus HA involved in endocytosis (Hay et al., 1985). The drug is thought to 
block the ion channel activity of the influenza virus membrane protein M2 so causing the 
pH of the lysosome to increase and preventing the low pH induced conformational change 
of HA (Hay et al., 1985).
After virus entry into the host cell and release of the viral nucleocapsid into the cytoplasm, 
the next stage in virus replication is transcription of the negative sense genomic RNA into 
mRNA. Associated with nucleocapsids released into the cell cytoplasm are multiple copies 
of the P-L polymerase. These complexes are scattered throughout the length of the RNP 
but can only initiate transcription from the 3’ end of the RNA.
The genomes of paramyxoviruses and rhabdoviruses are organised as a single 
transcriptional unit with only one promoter. In rubulaviruses the first gene is separated 
from the 3’ end of the viral genome by a leader sequence of 50 nucleotides, where the first 
twelve nucleotides are conserved throughout each genus. The rest of the leader sequence is 
rich in A and U sequences. After transcription of the leader sequence the viral polymerase 
terminates and reinitiates at the beginning of the first gene.
The frequency with which the polymerase reinitiates transcription after each termination 
sequence is not 100% in all cases. Therefore, there is a higher proportion of transcripts of 
the NP and P mRNAs, as compared to the L protein mRNA which is furthest downstream 
and transcribed last. This gradient of transcripts is one way in which the virus can control 
mRNA production. Another mechanism involves the inefficient termination of a transcript 
leading to the production of bicistronic mRNA where only the upstream ORF is translated. 
This is the case when measles virus down-regulates M gene expression during long term 
persistent infections, such as SSPE (Cattaneo et al., 1987; Hirano et al, 1993). A further
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mechanism of control of mRNA production involves genes with overlapping mRNA. For 
respiratory syncytial virus (RSV), the start sequence of the L gene is situated upstream 
within the M2 gene. Most transcripts that initiate transcription of the L protein terminate 
when the polymerase reaches the termination sequence for the M2 protein. Hence, 
functional L mRNAs are only produced occasionally when the polymerase reads through 
the M2 termination site (Collins et ai., 1987).
The accumulation of viral proteins, translated from the mRNAs initiates the switch from 
transcription to replication. The switch from transcription to replication has been 
extensively studied for VSV. Wertz et al (1994) demonstrated that the extent of terminal 
complementarity, rather than the exact sequence of the genome, is a major determinant of 
whether the template directs transcription or replication. In order to determine the cis- 
acting sequences necessary for RNA replication, Pattnaik et al (1995) constructed plasmids 
with a series of internal deletions in the DI cDNA. The data determined showed that 
signals necessary for RNA replication are contained in the 5*-terminal 36 nucleotides and 
the 3’-terminal 51 nucleotides of the DI RNA genome. Whelen & Wertz (1999) examined 
sequences of the 3’ leader and 5’ trailer for roles in transcription and replication by 
observing effects of alterations to the termini of subgenomic replicons, or infectious 
viruses. The authors concluded that distinct elements in the leader sequence were required 
for transcription but not for replication and abolishing the use of the leader sequence as a 
promoter for transcription enhanced replication. The leader sequence therefore is a less 
efficient promoter for replication that the trailer sequence, possibly because of its essential 
role in transcription.
Replication of the negative sense genome occurs via a full-length positive sense 
intermediate. To produce the full-length positive sense antigenome, the polymerase 
transcribes the genomic RNA but reads through the gene junctions. It is not clear how the 
viral polymerase ignores termination signals. It could be caused by the synthesis of NP
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and RNA occurring concomitantly (Kolakofsky and Ortin, 1991). Initially, when levels of 
unassembled NP are low, the polymerase preferentially engages in mRNA synthesis to 
raise levels of all virus proteins. Later, when levels of unassembled NP are high, the 
polymerase preferentially engages in genome replication. Genomic RNA synthesis from 
the antigenome is thought to occur in the same way as antigenome synthesis.
Defective-interfering (DI) particles are common products of MuV replication and are 
implicated in establishment and maintenance of persistent virus infections (Huang and 
Baltimore, 1970). During viral RNA replication, DI genomes arise as a result of replicative 
errors, where the polymerase creates internal deletions and hence, DI genomes are very 
variable in length. The deletions in the RNA genome may arise when the viral polymerase 
detaches from the RNA and either rejoins the RNA at a different point or attaches to the 
nascent strand. The generation of SeV DI genomes has been extensively studied (Leppert 
et al., 1977 & Amesse et al., 1982), and DI genomes have been observed to arise for two 
main reasons. A complementary copy of the 5* end replaces the 3’ end of the virus 
genome; this complementary sequence being identical to the 3* end of the antigenome 
template in replication; these DI genomes are known as ‘copy-back’ DI genomes. The 
second type of SeV DI genomes are known as ‘fusion’ Dis. Fusion Dis are capable of 
encoding the fusion protein with the amino-terminal of the NP protein and the carboxy- 
terminal of the L protein. These fusion Dis contain internal deletions but retain both 
termini of the genome. Defective-interfering viruses cannot replicate without the 
assistance of the infectious parental virus. Therefore, propagation of DI virus is optimal at 
a high multiplicity of infection (MOI) when all cells contain an infectious virus genome. 
Defective-interfering particles are composed of identical constituents apart from their RNA 
and deprive infectious virus of components for its own multiplication. Hence, the yield of 
infectious virus is significantly lowered. Propagation of virus at a low MOI results in 
production of less DI particles.
Addition or deletion of single nucleotides in SeV cDNA prevented efficient replication 
(Calain et al., 1993). Replication was resumed when further nucleotides were added or 
deleted but only if  the total length of the RNA was divisible by six. This “rule of six” is 
explained by each NP unit being associated with six nucleotides (Egelman et al., 1989). 
NDV strictly conforms to this “rule of six”, but some other rubulaviruses do not (Murphy 
and Parks, 1997).
Nucleocapsid assembly occurs in the cytoplasm and results in the production of the helical 
RNP complex, as observed by electron microscopy (Kolakofsky et al., 1998). After 
assembly of the RNP complex, the association of the P-L complex occurs. HN and F 
protein maturation occurs in the ER and only correctly folded and assembled proteins are 
transported out of the ER and through the Golgi apparatus. Here the oligosaccharide side 
chains can be modified and cleavage of the mature F protein into the two active subunits 
occurs. The HN and F proteins are then transported to the cell plasma membrane for 
budding. Here, it is assumed that the envelope glycoproteins make important contacts with 
the matrix protein and through this to the nucleocapsid. Budding of the nucleocapsid 
complex and the matrix protein then occurs through the plasma membrane containing the 
viral glycoproteins to release mature virions. The neuraminidase activity contained within 
the HN protein acts to allow efficient release of the virus preventing self-aggregation of the 
virus particles and re-adsorption to the cell.
1.5 VIRUS PATHOGENICITY
Natural MuV infection is acquired and spread through droplets (Johnson and Goodpasture, 
1935). Therefore, the virus needs close-living communities to cause an epidemic (Gordon 
and Heeren, 1940). After initiation of infection, the virus primarily replicates in the 
mucosal epithelium of the upper respiratory tract before spreading to the draining lymph 
nodes (Feldman et al., 1989), followed by a viraemia (Kilham et al., 1948) and infection of
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the parotid gland, which does not always occur (Kilham et al., 1949). Infection of the 
parotid gland involves the ductal epithelium and is accompanied by periductal interstitial 
edema and a local inflammatory reaction. This inflammation and swelling gives rise to the 
classical clinical symptoms of MuV infections. Virus can also spread to and infect other 
organs including the CNS. The virus can spread to the kidneys where it infects epithelial 
cells of the distal tubules and ureters. This can lead to a viruria, virus being shed in the 
urine of the infected patient for up to 14 days after onset of clinical symptoms (Utz et ah, 
1957). There is evidence that the virus invades the CNS possibly by crossing the chorioid 
plexus which is the primary site of replication following infection of newborn hamsters 
(Wolinsky et a l t 1976), and at least half of all MuV infections are associated with 
replication of the virus in the CNS. Neurological manifestations during mumps are usually 
limited to those arising from meningeal infection. Mumps meningoencephalitis is rarely 
fatal, and most cases resolve without sequelae, although instances of deafness have been 
reported. Other organs that can become affected by mumps virus infection include the 
testes, liver, pancreas, spleen, thyroid, kidneys, eyes, thymus, heart, mammary glands, 
lungs, bone marrow, joints, epididymis, prostate and ovary.
It has been suggested that the attachment proteins of MuV, the HN protein, and of MV, the 
H protein, have a leading role in determining virus pathogenicity (Love et al., 1985; 
Liebert et al., 1994). Monoclonal antibody mutants selected using anti-HN MAbs, grown 
in hamster for MuV and rat for MV, had altered affinity for neurones in the brains. The 
monoclonal antibodies were raised against the HN protein so it was suggested that 
differences in this protein were responsible for the change in pathogenicity.
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1.6 CLINICAL SYMPTOMS AND DIAGNOSIS
The incubation period, after the first exposure to MuV but before symptoms occur, is 
approximately 18 days (Henle et a l, 1948, Johnson et al., 1935). However, one third of all 
infections have been reported to be asymptomatic (Philip et al., 1959). Virus can be 
detected in the saliva several days before the onset of clinical symptoms and up to 5 days 
after the onset of the clinical disease (Chiba et al., 1973).
The most common clinical feature of mumps virus infection is parotitis, or swelling of the 
parotid glands which occurs in 95% of all symptomatic cases (Philip et al., 1959). 
Enlargement of glands is usually maximal at 48 hours when pain increases and the swollen 
gland can remain inflamed for one week or longer.
In males, MuV infection can give rise to orchitis in up to one quarter of cases. This 
comphcation is more common in young males infected after the onset of puberty (Philip et 
al., 1959). Orchitis involves painful swelling of the testes and can lead to the onset of 
testicular atrophy of the infected gland. Rarely this leads to sterility (Shiftman et al., 
1992). Analogous to this, females infected with MuV can suffer mastitis and oophoritis 
(Philip et al., 1959), and virus can be detected in breast milk (Kilham, 1951). Infection by 
mumps virus can also lead to CNS involvement. The frequency of CNS involvement was 
noted as 11% in a St. Lawrence Island epidemic in 1956-1957 (Philip et al., 1959) and 
17% in a study of mumps in university campuses (Sosin et al., 1989). CNS involvement as 
meningitis usually occurs 5 days after the onset of parotitis, commencing with symptoms 
such as fever, vomiting, neck stiffness, headache and lethargy (McDonald et al., 1989).
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1.7 IMMUNE RESPONSE TO MuV
Neutralisation assays, using polyclonal sera, determined that MuVs are monotypic viruses 
(Cantell., 1961), and re-infection by MuV, following natural infection, is rare. The 
immune response to a developing MuV infection is complex and can be divided into 
cellular and humoral responses. The exact time course of the development of specific 
cellular immunity following infection is not completely understood. The lymphocyte 
response leads to pathological changes including inflammation of MuV infected tissues. 
This inflammation is well established at the onset of clinical symptoms, suggesting that 
specific cellular responses develop during the incubation period. T lymphocytes and 
specifically sensitised cells in the blood and cerebrospinal fluid (CSF) of some patients 
with active mumps meningitis are also detected (Nagai et al., 1983).
Cytotoxic T cells have been observed following natural MuV infection, with peak 
responses detected 2 to 3 weeks after inoculation or immunisation (Chiba et al., 1982). 
Cytotoxic T cells, restricted to autologous infected target cells, have also been observed in 
the blood of patients during the first weeks of mumps meningitis (Kreth et al., 1982). 
MuV specific cytotoxic T cells have also been detected in the CSF of several patients. 
However, there is little evidence that the development of CMI against MuV is necessary 
for mumps resolution, as examples of persistent or atypical mumps infections in the T cell 
immunocompromised have not been reported.
Pre-exposure and post-exposure sera of vaccinated children have been examined, and a 
correlation established between serum neutralising antibody titres and clinical protection 
(Goncalves et al., 1999). Children with a serum neutralisation end point (NEP) of 4 or 
lower were found to be susceptible when naturally exposed to wild type virus. Those with 
a NEP of 6 or above were observed to be immune when exposed to the wild type whilst 
those with an NEP between 4 and 6 were classed as equivocal. Results of enzyme 
immunoassays (EIA) showed no correlation with the NEP results or with clinical
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observations. However, the NEP and EIA methods measure different properties of the 
virus; NEP measures antibody against a biological property (live virus particles) whereas 
EIA measures antibody against total viral antigen (the amount of HN present, whether or 
not part of a live virus).
MuV specific IgM responses usually exceed IgG responses early in infection but decline 
over a six month period. Virus-specific IgM levels are therefore the most useful indicator 
of a recent mumps infection. Virus specific IgG responses do not peak until 2 to 3 weeks 
into the clinical infection and persist indefinitely (Meurman et al., 1982). Neutralising 
monoclonal antibody, against the HN protein, can protect animals from challenge by lethal 
vims concentrations even if it is administered several days after virus inoculation 
(Wolinsky et al., 1985). Protection appeared to be the result of the anti-HN MAb limiting 
the spread of infection within the CNS. IgA responses are detected but only early in the 
course of the infection.
1.8 ANIMAL MODELS
Several attempts have been made to develop animal models for paramyxoviruses, the most 
successful to date being the study of MV in rhesus (Macaca mulatto) and cynomolgus 
(Macaca fascicularis) monkeys. Other attempts have involved the use of the hamster and 
rat for studying MuV and the use of chimpanzees and Cotton rats to study human 
parainfluenza virus (hPFV) and human respiratory syncytial virus (hRSV). The use of non­
human primates as animal models is limited due to availability, expense and ethical 
considerations, so the alternative of developing an animal model using smaller mammals, 
such as the hamster for studying MV and CDV and rats for studying MuV, RSV hPIV3, 
needs attention.
Man is the only natural host for MuV. However, the monkey, dog, cat, ferret, rabbit, 
guinea pig, adult and suckling hamster, suckling mouse and suckling rat have all been
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experimentally infected. A MuV, originally isolated from human breast milk, was adapted 
to newborn hamster brains, and the resultant virus strain produced meningoencephalitis 
after intracerebral inoculation of hamsters (Kilham and Overman, 1953). This hamster- 
neuroadapted virus strain (Kilham strain) has since been used by a number of workers to 
investigate factors that contribute to neurovirulence because it is a good animal model for 
this manifestation. The adapted virus was used to determine the mode of spread of the 
virus to the CNS after intraperitoneal inoculation into hamsters. Pathogenesis of MuV 
infection in the hamster can be compared to MuV infection of humans as in both cases 
viraemia and viruria occur, as does the spread of MuV to the CNS (Wolinsky et al., 1976).
Recent studies have suggested that the neonatal rat may be a good model of MuV infection 
(Rubin et al., 1998). When one-day-old rats were inoculated with either the attenuated JL 
vaccine strain or the neurovirulent Kilham (KH) strain, histopathological differences could 
be seen in the rat brain and titres of KH significantly exceeded those of JL. The weight of 
the rats also differed, with the KH infected rats losing weight but the JL infected rats 
remaining the same as the controls. The greater neurovirulence of the KH strain was 
apparent under histological examination of brain material, where hydrocephus and 
cerebellar abnormalities were seen for the KH infected rats. However, none of the infected 
rats developed encephalitis. Further work needs to be carried out using other MuV strains 
to observe whether the rat model can differentiate between other strains of mumps virus 
because the KH strain of MuV is adapted to growth in rodents, whereas JL is not, and this 
factor could account for the differences observed in the study.
Prior to the widespread use of the MuV vaccines, MuV was the leading cause of virus- 
induced central nervous system disease. Problems with neurovirulence of the MuV 
vaccines stem from the lack of an animal model capable of determining the potential for 
neurovirulence. Neurovirulence testing of MuV vaccines is currently performed in 
monkeys but these tests do not differentiate between neurovirulent and non-neurovirulent
strains effectively. The monkey neurovimlence test (MNVT) is required by the World 
Health Organisation (WHO) and other control agencies to enable evaluation of a seed virus 
and vaccines derived from it. The MNVT involves at least 20 monkeys, 10 for the test 
virus and 10 for a reference virus. A 0.5ml inoculum is injected into the thalamus and the 
infected animals are observed for clinical signs of disease over 7 to 21 days. The animals 
are then sacrificed under general anaesthetic, the formalin perfused brain is investigated, 
and specific histological lesions seen are graded on a score of 1-4. Grade 1 is minimal 
infection, grade 2 is moderate, grade 3 is severe and grade 4 is overwhelming infection 
where severe inflammatory infiltration occurs (Maximova et al., 1996). In a recent study 
(Afzal et al., 1999), vaccine strains and a wild type were inoculated into the thalamus of 
Macaca fasicularis monkeys. No strain was observed to produce significant clinical signs. 
The histological data presented did not distinguish between related strains of virus but did 
differentiate between vaccine and wild type strains. This study called into question the 
ability of the MNVT to differentiate between acceptable and unacceptable vaccine seeds 
and the value of the monkey as a model for MuV infection.
1.9 EPIDEMIOLOGY
MuV is a geographically unrestricted disease with the exception of remote islands and 
tribes. A study of such tribes (Black et a l, 1974) showed that antibodies to MuV were 
either absent, were present at a low frequency or found only in persons over a specific age. 
It was postulated that MuV was present in small tribes only on introduction from larger 
communities after which it spread rapidly but could not maintain itself. In urban 
populations, mumps occurs endemically, with peak incidences in winter and spring months 
(Modlin et a l,  1975). Cases are usually observed in school children where close contact 
occurs among susceptibles.
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The incidence of mumps has been decreasing since 1941 when there were 250 cases per
100.000 people. At the time of introduction of the first MuV vaccine in 1967, cases were 
76 per 100,000 people. Since then, cases of mumps have steadily declined with 1 case per
100.000 recorded by the CDCP in the USA in 1992. However, data of the incidence of 
mumps provide only a rough idea of the whole picture, as 30% of all mumps infections are 
considered asymptomatic.
Natural infection by MuV appears to give life-long immunity. Antigenic differences have 
been reported between MuV isolates but these do not seem to have any epidemiological 
significance because once acquired, immunity to mumps is valid world-wide. A study of 
Dutch families detected antibody to MuV in approximately 95% of young adults 
(Wagenvoort et al.t 1980). The remaining 5%, when exposed to the virus, proved to be 
immune.
Epidemics in isolated populations without prior immunity have been useful in studying 
MuV epidemiology. An epidemic on St. Lawrence Island in the Bering Sea in 1957 was 
thoroughly studied (Meyer et al„ 1962), Only those under 50 years of age were included in 
the study as some prior immunity was observed in the older members of the community. 
Ninety-three percent developed mumps complement fixing antibody but only 70% had 
recognisable clinical symptoms. The majority of cases occurred in children under the age 
of 10. Ninety five percent of symptomatic cases showed parotitis; Orchitis was observed 
for all ages of males infected, from 3 to 51 years but was more common in those post 
puberty. Thirty-eight percent of men above 15 had orchitis, and 5% of orchitis patients had 
no signs of parotitis. Neurological symptoms were observed in 11% with 4 cases of 
encephalitis and 40 cases with a stiff neck. In the St. Lawrence Island epidemic, long 
incubation periods were observed where in 95% of cases the incubation period was 
between 14 and 21 days. Children were the most at risk from acquiring mumps but the 
incidence of mumps encephalitis increased with age.
1.10 VACCINES
At least 10 different mumps vaccines are in use throughout the world and Table 1.3 
summarises the main MuV vaccines in use and their passage history. The vaccine against 
mumps is administered either as a monovalent mumps vaccine or in a trivalent form known 
as the MMR vaccine, the other components being vaccines against measles and rubella. 
The mechanism of attenuation of the live mumps vaccine is unknown, as is the length of 
protective immunity after vaccination, although it is thought that the vaccines may not 
confer life long immunity.
Table 1.3: Summary of the main MuV vaccines in use.
VACCINE
STRAIN
PASSAGE HISTORY REFERENCE
UrAm9 Chick embryo amniotic cavity, QEF, amniotic 
membrane of hens’ eggs
Yamanishi et al 
(1973)
Jeryl Lynn Embryonated hen’s eggs, CEF Hilleman et al (1968)
Rubini WI-38 cells, MRC-5 cells Gluck et al (1986)
Leningrad-3 Chick embryos, Japanese QEF Smorodintsev et al 
(1965)
Sofia 6 Guinea-pig kidney primary cells Odisseev and 
Gacheva (1994)
QEF = Quail embryo fibroblasts 
CEF = Chick embryo fibroblasts
The first live attenuated vaccine was produced by seven passages of a wild type mumps 
virus in the chicken embryo amniotic cavity followed by ten passages on chick embryo 
fibroblast cells. This vaccine strain is known as the Jeryl Lynn strain (Buynak and 
Hilleman, 1966), named after the child from whom the virus was isolated. The Jeryl Lynn 
strain has been shown to be composed of two sub-populations of virus, known as JL-2 and 
•JL-5 (Afzal et al., 1993). The components can be distinguished by their plaque 
morphology on Vero cells and genetically. This vaccine has been in use since 1967 and
clinical protection studies have shown it produces 95% seroconversion (Hilleman et al., 
1968). A second live attenuated mumps vaccine, the Urabe Am9 strain (Yamanishi et al., 
1973), was introduced in 1973 into Canada, UK and Europe and Japan. This vaccine was 
produced from a wild type isolate by two passages in the chick embryo amniotic cavity, 
four passages in African Green monkey kidney cells, further passaged in embryonated 
hens’ eggs and five passages in quail embryo fibroblasts. Finally, the virus was passaged 
four times in the amniotic cavity of hens’ eggs. The Urabe vaccine causes mild vaccine 
associated meningitis (Forsey et al., 1990) in up to 1 in 3,800 vaccine recipients (Balraj 
and Miller, 1995). This resulted in its use in Canada and the UK being terminated. The 
Urabe vaccine continued being used in France as it provides a higher seroconversion rate of 
up to 97.8%. The Jeryl Lynn strain has not been implicated in any case of vaccine 
associated meningitis and is routinely used in the UK, although it may give a lower 
seroconversion rate than the Urabe strain. Both the Urabe and Jeryl Lynn vaccine strains 
have been implicated in vaccine associated parotitis in a minority of patients, estimated at 
approximately 0.7% (Fujinaga et al., 1991).
Other vaccine strains include the Leningrad-3 strain used in Russia (Smorodintsev et al 
(1965)), Sofia 6 used in Bulgaria (Odisseev & Gacheva, 1994) and the Rubini strain (Gluck 
et a l, 1986), which is in use in Switzerland, Portugal, Spain and in some developing 
countries. The Rubini vaccine was isolated from the urine of a child with mumps and was 
attenuated by two passages in WI-38 cells, thirteen passages in hens’ eggs, and finally the 
virus was adapted to MRC-5 cells. Recently, investigations have suggested that the Rubini 
vaccine strain gave less protection in vaccinated individuals as outbreaks have occurred in 
Portugal (Afzal et a l, 1997), Western Switzerland (Germann et a l, 1996) and Singapore 
(Goh et a l, 1999).
MuV vaccine strains have mutations in their HN envelope glycoprotein as compared to 
their progenitor wild type. For example, the Urabe vaccine contains a mixture of two
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variants differing at certain positions within the HN gene, one of them at nucleotide 
position 1081 (Afzal et al., 1998; Brown and Wright, 1998). One variant had an A at this 
position, which translates to a Lys at amino acid position 335 and the other variant had a G 
at this position, which translates to a Glu at amino acid position 335. It was suggested that 
Lys335 was the disease associated form of the virus because it escaped neutralisation by a 
monoclonal antibody, in contrast to Glu335, which was associated with attenuation. These 
results show that vaccine associated meningitis in recipients of the Urabe vaccine was not 
caused by reversion to the virulent type but by a variant of the vaccine strain, present in the 
vaccine (Brown and Wright, 1998). The results also indicate that a vaccine composed 
solely of the Glu335 virus would be safer than the existing Urabe vaccine.
There has been a dramatic decrease in mumps incidence in countries where an effective 
vaccination programme exists. After vaccination was introduced in the UK in 1988, a drop 
of 79% was recorded by the PHLS between 1989 and 1990. Recent studies have 
recommended re-vaccination with the MMR vaccine to provide a booster reaction (Tischer 
and Gerike, 2000, Brôliden et a i, 1998). Sweden commenced a two-dose programme of 
MMR vaccination in 1982 to be carried out at the ages of 18 months and 12 years. In 
1992-1993 the first group vaccinated at 18 months reached the age of 12 years. Before and 
after receiving the second dose neutralisation antibodies were tested (Broliden et aL, 1998), 
and it was concluded that a booster vaccine was necessary because the level of 
neutralisation antibody had waned in the previously vaccinated individuals.
1.11 VIRAL QUASISPECIES AND ADAPTATION
Mumps virus is a negative sense, single-stranded RNA virus. The error rate of eukaryotic 
viruses has been extensively reviewed by Smith and Inglis (1987). Error rates of viruses 
have been measured using both direct and indirect techniques. By directly measuring the in 
vitro error rate of the polymerase that is responsible for virus genome replication, by
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measuring the frequency of nucleotide misincorporation during transcription, estimations 
of error rates have been made. This error rate has been estimated at between 10"2 4 and 10" 
2 8 for the reverse transcriptase encoded by retroviruses. The error rate of the VSV RNA 
polymerase has also been directly determined by measuring the proportion of transcripts of 
defective interfering particle RNA, no longer susceptible to cleavage by ribonucleotide T1 
at a particular site. The error rate was determined to be approximately 10"3'15. Nucleotide 
substitution frequencies have also been measured by direct nucleotide sequencing of virus 
clones derived from the same plaque. Using this technique, frequencies of 10"4 1 for the 
influenza NS segment and <10"5 for the poliovirus type 1 VP1 gene have been obtained. 
Nucleotide substitution frequencies have also been measured using indirect techniques, 
such as by analysis of MAR mutants in a cloned virus stock (Smith and Inglis, 1987).
This genetic diversity is known as quasispecies (Eigen et al., 1981) and viral quasispecies 
is mainly caused by the infidelity of genome replication, large population sizes, 
recombination and reassortment. Within a viral quasispecies population, variants exist 
with unique biological properties and therefore, potential exists for modified forms of 
diseases to arise and emergence of new diseases. Such individual variants have altered 
genotypic and may have altered phenotypic characteristics when compared to the 
consensus virus population but which only become apparent if  the variant outgrows 
dominant phenotype of the virus population. Any change in environmental conditions, by 
which the variants in a virus population are given the opportunity to compete favourably 
with the consensus virus population, can shift the ratio of variant to parent. Factors that are 
included as environmental conditions encompass growth of a virus in alternate host cell 
lines or hosts, interference by defective interfering particles, immune selection and 
temperature shifts. The quasispecies nature of RNA virus populations complicates vaccine 
design because of the potential antigenic diversity. Therefore, vaccines against RNA virus
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populations need to be designed to encompass a broad range of antigenic types and live 
vaccines have the advantage over inactive ones by being of a live quasispecies nature.
Viral quasispecies facilitates adaptation to and improved fitness in existing or changing 
environments through natural selection. Some of the variants may have a selective 
advantage over the predominant population, which could enable a variant to become 
dominant under different environmental conditions of which host cell type may be an 
example. After one passage in a cell line, which exerts a strong restrictive pressure and in 
which the predominant population is not able to attach, penetrate or replicate, a single 
variant may be able to do so; hence, the host cell has selected the variant. If the host cell 
exerts a weaker selective pressure, then the variant might only slowly become dominant or 
may remain at the same titre as the predominant population.
A variety of cell lines have been observed to exert pressures that affect the phenotype of 
RNA viruses. For example, when two related sub-populations of a picomavirus, foot and 
mouth disease virus (FMDV), were subjected to growth-competition experiments in BHK- 
21 cells (Sevilla et al., 1998), one sub-population was observed to have a selective 
advantage over the other population but only when the competition passages were carried 
out at a low MOL At a high MOI both sub-populations coexisted. These results suggest 
that small differences in the virus-cell interaction can contribute to an MOI dependent 
selective advantage of one viral sub-population over a related one. A second example is 
that of rhabdovirus VSV fitness on different cell lines (Novella et al., 1995). Following 
persistent replication in insect cells, VSV increased in fitness, in comparison to the 
decrease in fitness observed after replication of VSV in mammalian cells. Fitness is 
measured by the ability of virus to produce infectious progeny.
Cell passage of MuV has been observed to select variants with a different antigenic pattern 
compared to the previous, predominant population (Yates., 1995). A Vero adapted Urabe 
vaccine strain of MuV was neutralised by a panel of anti-HN MAbs, whereas the
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commercial bulk Urabe vaccine, adapted to CEF cells, was not neutralised by one of the 
MAbs. Sequencing of the HN gene revealed one amino acid difference at position 335. In 
the CEF isolate, this was a Lys and a Glu in the Vero adapted virus. The authors also 
observed that passage in Vero cells appeared to select either a virus with a Lys, instead of 
an Asn, at position 464 or a Glu, instead of a Lys, at position 335, but not both. Therefore, 
amino acids 335 and 464 were implicated in host cell selection. A second study by Yates 
et al (1996), also showed the selection of MAR mutants from the Urabe strain, with amino 
acid differences in the HN protein at position 335; a Glu in the wild-type and a Lys in the 
mutant. Again, the authors concluded that amino acid 335 was potentially responsible for 
adaptation to the cell culture system used in the study. No other genes were investigated in 
this study.
Structural changes and alterations in pathogenicity of a virulent virus have also been 
observed during serial passage in vivo (Love et al., 1986). The Kilham strain of MuV was 
passaged in the brains of newborn hamsters, either with an interval of 4-5 days between 
inoculation and harvest or with an interval of 10-12 days. This difference in the mode of 
passaging resulted in the selection of variants which differed in their pathogenicity. 
Changes were observed, using monoclonal antibodies, in the NP protein and slight changes 
were also observed in the HN and P proteins. Differences in the fusion capability of the 
two variants as well as different tropisms for different cell types were observed.
B95a cells are a marmoset lymphoid cell line, transformed with EBV and have previously 
been shown to support the growth of other paramyxoviruses related to MuV, such as MV 
(Kobune et al., 1990). It was observed that MV was subjected to host cell-mediated 
selection and that MVs grown in B95a cells were more representative of MV circulating 
among humans than were the viruses selected in Vero cells. Morbilhvirus strains, RPV 
and CDV, have also been grown on B95a cells (Kobune et al., 1991; Kai et al., 1993), 
where similar observations were noted.
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Selection of variants by the host cell has also been observed for influenza virus 
(Robertson., 1993). Influenza virus grown in MDCK cells was shown to resemble the 
original wild type virus, whereas virus growth in hen’s egg selected a virus with less 
resemblance to the wild type virus. Egg-adapted virus can be passaged in MDCK cells 
with no variant selection but MDCK-adapted virus passaged in the hen’s egg selected a 
variant, suggesting that passage in the hen’s egg was more restrictive than passage in cells. 
Substitutions were found in the egg-adapted virus located around the KBS in the HA 
protein, suggesting the involvement of the RBS in variant selection. Antigenic differences 
and differences in immunogenicity were also observed on occasion between the two types 
of variants. A second study by Robertson et al (1995) indicated that when MDCK-adapted 
virus was spiked with egg-adapted virus, the egg-adapted virus showed superior growth. 
The egg-adapted virus was shown to bind to and be internalised by MDCK cells with 
higher efficiency that the cell-adapted virus. The authors concluded that although the 
MDCK-adapted virus is indistinguishable from the wild type it is not the best fit for the 
MDCK receptor. The results of these studies by Robertson et al (1993 & 1995) can be 
related to a study by Ito et al (1997). Ito et al (1997) showed that a lack of SAa2,6Gal 
linkages in the allantois of chicken eggs is a selective pressure for the appearance of viral 
host cell variants with altered receptor specificity. The authors showed that viruses 
maintained high SAo2,6Gal specificity when grown in MDCK cells but passage in the 
allantois or amnion resulted in a complete shift to SAo2,3Gal specificity.
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1.12 THE AIMS OF THIS THESIS
Prior to the commencement of this project only two cell substrates (Vero and CEF cells) 
were in use at NIBSC for studies relating to MuV infection in vitro. The suitability of 
Vero cells for the isolation and propagation of clinical samples and the assaying of mumps 
vaccines is under question after a previous studies have concluded that growth of MuV in 
Vero cells produces virus populations that are different from the original isolate (Yates, 
1995 & Yates et aL, 1996). The major aim of this project was to give an understanding to 
the mechanisms involved in host cell passage of MuV and to move towards an optimum 
cell substrate with which to study MuV infection in vitro. The aim was achieved by the 
application o f  tissue culture and molecular biology techniques including:
• Analysis of virus infectivity after growth in different cell substrates using the TCID50, 
HA and NA assays.
• Analysis of plaque morphology and antigenicity of viruses after growth in different cell 
lines.
•  Molecular analysis of the nucleotide and amino acid sequences of the two envelope 
glycoproteins.
This project was undertaken to determine if an optimum host cell line, more appropriate for 
growth of MuVs, is available. The significance of growing MuVs in an optimum cell line 
is that analysis of in vitro MuV infection would more closely resemble infection of wild- 
type MuV.
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CHAPTER H 
MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 CELL CULTURE MEDIA AND SOLUTIONS
R PM I1640;
MEM;
PENSTREP;
FUNGIZONE; 
BICARBONATE STOCK;
L-GLUTAMINE STOCK; 
FCS
GROWTH MEDIUM;
MAINTENANCE MEDIUM;
SALINE ‘A’;
PBS;
PBS 'A ';
SIGMA 
pH 7.0
GIBCO
0.97g MEM in 100ml GDW 
pH 7.0
1.25g penicillin-G sodium sait
1g streptomycin sulphate
in a final volume of 100ml MEM
0.02g fungizone
in a final volume of 100ml GDW
4.4g NaHC03 
0.5g phenol red
in a final volume of 100ml GDW 
2.9g glutamine
in a final volume of 100ml GDW 
SIGMA
3% (y/v) Bicarbonate stock 
1% (v/v) penstrep 
1% (v/v) fungizone 
4% (v/v) FCS 
in MEM 
pH 7.0
3% (v/v) Bicarbonate stock 
1% (v/v) penstrep 
1% (v/v) fungizone 
2% (v/v) FCS 
in MEM 
pH 7.0
0.8g NaCl 
0.04g KC1 
0.1g glucose
in a final volume of 100ml GDW
1.07g NaCl 
0.03g KC1 
0.017g CaCl2.2H20 
0.013g MgCl2.6H20  
0.40g Na2HPÔ4.12H20  
0.03g KH2PO4
in a final volume of 100ml GipW 
pH 7.4
1 g NaCl 
0.025g KC1
0.144g Na2HPG4 anhydrous
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CEF WASH BUFFER;
TRYPSIN STOCK;
EDTA STOCK;
TRYPSIN SOLUTION;
CEF TRYPSIN SOLUTION; 
CMC;
CMC for overlay; 
BACTOAGAR;
METHYL VIOLET STAIN;
0.025g KH2PO4
in a final volume of 100ml GDW 
pH 7.4
1ml penstrep 
1ml fungizone 
in 100ml PBS'A
SIGMA
1000-1500 BAEE units/mg 
6ml trypsin 
in 100ml saline 'A'
0.4g EDTA in a final volume of 100ml 
saline ‘A’
1ml trypsin stock 
1ml EDTA stock 
1ml Bicarbonate stock 
in 100ml saline ‘A*
1ml trypsin solution 
in 100ml CEF wash buffer
SIGMA
3.2g CMC in 100ml PBS A
1.4g bactoagar in 100ml dH20
2.5g methyl violet stain 
100ml ethanol
in a final volume of 500ml GDW
2.1.2 NEURAMINIDASE ASSAY REAGENTS 
PERIODATE REAGENT;
ARSEN1TE REAGENT;
THIOBARBITURIC ACID REAGENT; 
FETUIN
42.8g sodium metaperiodate 
62ml orthophosphoric acid 
in 100ml dH20
10g sodium arsenite
7.1 g sodium sulphite
0.3ml concentrated sulphuric acid 
in 100ml dH20
7.1 g sodium sulphate 
0.6g thiobarbituric acid 
in 100ml dH20
SIGMA
2.1.3 MOLECULAR BIOLOGY SOLUTIONS 
TRIS;
SDS;
PROTEINASE K COCKTAIL;
1M Tris-HCL 
pH 7.5
10% SDS in GDW
O.IM TrispH 8.4 
0.02M EDTA stock
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0.4M NaCl
40% (v/v) SDS stock solution 
10% (v/v) proteinase K (20mg/ml) 
0.4% glycogen (20mg/ml) 
in a final volume of 1ml GDW
PHENOL SOLUTION; 
lOxTBE;
2mM dNTPs;
1.25mM dNTPs;
ddATP;
ddCTP;
ddGTP;
ddTTP;
PHIGEL 1;
SEQUENCING GEL MIXTURE; 
(For one gel (50ml))
AquaPhenol, Appligene
equal amount chloroform added
54.5g Tris-HCL (pH 7.5)
27.85g 7.5M boric acid
4.65g lOmM EDTA
in a final volume of 500ml GDW
Boehringer Mannheim Reagents
lOmMdATP
lOmM dCTP
lOmMdGTP
lOmMdTTP
in (IH2O
Boehringer Mannheim Reagents
lOOmMdATP
lOOmM dCTP
lOOmM dGTP
lOOmM dTTP
in (IH2O
Boehringer Mannheim Reagents 
350mM ddATP 
lOmMdATP
lOmM dCTP, dGTP, dTTP 
in CIH2O
Boehringer Mannheim Reagents 
16mM ddCTP 
lOmMdCTP
lOmM dATP, dGTP, dTTP 
indH20
Boehringer Mannheim Reagents 
50mM ddGTP 
lOmM dGTP
lOmM dATP, dCTP, dTTP 
in dH20
Boehringer Mannheim Reagents 
600mM ddTTP 
lOmMdTTP
lOmM dATP, dCTP, dGTP 
in CIH2O
Fisher Scientific 
acrylamide/bisacrylamide (19:1)
21gurea 
7.5ml Phigel 1 
22.5ml H20
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5ml lOxTBE buffer
BPB DYE;
FORMAMTOE DYE;
DTT;
PREP-A-GENE BINDING BUFFER; 
PREP-A-GENE WASH BUFFER;
WACKER SOLUTION; 
NUCLEICLEAN WASH BUFFER;
0.025g BPB 
0.025g xylene cyanol 
in 1ml lOxTBE 
3ml glycerol 
6ml (IH2O
0.8ml 0.5MEDTA 
0.1% (w/v) xylene cyanol 
0.1% (w/v) BPB 
in formamide (saturated with 
Amberlite)
0.1MDTT
Prepared in 20ml 0.01M sodium 
acetate, pH 5.2
6M sodium perchlorate 
50mM Tris-HCL pH 7.5 
lOmMEDTA 
in GDW
20mM Tris-HCL pH 7.5 
2mM EDTA 
0.4M sodium chloride 
in GDW
In an equal volume of ethanol 
2.5ml ethanol
75pl, 10% glacial acetic acid 
7.5pl, methmethylacryloxypropyl 
-trimethyloxysilane
Sigma
3 ml wash buffer from kit 
6.75ml GDW 
10.25ml ethanol
2.1.4 OLIGONUCLEOTIDE PRIMERS
HN GENE PRIMERS (positions are expressed in relation to the HN gene, a diagram of the 
genome is presented in section 1.2.3):
SH-7 mRNA sense, at position -109 to -88 
GAT CAA TCA CTC TAG AAA GAT C
HN-6 mRNA sense, at position 258 to 276 
GAT CAA CTT GAG CAA TCA G
HN-18 mRNA sense, at position 572 to 592 
GCC TAG CTT TAT CCA ACT GC
HN-19 reverse sense, at position 591 to 574 
GCA GTT GGG ATA AAG CTA GGC
HN-2 reverse sense, at position 1059 to 1038 
CCT GCA TAT GGG GGT GTC TTG C
HN-3 mRNA sense, at position 888 to 907
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TCC ACC CCA CCT ACC GAA AC
HN-5 reverse sense, at position 1272 to 1252 
GCG AGC TAG TTG TCC CCT CAA
HN-7 mRNA sense, at position 1148 to 1168 
AGA TCA GCG TGC TTT GAG ATC
HN-8 mRNA sense, at position 1416 to 1435 
GTG AAT ATG TCC TGG ATA CC
HN-9 reverse sense, at position 1725 to 1706 
CAC CTG CTT TCA AGA TAC CG
L-19 reverse sense, at position + 111 to + 92 
CAT TTG GTA ACT GGC CAT GC
F GENE PRIMERS (positions are expressed in relation to the F gene, a diagram of the 
genome is presented in section 1.2.3):
M-4 mRNA sense, at position -430 to - 409 
ACC AAC CAT TCT AGT CCA TGC
F-9 reverse sense, at position 186 to 165 
GTC AGG CAA CTA AGC TAT TAC
F-3 reverse sense, at position 448 to 430 
GCC GCT GTC TCA TTC GTT CA
F-4 reverse sense, at position 748 to 729 
GCC TTG AGG TCT TTG CTT GG
F-10 mRNA sense, at position 553 to 574 
GCG GTA CAA GCA ATA CAA GAC C
F-16 reverse sense, at position 996 to 978 
GCC AGA CAG GAT CTT GGA G
F-12 reverse sense, at position 1170 to 1151 
GGA GTT ATA TGA GGC GAT T
F-6 mRNA sense, at position 1083 to 1105 
GCC AAT ACA ATG AGG CAG AGA G
F-14 reverse sense, at position 1334 to 1317 
GGA TTT CAG CAT TGT CTC
F-2 reverse sense, at position +49 to + 27 
AAG AAT GAA TCT CCT AGG GTC G
63
2.2 METHODS
2.2.1 CELL LINES
Six cell lines were used in this project; B95a, BCL, CEF, HeLa, MRC-5 and Vero.
B95a cells
Transformed monkey B-lymphocytes (B95a), were a gift from Dr. K. Katrack at NIBSC. 
The cells secrete a high titre of Epstein Barr virus (EBV), providing a source of EBV to 
establish continuous transformed cells. B95a cells were grown in 25cm2 tissue culture 
flasks, in RPMI 1640 (SIGMA) containing 1% L-glutamine, 1% penstrep and 8% foetal 
calf serum (FCS) at 35°C, 5% CO2. The cells were subcultured every four days by gentle 
resuspension of the cell monolayer to remove clumps of cells and the content of each flask 
split between three new 25cm2 tissue culture flasks (a split ratio of 1:3) and 10ml fresh 
medium added.
BCL cells
Mouse B cell leukaemia cells (BCL), were a gift from Dr. A. Meager at NIBSC. BCL cells 
were grown in suspension in 25cm2 tissue culture flasks with RPMI 1640 containing 10% 
FCS, 1% penstrep and 1% fungizone at 35°C, 5%CC>2. The cells were subcultured every 
four days by gentle resuspension of the cell suspension to remove clumps of cells and 
subcultured at a ratio of 1:4.
CEF cells
Chick embryo fibroblast cells (CEF) were prepared as required. A hen egg was swabbed 
with 70% IMS, the embryo removed using scissors and forceps and placed in a petri-dish 
containing wash buffer. The head, limbs and gut were removed and the embryo body 
rinsed twice in clean CEF wash buffer. The embryo body was cut up finely with scissors, 
placed into a conical flask containing 15ml CEF trypsin solution and stirred at 37°C for 30 
minutes. The resulting cell suspension was filtered through Whatman filter paper, grade 1
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and the cells in the filtrate pelleted by centrifugation at 1,000 rpm for 10 minutes. The 
supernatant fluid was discarded, the cells resuspended in growth medium containing 5% 
FCS, dispensed into two 25cm2 tissue culture flasks and incubated at 35°C, 5% CO2 until 
confluent.
HeLa cells
Human carcinoma epithelial cells (HeLa) were derived originally from a cervical 
carcinoma of a 31 year old woman and were available from stock at NIBSC. HeLa cells 
were grown routinely in 75cm2 tissue culture flasks in growth medium containing 5% FCS 
at 35°C. The cells were subcultured every week by trypsinisation; the cell monolayer was 
washed twice with trypsin solution and incubated with a small amount of the final wash 
until the cells lifted off from the tissue culture flask. The cell suspension was finally 
aspirated with 10ml growth medium and subcultured at a ratio of 1:10.
MRC-5 cells (ATCC number CCL-171)
Human foetal lung cells (MRC-5) (Jacobs et aL, 1970) were originally derived from the 
lung of a normal human male foetus and were held in stock at NIBSC. MRC-5 cells were 
grown routinely in 75cm2 tissue culture flasks in growth medium at 35°C and were 
subcultured each week by trypsinisation and gently resuspending the cell suspension with 
8ml growth medium containing 5% FCS. The cells were subcultured at a ratio of 1:4.
Vero cells (ATCC number CCL-81)
African Green Monkey kidney cells (Vero) (Yasmura and Kawakita, 1963) were derived 
originally from the kidney of a normal African Green monkey. The cells were originally 
obtained from Merck Sharpe and Dohme (MSD). Vero cells were grown routinely in 16oz 
glass tissue culture bottles in growth medium at 35°C and were subcultured every three to 
four days by trypsinisation and gently resuspending the cell suspension with 6ml of growth 
medium. The cells were subcultured at a ratio of 1:6.
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2.2.2 VIRUS STOCKS
Seven mumps strains were Used in this project, JL-2, JL-5, Ur PT1, Ur PT3, Enders, Rubini 
and Pol5/t. The two components of the Jeryl Lynn bulk vaccine, JL-2 and JL-5, were 
plaque purified three times in Vero cells from the original vaccine (the original JL vaccine 
was obtained from MSD). The two components of the Urabe bulk vaccine, 035 1.2.1 (Ur 
PT1) and 035 2.2.1 (Ur PT3) were also plaque purified three times in Vero cells from the 
original vaccine (the original Urabe vaccine was obtained from SmithKline Beecham 
(SKB)). Plaque purification involved performing a plaque assay (section 2.2.7), picking an 
isolated plaque and resuspending the plaque in 0.1ml maintenance medium. This 
resuspended plaque was passaged once, a plaque assay performed on the harvested material 
and the cycle repeated.
The Enders strain was a gift from B. K. Rima, Queens University, Belfast and the stock 
held at NIBSC was obtained by passaging this virus once on Vero cells. The Rubini strain 
was obtained from the Swiss Serum Institute and the stock held at NIBSC was obtained by 
passaging this virus four times on Vero cells. The Pol5/t strain was isolated in Vero cells 
from a throat swab of a patient showing clinical symptoms of mumps in Portugal in 1996, 
and this isolated virus was passaged a further two times in Vero cells to produce the stock 
held at NIBSC. All viruses were stored at -70°C at NIBSC.
The working stocks of JL-2, JL-5, Ur PT1, Ur PT3 and Pol5/t used in this study were 
obtained from the stock held at NIBSC. The Enders and Rubini strains used in this study 
were obtained from the stocks held at NIBSC but were passaged one further time in Vero 
cells to produce a working stock.
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2.2.3 VIRUS PROPAGATION
Viruses were propagated using the following technique:
Growth medium was aspirated from a 25cm2 tissue culture flask containing an 80% 
confluent cell monolayer of the appropriate cell type (approximately 5x106 cells) and the 
appropriate dilution of virus inoculum, diluted in maintenance medium, added. The 
appropriate dilution of virus inoculum was initially 3 logio TCIDso/ml of virus, giving an 
approximate multiplicity of infection (MOI) of 0.0002 (1 TCID50 per 5000 cells). The 
cells were incubated with virus for approximately 2 hours in a humidified incubator at 
35°C, 5% CO2, after which the inoculum was aspirated and fresh maintenance medium 
added. The infected cells were incubated at 35®C, 5%COz until 80% CPE was observed. 
If no CPE was observed the infected cells were harvested 10 days post infection. Virus 
was propagated in BCL cells by adding virus inoculum into the freshly subcultured cell 
suspension and the cells incubated without the removal of the inoculum.
Virus was harvested by freezing the tissue culture flask containing infected cells at -70°C 
and thawing at room temperature to release any cell bound virus. The cell debris was then 
removed from the virus by centrifugation at 160 x g for 10 minutes. The supernatant fluid, 
containing virus, was aliquoted and stored at -70°C.
2.2.4 VIRUS TISSUE CULTURE INFECTIVITY DOSE ASSAY (TCID50)
The infectivity of the viruses was determined using the TÇID50 assay. Virus was diluted 
1/3 in maintenance medium and 150pl of this dilution dispensed into each of eight wells in 
the first column of a 96 well tissue culture plate. One hundred microlitres of maintenance 
medium were added to all other wells. Fifty microlitres of virus were sequentially 
transferred across the tissue culture plate resulting in a 1 in 3 dilution series of virus. One 
hundred microlitres of Vero cells were added to each well (approximately 1-5x10* 
cells/well) and the plate incubated at 35°C for 7 days. The microscopic observation of
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CPE indicated a positive result. The titre of the virus was the dilution producing CPE in 
50% of tissue culture wells and was calculated using this simplified form of the Spearman- 
Karber formula:
m = Xk + d/2 - dZpi
where:
m = the logarithm of the titre, relative to the test volume.
Xk — the logarithm of the smallest dose which induces infection of all cultures,
d = the logarithm of the dilution factor
pi = the observed reaction rate
2.2.5 HAEMAGGLUTINATION ASSAY
Infectious tissue culture fluid was diluted in PBS 'A* in a doubling dilution series, from 
neat, across a 96 well V bottomed tissue culture plate in 50pl amounts. Fifty microlitres of 
0.7 % (v/v in PBS) red blood cells (turkey, monkey, sheep or horse) were added to each 
well and the plate incubated at 4°C for 1 hour. The HA litre in HA units (HAU) of the 
virus was the reciprocal of the highest dilution observed to give complete agglutination of 
red blood cells (Fazekas de St Groth and Webster, 1966).
2.2.6 NEURAMINIDASE ASSAY
The neuraminidase assay used in this study was a colorimetric assay using fetuin as a 
substrate. The assay is based on measurement of the amount of sialic acid released from 
fetuin.
Virus was titrated in a doubling dilution series from neat tissue culture fluid to 1/128 in 
dHjO. Fifty microlitres of each dilution were transferred to separate test tubes and 50pl 
fetuin (50mg/ml) added. The samples were incubated at 37°C for 18 hours, allowed to
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cool to room temperature and lOOpl periodate reagent added to each sample, after which 
the samples were incubated at room temperature for 20 minutes. One millilitre of arsenite 
reagent was added to each sample and vortexed until the colour disappeared. Two and a 
half millilitres of thiobarbituric acid reagent were added to each sample, the samples mixed 
and placed in a boiling water bath for 15 minutes. The titre of the viral NA was taken as 
the reciprocal of the highest dilution of virus to show a pink colour and was expressed in 
NA units (NAU).
2.2.7 ASSESSING PLAQUE MORPHOLOGY
Appropriate dilutions of virus were prepared in maintenance medium. One hundred and 
fifty microlitres of each dilution were dispensed into separate wells of a six well tissue 
culture plate and 3ml Vero cell suspension added per well (IxlO6 cells/well). The plate 
was incubated in a humidified incubator at 35°C, 5% CO2 for 3 to 4 hours until the cells 
formed a confluent cell monolayer. The medium, containing virus inoculum, was aspirated 
and 3ml CMC. CMC overlay was prepared by adding 100ml IxMEM to 50ml CMC and 
mixing. Eight ml FCS, 2ml fungizone, 2ml penstrep and 6ml sodium bicarbonate were then 
added. The tissue culture plate was incubated at 35°C, 5%CO] for 7 days.
After 7 days the overlay was removed, the cell sheet washed in PBS and stained with 
methyl violet solution for thirty minutes. The unbound stain was removed with water. The 
titre of the virus, expressed as pfu/ml, was determined by counting the observed plaques 
and taking into account inoculum volume and dilutions made.
2.2.8 MONOCLONAL ANTIBODIES
The monoclonal antibodies used in this project were either held in stock at NIBSC at -20°C 
as ascites fluid or were stored in liquid nitrogen as hybridoma cell lines that were grown as 
and when needed.
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Hybridoma cells
Hybridoma cell lines were reconstituted for use by washing the cells twice in RPMI 1640 
medium containing 20% FCS, at 160 x g. The pellet of cells was then resuspended in 10ml 
growth medium containing 10% FCS, dispensed into a 25cm2 tissue culture flask and 
incubated at 35°C until confluent. The cells were resuspended by gentle aspiration, 
dispensed into a 75cm2 tissue culture flask and incubated at 35°C until confluent. The cells 
were resuspended by gentle aspiration and split between two 75cm2 tissue culture flasks. 
This process was repeated until six confluent 75cm2 tissue culture flasks were obtained.
Production of tissue culture fluid containing monoclonal antibody
Hybridoma cell tissue culture fluid usually contained microgram quantities of monoclonal 
antibody; this was increased to milligram quantities by propagating the hybridoma cells in 
a mini-perm fermenter (Heraeus Instruments). The hybridoma cells of six confluent 75cm2 
tissue culture flasks were pelleted by centrifugation at 160 x g for 7 minutes. The pellets 
were pooled and resuspended in 37ml growth medium containing 20% FCS. Two 
millilitres of the cell suspension was used to re-seed a 25cm2 tissue culture flask. A mini­
perm fermenter was assembled according to the manufacturer’s instructions and 400ml of 
growth medium, containing 10% FCS, decanted into the top compartment. Thirty-five 
millilitres of cell suspension was injected into the cell unit using a syringe to deliver the 
cells through a small porthole. The mini-perm fermenter was placed on rollers in an 
incubator at 35°C. The growth medium was replaced every 2 to 3 days.
After 3 weeks, 15ml cell suspension was removed from the cell unit and the cells pelleted 
by centrifugation at 160 x g for 5 minutes. The supernatant fluid, containing monoclonal 
antibody, was stored at -20°C for use and the pellet was resuspended in growth medium 
containing 20% FCS and replaced in the mini-perm fermenter. The dilution of tissue 
culture fluid containing monoclonal antibody to use in virus antigenic assays was then 
determined.
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Ascites fluid
Ascites fluid containing monoclonal antibody had been produced previously (Yates et al., 
1996) and was held at -20°C. The following method had been used to produce the ascites 
fluid: hybridoma cells from six 75cm2 confluent tissue culture flasks were pelleted by 
centrifugation and the supernatant fluid discarded. The pellets were resuspended and 
pooled in serum-free growth medium. The resuspended pellets were centrifuged for 5 
minutes at 160 x g and the supernatant fluid discarded. The pellet of cells was resuspended 
in 3ml serum-free growth medium. Half a millilitre of the cell suspension was then 
injected into each of six mice previously inoculated intraperitoneally with 0.5ml of pristane 
oil, to condition the abdomen. After 1 week the mice had produced ascites fluid and were 
sacrificed. The ascites fluid was collected and placed at 4°C overnight to clot. The top 
layer of fluid was removed and centrifuged at 880 x g for 5 minutes. The supernatant fluid 
was removed and stored at -20°C ready for use.
2.2.9 VIRUS NEUTRALISATION ASSAYS
Virus was diluted in maintenance medium containing 1/100 monoclonal antibody dilution 
(MAb neutralisation titres had been determined previously by Yates et aL, (1996) and are 
presented in Table 2.1) to give SOOTCIDso/ml or, where virus was at a lower titre than this, 
virus was used undiluted. Respective positive control virus was also included with no 
addition of MAb. The sample was then incubated at 4°C for 90 minutes. Fifty microlitres 
of sample were added to triplicate wells on a 24 well tissue culture plate and 1ml Vero cell 
suspension at l-5xl05 cells/ml containing a 1/100 dilution of monoclonal antibody added.
After incubation of the samples at 35°C for 3 hours the medium was aspirated and 1ml 
CMC overlay containing a 1/100 dilution of monoclonal antibody added. The plates were 
incubated at 35°C for 7 days, washed in PBS and stained with methyl violet and this stain
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removed with water. The reactivity of seven different MAbs was analysed for each virus, 
MAbs 1637, 1641,1648, 1689,1721,1726 and 1970.
Table 2.1: The biological activity of monoclonal antibodies against the parental (Urabe) 
strain of mumps (Yates et aL, 1996).
MAB NEUTRALISATION
TITRE
m  TITRE NI TITRE
1637 100 000 <20 500
1641 1 000 <20 500
1648 10 000 <20 1 000
1689 100 000 >2560 100
1721 100 000 5 000 >100
1726 10 000 1280 >100
1970 100 000 >20 480 >100
2.2.10 RNA EXTRACTION
RNA was extracted from infectious tissue culture fluid using a modified method of 
Chomzynski and Sacchi (1987). Two hundred and fifty microlitres of infectious tissue 
culture fluid were incubated at 50-55°C with 250pl Proteinase K cocktail. To this mixture 
SOOpl phenol solution was added, vortexed for 1 minute and centrifuged at 11,600 x g for 
10 minutes. The tissue culture fluid was removed from the phenolic layer, placed in a 
clean tube and 400pl chloroform added to remove excess phenol. The sample was 
vortexed and centrifuged at 11,600 x g for 5 minutes. The tissue culture fluid was removed 
from the chloroform layer, placed in a clean tube and 750pl ethanol added. The sample 
was inverted to mix and the RNA precipitated at -20°C for at least 60 minutes.
2.2.12 cDNA SYNTHESIS
The precipitated RNA was centrifuged at 11,600 x g for 30 minutes at 4°C, washed with 
ice cold ethanol and pelleted at 11,600 x g for 5 minutes and the pellet freeze-dried under 
vacuum for 20 minutes. The freeze-dried RNA pellet was resuspended in 4pl 2-
mercaptoethanol (1/20 dilution of stock, BDH Biochemicals), 2^1 dB^O and 2^1 random 
primer (random hexamer) (1/30 dilution of stock at SOOpg/ml, Promega) and incubated at 
65°C for 5 minutes. The solution was then incubated at room temperature for 5 minutes. 
To the solution, the following was added; 1.5 pi lOxAMV reverse transcriptase buffer 
(NBL Gene Sciences), l.Spl dB^G, 2.0pl 2mM dNTPs, l.Opl 0.1M DTT, and 0.7pl AMV 
RTase enzyme (NBL Gene Sciences (20units/pl)). The mixture was incubated at 42°C for 
45 minutes, after which the mixture was heated to 90°C for 30 seconds to destroy enzyme 
activity. The RNA-cDNA mixture was stored at -20°C until used in a PCR reaction.
2.2.12 POLYMERASE CBAIN REACTION 
Oligonucleotide primers
The primers used in PCR were either held in stock at NIBSC or were obtained from Gibco 
BRL. Primers obtained from the manufacturers were reconstituted in 500pl lOxTE for 2 
minutes. The optical density of a 1/20 dilution of this stock in dB^O was determined at. 
260nm and the readings used to calculate the concentration of primer necessary for use in 
the PCR reaction using the following formula (provided by Gibco BRL);
Concentration pg/ml = A260 x molecular weight of primer x dilution factor
The concentration was then converted to picomoles and the dilution required to give 3.2 
picomoles calculated (PCR and sequencing reactions were performed with primer at 3.2 
picomoles, a value recommended for primer use by the manufacturers of the ABI Prism 
310 Genetic Analyser, Perkin Elmer).
PCR reaction
To 4pl of cDNA the following reagents were added; lOpl lOxPCR buffer (containing 
15mM MgCl], Perkin Elmer), 16pl 1.25 mM dNTPs, 5pi mRNA sense primer, 5pi 
antisense primer, 59.5pl dB^O and 0.5pl AmpliTaq DNA polymerase, a polymerase from
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the bacterium Thermus aquaticus, Perkin Elmer (Sunits/^il). To prevent evaporation of the 
sample, 80pl of paraffin oil was added to the sample. The sample was then amplified for 
thirty cycles of 94°C for 60 seconds, 55°C for 60 seconds and 72°C for 90 seconds using a 
Techne Cyclogene thermocycler.
Examination of PCR product
Eight microlitres of PCR product were mixed with 3 pi BPB dye and loaded onto a 1% 
agarose gel, (Seakem), in IxTBE containing 30pl ethidium bromide (lOmg/ml) per 100ml 
of agarose. The samples were then electrophoresed at 60mA for 60 minutes. The DNA 
bands in the gel were then visualised using an UV transilluminator.
2.2.13 MANUAL DNA SEQUENCING 
Purification of PCR product
The paraffin oil was removed from the PCR product and 80jil chloroform added to absorb
any remaining oil, the samples were mixed and centrifuged for 2 to 3 minutes at 11,600 x
g. The aqueous layer containing the PCR product was removed from the chloroform and
transferred to a 1.5ml reaction tube containing 200pl binding buffer and 3 pi glass milk
(Prep-a-Gene kit, Promega). The sample was incubated at room temperature for 20
minutes to allow the DNA to bind to the glass milk. The glass milk binds DNA fragments
greater then 200 bases in length. This sample was centrifuged at 11,600 x g for 2 minutes,
the supernatant fluid removed and the pellet resuspended in 500pl wash buffer. This wash
process was repeated twice more. The final pellet was resuspended in 16pl dtLO and
incubated at room temperature for 20 minutes to allow release of the DNA from the glass
milk. The purified DNA was collected by centrifugation at 11,600 x g for 30 seconds and
the supernatant fluid, containing purified DNA, transferred to a clean tube. The purified
DNA was quantified by loading Ipl DNA with 3 pi BPB dye on an agarose gel. After
electrophoresis the DNA was quantified approximately by visual inspection (a visual band
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was approximately 50-100ng). Approximately lOOng of purified DNA were then used in 
sequencing reactions.
DNA sequencing primers
Messenger-RNA sense and antisense primers were used for nucleotide analysis of the HN 
and F genës. The primers were prepared for use as described previously. A fist of the 
primers, their positions in relation to the genes and their nucleotide sequences can be found 
in the Materials section.
Radiolabelling of oligonucleotide primers (primer kinàtion) (Maxam and Gilbert, 1980)
Three microlitres of primer, 2pl dHjO, Ipl lOx polynucleotide kinase (PNK) buffer 
(Pharmacia Biotech), 3 pi y-P32 ATP and Ipl T4PNK enzyme (Pharmacia Biotech at 1000 
units/pl) were added to a reaction tube, mixed and incubated at 37°C for 12 minutes. The 
mixture was then incubated for 30 seconds at 90°C to inactivate the enzyme and used in 
sequencing reactions.
Sequencing reactions
To a reaction tube, 2.3pl of lOxSuper Taq PCR buffer (HT Biotechnology), 3.3pl dH^D, 
1.5pl of radiolabelled oligonucleotide primer and 0.1 pi Super Taq enzyme (HT 
Biotechnology), were added and mixed. Seven microlitres of this mixture were added to a 
reaction tube containing 4.0pl of purified DNA and mixed well. Two microlitres of this 
mixture were then transferred to each of four 0.5ml reaction tubes containing one of the 
four ddNTPs mixtures (A, C, G or T) and mixed well. One drop of paraffin oil was added 
to the samples, to prevent evaporation and the sequencing reactions subjected to 
amplification for twelve cycles of 94°C for 60 seconds, 50°C for 30 seconds and 72°C for 
60 seconds. Two microlitres of formamide dye were then added to each tube and the 
sequence reactions were stored at -20°C until used.
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Polyacrylamide gel electrophoresis
Two glass plates (20cm x 38cm x 0.4cm) were cleaned thoroughly and wiped with ethanol. 
One of the plates was coated with wacker solution and the second plate was coated with 
Repelcote (BDH Silicone Products), a water repellent. The plates were taped together to 
ensure no leakage of gel, wacker and repelcote sides facing together and separated with 
spacer strips (approximately 0.5mm thick).
The sequence gel mix was prepared and immediately prior to use, 500pl 10% ammonium 
persulphate, BDH Chemicals and 14pl N,N,N%N"-tetramethylethylenediamine (TEMED, 
Sigma) were added to the gel mix. The gel mix was poured carefully between the glass 
plates, a comb inserted and held in place with clips. After polymerisation, the tape was 
removed from the bottom of the plates, the gel placed in a gel tank with IxTBE buffer, the 
comb slowly removed and the wells washed out with buffer.
Prior to sample loading the gel was pre-run for 30 minutes at a voltage of < 1,000V. 
Sequencing reaction samples were incubated in a boiling water bath for two minutes and 
placed directly on ice. One microhtre of each sequence reaction sample (A, C, G and T) 
was then loaded into each of four consecutive wells and electrophoresis performed at 
1,300V for varying lengths of time, depending on the length of product under analysis 
(approximately 2-4 hours). After electrophoresis the gel was fixed in 10% glacial acetic 
acid for 20 minutes, rinsed in H2O for 10 minutes to remove traces of urea and dried. An 
X-ray film was placed on top of the gel and placed in an autoradiograph cassette until 
ready to be developed.
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2.2.14 NUCLEOTIDE SEQUENCING, using the ABI PRISM 310 GENETIC 
ANALYSER
Purification of the PCR product
Thirty microhtres of PCR product were added to 5 pi BPB dye and loaded onto a midi-gel 
prepared as follows; 1% agarose in IxTBE with 30pi ethidium bromide per 100ml agarose. 
The gel was electrophoresed at 60V for 60 minutes. DNA bands were visualised using an 
UV transilluminator, excised from the gel and placed in 1.5ml reaction tubes.
The PCR product was cleaned using a Nucleiclean kit obtained from SIGMA. The 
Nucleiclean kit provides a fast and simple method for the isolation of DNA or RNA from 
agarose gels. Five hundred microhtres of salt buffer (Nucleiclean kit, SIGMA) were added 
to each sample and the gel left to dissolve at 35°C for 30 minutes. Five microhtres of glass 
beads (Nucleiclean kit, SIGMA) were then added, each sample was vortexed and incubated 
at room temperature for 5 minutes to allow DNA to bind to the glass beads. The samples 
were centrifuged at 11,600 x g for 10 seconds, the supernatant fluid removed and 500pl 
wash buffer (Nucleiclean kit, SIGMA) added. The pehet was resuspended and centrifuged 
at 11,600 x g for 10 seconds. The wash process was repeated a further two times. After 
the final wash, the glass beads were resuspended in lOpl dHzO and incubated at room 
temperature for 5 minutes to allow release of the DNA from the glass beads. The sample 
was then centrifuged for 10 seconds at 11,600 x g and the resultant supernatant fluid 
containing DNA transferred to a clean tube and stored at -20°C until used for sequencing 
reactions.
Oligonucleotide primers
Oligonucleotide primers used were the same as described previously.
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Sequencing reactions
Sequence reactions were carried out using the dRhodamine Big Dye terminator cycle 
sequencing kit, (PE Applied Biosystems). To a 0.5ml reaction tube, 50-lOOng of purified 
PCR product, 1 pi of a 3.2pmole oligonucleotide primer dilution and 8pi terminator ready 
reaction mix (PE Applied Biosystems) were added. The quantity was made up to 20pl 
with dHiO, mixed well and overlaid with 40pl paraffin oil. The terminator ready reaction 
mix contained four dideoxynucleotide terminators each separately labelled with a 3’- 
fluorescent dye, instead of the radioactive labels. The reactions were then subjected to 
amplification with the following conditions; 96°C for 1 minute and then twenty-five cycles 
of 96°C for 10 seconds and 55°C for 3 minutes.
Purification of extension products
To remove excess dye terminators and salt, both of which lowered the quality of the 
extension products, the reaction mixtures were subjected to an ethanol/sodium acetate 
precipitation procedure. For this, the 20pl extension product was transferred to a 0.5ml 
reaction tube containing 200pl ethanol, lOpl 3M sodium acetate and 70pl dl^O. This 
mixture was left on ice for 10 minutes to allow precipitation of the DNA. The sample was 
centrifuged for 20 minutes at 4°C at 11,600 x g and washed twice in ice cold 70% ethanol. 
After the second wash, the pellet was air dried and then resuspended in 20pl template 
suppression reagent (ABI Prism kit, Perkin Elmer). The samples were heated to 96°C for 
10 minutes prior to analysis in the ABI Prism 310 Genetic Analyser.
The ABI Prism 310 Genetic Analyser
The ABI Prism 310 Genetic Analyser, obtained from Perkin Elmer, was prepared 
according to the manufacturer guidelines. The genetic analyser is an automated instrument 
system capable o f determining nucleotide sequences. After the DNA fragments are 
labelled, the genetic analyser automatically introduces the samples into a polymer filled
78
capillary for electrophoresis. The dye-labelled DNA fragments electrophorese through the 
polymer and separate according to size. A laser illuminates the samples, the fluorescent 
dyes become excited and emit a light at a specific wavelength. The fluorescent signal is 
collected and separated by a spectrograph according to wavelength and at the end of the 
run the computer automatically analyses the collected data.
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CHAPTER in
GROWTH OF MuV IN DIFFERENT CELL SUBSTRATES
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3.1 INTRODUCTION
Propagation of MuVs in Vero or CEF cells can alter their phenotypic and genotypic 
characters (Yates., 1995, Afzal et al., 1998). For example, after two passages of the Urabe 
strain of MuV in Vero cells, the lysine at position 335 in the HN gene was replaced by 
glutamic acid, whereas, after two passages in CEF cells, no selection occurred (Yates, 
1995). The Jeryl Lynn (JL) virus is heterogeneous, being composed of two variants, JL-2 
and JL-5 (Afzal et al., 1993). After passage of the JL virus in Vero cells, JL-2 outgrew JL- 
5. In contrast, JL-5 outgrew JL-2 after passage in CEF cells (Afzal, unpublished data).
The aim of this chapter is to determine whether an alternative cell line to Vero cells is 
available and appropriate for studying MuVs in vitro. An appropriate, alternative cell line 
is one in which infectious virus progeny is produced and where no, or little, genetic or 
phenotypic variation from the parental virus occurs.
3.2 EXPERIMENTAL PROCEDURES
JL-2, JL-5, Ur PT1, Ur PT3, Enders, Rubini and Pol5/t (prepared in Vero cells as 
described in Chapter II and summarised in Table 3.1) were passaged five times in five 
different cell lines; B95a, BCL, CEF, HeLa and MRC-5 (Chapter II).
Table 3.1: Passage histories of the Vero-grown parental viruses.
Virus Passage History
JL-2 From CEP-derived JL vaccine plaque purified three times in Vero cells
JL-5 From CEF-derived JL vaccine plaque purified three times in Vero cells
UrPTl From CEF-derived Urabe vaccine plaque purified three times in Vero cells
Ur PT3 From CEF-derived Urabe vaccine plaque purified three times in Vero cells
Enders Passaged twice in Vero cells
Rubini From MRC-5-derived vaccine and passaged 5 times in Vero cells
Pol5/t Wild-type virus, isolated by three passages in Vero cells
The viruses were grown on the different cell lines at an approximate multiplicity of 
infection (MOI) of 0.0002 (1 virus particle per 5000 cells). After an adsorption period of
2 -3  hours the inoculum was aspirated and replaced with fresh maintenance medium 
(Chapter II). BCL cells grow in suspension and hence, virus at a MOI of 0.0002, was 
added into a freshly sub-cultured cell suspension and not aspirated after the adsorption 
period. The virus progeny were harvested, as described in Chapter U, when either 80-90% 
CPE was observed or after 10  days, if no CPE was observed. The progeny virus was 
passaged a further four times using the same procedure.
Cytopathic effect observed during virus passage was recorded for type and for the time 
taken (in days) between inoculation and appearance of CPE. The TCID50 assay, performed 
on Vero cells (Chapter II) was used to determine the infectivity titre of virus after each 
passage level, and the infectivity titre was expressed in logic T d D 5o/ml. Where a virus 
titre was <3 logm TCIDso/ml, the inoculum volume used for further passage was increased, 
to attempt to increase production of infectious virus. The haemagglutination (HA) and 
neuraminidase (NA) activities of the viruses were analysed after each passage level and the 
ratios between TCID50 and HA, TCID50 and NA, and HA and NA were also calculated.
3.3 RESULTS
3.3.1 CYTOPATHIC EFFECT OF MuV on its HOST CELL
Cytopathic effect is defined as any observed histological affect caused to cells when 
infected by a virus.
When grown in B95a cells (Figure 3.1) all viruses caused CPE at each passage level. 
Cytopathic effect became visible on the fifth day during the first passage in B95a cells but 
appeared earlier after subsequent passages until CPE was observed after the third day for 
fifth-passage virus. Cytopathic effect caused by JL-2, JL-5, Enders, Rubini and Pol5/t was 
observed as multiple cell fusion, resulting in the appearance of multinucleated cells, cell 
death and in the production of formations of cells called spindle cells (Figure 3.2).
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Cytopathic effect caused by Ur PT1 and Ur PT3 was mainly in the form of cell death; some 
cell fusion was observed but spindle cells were not formed (Figure 3.3).
The various MuVs, during the first passage in HeLa cells, caused CPE in the form of cell 
death and minimal cell fusion. However, during further passage increased cell fusion was 
observed. In contrast to the other viruses, Ur PT1 and Ur PT3 caused less cell fusion. 
Cytopathic effect was initially observed 5 days post inoculation; after further passage CPE 
was observed 3 days post inoculation.
No CPE was observed in MuV-infected BCL, CEF or MRC-5 cells.
3.3.2 EFFECT of CELL PASSAGE on MuV INFECTIVITY TITRES 
Infectivity titres were measured for the Vero-grown parental viruses. The TCIDso/ml of Ur 
PT1 and Ur PT3 were the highest at 6.16 logio and 6.01 logio, respectively (Table 3.2). 
The infectivity titre of Enders was intermediate at 5.11 logio and the infectivity titres of JL- 
2, JL-5, Rubini and Pol5/t were slightly lower at 4.6 logio, 4.72 logio and 4.36 logio 
respectively. The infectivity of each virus after each passage in each cell line was 
determined and the results are presented in Table 3.2 and are summarised in Table 3.3. 
Assays were performed in duplicate and an average value taken as the TCIDso/ml. 
Significant changes in infectivity titre were taken to be where an increase or decrease of > 
1 logio in the value of TCIDso/ml was observed.
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Figuré 3.1: A confluent uninfected B95a cell monolayer. The stippling effect observed is 
an artefact.
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Figure 3.2: Cytopathic effect observed when B95a cells were infected with End«s; similar 
cytopathic effect was observed when B95a cells were infected with JL-2, JL-5, Rubini and
Pol5/t.
Spindle cell Multinucleated
cells
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Figure 3.3: Cytopathic effect observed when B95a cells were infected with U rPT l; a 
similar effect was observed when B95a cells were infected with Ur PT3.
Fused cells
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Table 3.2: Infectivity titres, expressed in logio TCIDso/ml, of the parent and progeny
viruses after passage in different cell lines.
VIRUS LOGio CELL LOG,0 TITRE at PASSAGE LEVEL
TITRE1 LINE PI P2 P3 P4 P5
JL-2 4.60 B95a 4.42 4.96 7.06 6.94 5.86
BCL 2.11 2.11 2.11 2.11 2.11
CEF 3.22 2.11 2.11 2.11 2.11
HeLa 2.38. 5.32 5.14 5.86 5.44
MRC-5 2.11 2.11 2.11 2.11 2.11
JL-5 4.72 B95a 2.11 2.11 5.26 6.10 6.94
BCL 2.11 2.11 2.11 2.11 2.11
CEF 2.18 2.11 2.11 2.11 2.11
HeLa 2.44 2.80 4.90 6.28 6.22
MRC-5 2.11 2.11 2.11 2.11 2.11
UrPTl 6.16 B95a 5.62 6.28 6.10 6.82 7.42
BCL 4.42 4.06 2.44 2.11 2.11
CEF 2.38 5.80 2.11 2.11 2.11
HeLa 5.14 5.92 5.50 6.28 7.24
MRC-5 2.11 2.11 2.11 2.11 2.11
Ur PT3 6.01 B95a 6.64 6.34 5.44 5.58 7.06
BCL 3.28 2.11 2.11 2.11 2.11
CEF 3.28 2.11 2.11 2.11 2.11
HeLa 4.90 5.74 6.70 7.36 6.88
MRC-5 2.11 4.12 4.18 3.28 5.20
Enders 5.11 B95a 5.98 5.08 6.28 6.28 7.42
BCL 2.11 2.11 2.11 2.11 2.11
CEF 2.80 2.11 2.11 2.11 2.11
HeLa 2.38 2.80 4.90 6.55 6.88
MRC-5 2.11 2.11 2.11 2.11 2.11
Rubini 4.32 B95a 5.32 5.20 4.77 6.58 6.34
BCL 2.74 2.11 2.11 2.11 2.11
CEF 2.11 2.11 2.11 2.11 2.11
HeLa 2.11 3.28 3.82 6.22 6.64
MRC-5 2.11 4.00 2.11 2.11 2.11
Pol5/t 4.36 B95a 5.20 4.96 7.00 7.18 6.58
BCL 2.11 2.11 2.11 2.11 2.11
CEF 2.11 2.11 2.11 2.11 2.11
HeLa 2.92 3.22 6.88 6.58 5.20
MRC-5 2.11 2.11 2.11 2.11 2.11
1 Titre o f Vero-grown parental virus
87
Table 3.3: Summary of the results of MuV passage in different cell lines.
CELL VIRUS PASSAGE LEVEL
. LINE PI P2 P3 P4 P5
B95a JL-2 j - Î2 Î Î
JL-5 i 3 1 - Î Î
UrPTl - - - Î
Ur PT3 - - - Î
ENDERS - - Î Î Î
RUBINI - - - Î Î
Pol5/t - - Î Î
BCL JL-2 i 1 i 1 I
. JL-5 i I 1 i i
UrPTl i i 1 i
Ur PT3 i i I I 1
ENDERS 1 i i Ï i
RUBINI 1 i i i i
Pol5/t I 1 i i i
CEF JL-2 i i 1 i i
JL-5 i i I I
UrPTl i I ! I
UrPT3 I Ï I i I
ENDERS i i i i I
RUBINI 1 I i
Pol5/t i i i i
HeLa JL-2 i - Î
JL-5 I i - Î T
UrPTl i - Î
Ur PT3 - Î
ENDERS I i - T Î
RUBINI i i - Î Î
Pol5/t i i Î Î
MRC-5 JL-2 i i 1 Ï
JL-5 i 1 i
UrPTl i Ï i i i
Ur PT3 i i i i
ENDERS i i i i i
RUBINI i - i i I
Pol5/t i 1 1 1 I
1 No significant difference from the titre of Vero-grown parental virus
2 Significant increase from the titre of the Vero-grown parental virus
3 Significant decrease from the titre of the Vero-grown parental virus
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B95a-derived MuVs
After five passages in B95a cells, all the MuVs had increased infectivity in comparison to 
their Vero-grown parental viruses (Table 3.2 and 3.3 and Figure 3.1).
Growth of the 7 MuVs in B95a cells appeared to stimulate the production of actively 
replicating progeny with significantly higher infectivity titres (by 1-2 logio TCIDso/ml), 
than their respective parent virus (Tables 3.2 and 3.3). No apparent adaptation period was 
observed, with the possible exception of the JL-5 virus. The infectivity of this JL-5 virus 
dropped, by a significant value, for the initial two passages and then increased, suggesting 
adaptation to the cell line on, or after, the third passage. All other viruses increased in 
infectivity over increasing passage without an initial period of decreased infectivity.
HeLa-derived MuVs
In addition to B95a cells, growth in HeLa cells also appeared to support active replication 
of the 7 MuVs, with significantly higher infectivity titres for 4 of the MuVs when 
compared to the Vero grown parental, after an initial lag period of decreased infectivity 
(Tables 3.2 and 3.3 and Figure 3.2). The initial decreased infectivity, followed by an 
increase after the third passage, suggests the occurrence of adaptation to the cell line by the 
viruses. After the fourth passage, six of the MuVs had significantly higher infectivity titres 
than their respective parental virus, this value then appeared to plateau, with only four of 
these viruses having significantly higher infectivity titres after the fifth passage.
Growth of MuV in BCL, CEF or MRC-5 cells
After five passages in BCL and CEF cells, all the MuVs had decreased infectivity in 
comparison to their Vero-grown parental Viruses (Tables 3.2 and 3.3). After five passages 
in MRC-5 cells, all the MuVs, bar one (Ur PT3), had decreased infectivity in comparison 
to their Vero-grown parental viruses; Ur PT3 had a similar level of infectivity to its Vero- 
grown parent (Table 3.2). The titres observed probably arise from remaining input virus
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Figure 3.4: Growth of MuV in B95a cells
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Figure 3.5: Growth of MuV in HeLa cells
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(with the exception of Ur PT3 grown in MRC-5 cells) and it is likely that no productive 
replication was taking place.
3.3.3 EFFECT of CELL PASSAGE on MuV HA TITRES
Haemagglutination assays were performed as described in Chapter II at 4°C to avoid 
interference of haemagglutination by neuraminidase activity and were performed on all 
Vero-grown viruses and their progeny from each passage level. Neat tissue culture 
supernatant from infected cells was assayed and four species of erythrocyte, turkey, sheep, 
horse and monkey, were employed. Turkey erythrocytes are routinely used for assessing 
the HA titre of MuV and influenza viruses. Sheep, horse and monkey erythrocytes were 
included in this assay to determine if  any significant differences in HA occur with the use 
of these erythrocytes, in comparison to the turkey erythrocytes.
Results of the HA assays performed on the parental viruses are presented in Table 3.4 (A 
and B). No HA activity was detected for the JL-2 parental virus, whilst JL-5 had an 
average HA titre of 8 HAU. The HA of Ur PT1 ranged from 2 HAU with horse RBCs to 
16 HAU with sheep RBCs, whilst the HA titre of Ur PT3 was several fold higher at 64 
HAU. Enders had an HA titre of between 16 to 32 HAU, whilst Rubini had a higher HA 
titre of 64 HAU. Pol5/t had a range of HA titres from undetectable with horse RBCs to 16 
HAU with monkey and sheep RBCs. These results suggested that HA assays performed 
with horse erythrocytes may give poor results for Ur PT1 and Pol5/t progeny viruses and 
that JL-2 progeny viruses could also give poor results with all four RBC types. Significant 
changes in HA activity were taken where a > 4-fold increase or decrease was observed 
between parent and progeny viruses.
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Table 3.4: Results of the HA assays performed on virus progeny. HA assays were 
performed at 4°C, using four species of erythrocyte.
A) HA assay results for MuV grown in B95a cells.
. VIRUS RBC1 PO2 PI P2 P3 P4 P5
JL-2 Turkey _3 64 - 4 32 4
Sheep - 64 2 16 32 8
Horse - 64 - - 32 2
Monkey - 64 I4 16 16 4
JL-5 Turkey 8 - - - 16 32
Sheep 16 - - 32 64 64
Horse 4 - - - 32 64
Monkey 8 - - - 16 32
U rPTl Turkey 4 - 16 8 8 32
Sheep 16 - 16 16 16 32
Horse 2 - 1 - - -
Monkey 8 2 2 16 16 32
Ur PT3 Turkey 64 64 64 64 64 64
Sheep 64 64 128 128 128 64
Horse 64 8 8 8 16 16
Monkey 64 64 128 256 128 64
Enders Turkey 16 32 32 64 16 64
Sheep 32 16 32 128 16 64
Horse 16 16 16 64 8 64
Monkey 16 32 32 64 16 64
Rubini Turkey 64 32 64 32 16 16
Sheep 64 32 64 32 16 16
Horse 64 32 64 16 16 16
Monkey 64 64 64 16 16 16
Pol5/t Turkey 4 16 8 8 32 4
Sheep 16 32 16 16 64 8
Horse - - - - - -
Monkey 16 32 16 16 64 16
1 RBC = Red blood cell
2 PO = Vero-grown parental virus
3 - = Negative
4 1 = Neat only was positive for haemagglutination
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Table 3.4 continued:
B) HA assay results for MuV grown in HeLa cells.
VIRUS RBC1 PO2 PI P2 P3 P4 P5
JL-2 Turkey 3 - 8 32 16 32
Sheep - - 8 32 32 32
Horse - - 4 16 16 16
Monkey — - 8 16 16 32
JL-5 Turkey 8 - - - 8 32
Sheep 16 - - 2 16 32
Horse 4 - - - - 8
Monkey 8 - I4 2 8 32
U rPTl Turkey 4 2 8 4 32 16
Sheep 16 1 8 16 64 32
Horse 2 - - - - -
Monkey 8 4 8 16 32 16
Ur PT3 Turkey 64 4 16 64 64 64
Sheep 64 2 16 64 64 64
Horse 64 - - 16 32 32
Monkey 64 16 16 64 128 64
Enders Turkey 16 - - 32 32 128
Sheep 32 - - 16 32 128
Horse 16 - - 8 16 64
Monkey 16 4 1 16 16 64
Rubini Turkey 64 16 - 4 32 32
Sheep 64 16 - 4 32 64
Horse 64 8 - - 32 32
Monkey 64 16 4 16 32 32
Pol5/t Turkey 4 - 4 16 - -
Sheep 16 32 16 16 64 8
Horse - - - - - -
Monkey 16 8 8 16 64 16
1 RBC = Red blood cell
2 PO = Vero-grown parental virus
3 - = Negative
4 1 = Neat only was positive for haemagglutination
M
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B95a-derived and HeLa derived MuVs
In addition to increased infectivity titre, as measured by the TCID50 assay, growth of the 7 
MuVs in B95a or HeLa cells appeared to promote the production of progeny virus with 
identical or increased ability to cause haemagglutination in comparison to their parent 
viruses. The main example being JL-2, which was negative for haemagglutination prior to 
passage in B95a or HeLa cells (Tables 3.4A and B), but after passage caused 
haemagglutination up to 64 HAU.
No significant difference in HA activity was detected for MuVs, Ur PT3, Enders and 
Rubini after passage in B95a cells (Table 3.4A). Significant changes were detected for the 
other MuVs during passage in B95a cells (Table 3.4A), however, after the fifth passage, 
only the HA titre of JL-2 was significantly different to that of the Vero-grown parent with 
all four RBC types.
Significant decreases in HA activity were observed for all the MuVs after the initial 
passages in HeLa cells (Table 3.4B), corresponding to initial decrease in TCIDso/ml titre 
(Tables 3.2 and 3.3). The HA activity of all viruses then increased to a level not 
significantly different to the level of the respective parent virus, with the exception of JL-2. 
The JL-2 progeny had significantly higher HA activity than its parent virus.
After passage in B95a or HeLa cells, no haemagglutination was observed for Ur PT1 and 
Pol5/t with horse RBCs.
BCL, CEF and MRC-5 derived MuVs
No haemagglutination activity was detected for any virus derived from passage in BCL, 
CEF or MRC-5 cells, with any of the erythrocyte species.
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3.3.4 The RELATIONSHIP BETWEEN TCID50 and HA
A TCID50/HA ratio was calculated to determine if, over the five passages, there was any 
significant difference in the amount of TCID50 units per HA unit. The relationship between 
TCID50 and HA was determined after each passage of viruses in B95a and HeLa cells. The 
ratio was calculated by dividing the value for TCID50 titre (fable 3.2) by an average value 
of HA titre (Table 3.4), excluding the values for horse RBCs because considerably lower 
results were observed with these erythrocytes with some viruses.
The value for the ratio of the parent viruses (Tables 3.5A and B) varied by > 3 logio and 
was incalculable for JL-2, due to the absence of HA activity. However, after the fifth 
passage in B95a cells (Table 3.5A) the ratios were similar for all the viruses, ranging from 
5.15 logio to 5.91 logio- After five passages in HeLa cells (Table 3.4B) the TCID50/HA 
values were also higher than the original Vero-grown parental values, ranging from 4.08 
logio to 5.91 logio.
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Table 3.5A: Calculated ratio of TCID50/HA for each virus passaged in B95a cells. Values
are express in Logio.
VIRUS PASSAG]E LEVEL
PO1 1 2 3 4 5
JL-2 _i 2.61 4.96 5.98 5.52 5.15
JL-5 3.69 - - 4.23 4.59 5.30
U rPTl 5.18 5.80 5.23 4.97 5.70 5.91
Ur PT3 5.20 4.83 4.32 3.26 3.56 5.26
Enders 3.78 4.54 3.58 4.34 5.08 5.61
Rubini 2.52 3.69 3.40 . 4.34 5.38 5.15
Pol5/t 3.28 3.77 3.83 5.88 5.45 5.61
'PO, parental virus, prior to passage
2-, incalculable, due to the absence of HA activity
Table 3.5B: Calculated ratio of TCID50/HA for each virus passaged in HeLa cells. Values 
are expressed in Logio-
VIRUS PASSAG]E LEVEL
P01 1 2 3 4 5
JL-2 _i - 4.41 3.63 4.62 4.36
JL-5 3.69 - 3.28 4.78 5.26 5.43
U rPTl 5.18 4.78 5.56 4.41 4.65 5.91
Ur PT3 5.20 4.04 4.53 4.89 5.43 4.08
Enders 3.78 2.26 .3.28 3.57 5.11 4.85
Rubini 2.52 0.91 3.15 2.92 4.72 5.00
Pol5/t 3.28 1.78 2.26 5.67 4.95 4.30
1 PO, Parental virus, prior to passage
2 -, incalculable, due to absence of HA activity
96
3.3.5 EFFECT of CELL PASSAGE on MuV NA ACTIVITY
Neuraminidase assays were performed as described in Chapter EL Neuraminidase activity 
was detected only for Vero-grown parental viruses Enders and Rubini; both had an NA 
titre of 8 (Table 3.6). Significant changes in NA activity between viruses were taken to be 
where a > 4-fold change was observed.
B95a-derived MuVs
In addition to increasing TCID50 titres and HA titres, growth of the 7 MuVs in B95a cells 
appears to produce progeny viruses with an increased neuraminidase activity (Table 3.6), 
than their respective parent virus. After five passages in B95a cells, all the MuVs, except 
for Rubini, had increased NA in comparison to their Vero-grown parental viruses. The NA 
activity of Rubini was similar to its parental virus.
The NA activity of JL-2, JL-5 and Pol5/t became detectable at the third passage (Table 
3.6), the NA activity of Ur PT1 and Ur PT3 became detectable after the first and second 
passages respectively (Table 3.6) and remained positive thereafter. NA activity was 
detected in Enders and Rubini at each passage level. The NA titre of Enders virus, derived 
after three and five passages, had a NA titre of 128 NAU and 64 NAU respectively, the 
highest value of all viruses studied (Table 3.6).
HeLa-derived MuVs
Corresponding to the apparent adaptation period (as determined by the TCED50 assay) for 
MuV growth in HeLa cells, NA activity was only observed after the third or fourth passage 
for all MuVs (Table 3.6). Thereafter, for most of the viruses, NA activity was retained at a 
similar level, with the exception of Pol5/t, where NA activity was detected at its third 
passage only and not thereafter (Table 3.6). For all the MuVs, bar Rubini and Pol5/t, the 
NA activity after the fifth passage was significantly higher than that of their parent virus.
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Table 3.6: Neuraminidase assay results
CELL VIRUS PASSAG]E LEVEL
LINE PO1 PI P2 P3 P4 P5
B95a JL-2 ND3 - 4 4 1
JL-5 - ND - 1 8 8
U rPTl - - 1 4 2 8
UrPT3 - 16 8 16 16 8
Enders 8 16 32 128 16 64
Rubini 8 32 16 16 8 16
Pol5/t - ND - 2 8 8
BCL JL-2 - ND - - - -
JL-5 - ND - - - -
U rPT l - ND - - - -
UrPT3 - ND - - - -
Enders 8 ND - - - -
Rubini 8 ND - - - -
Pol5/t - ND - - - -
CEF JL-2 - ND - - - -
JL-5 - ND -  • - - -
U rPTl - ND - - - -
UrPT3 - ND - - - ' -
Enders 8 ND - - - -
Rubini 8 " ND 4 - - -
Pol5/t - ■ND - - - -
HeLa JL-2 - ND - 16 16 8
JL-5 - ND - - 16 8
U rPTl - ND - -  - 4 4
Ur PT3 - ND - 8 8 8
Enders 8 ND - 8 16 64
Rubini 8 ND - 2 32 32
Pol5/t - ND - 8 - -
MRC-5 JL-2 - ND - - - -
JL-5 - ND - - - -
U rPT l - ND - - - -
Ur PT3 - ND - - - -
Enders 8 ND - - - -
Rubini 8 ND 4 1 - -
Pol5/t - ND - - - -
*P0, Vero-grown parental virus
2 -, Negative
3 ND, Not done
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BCL, CEF and MRC-5 -derived MuVs
No NA activity was detected for JL-2, JL-5, Ur PT1, Ur PT3, Enders and Pol5/t derived 
from passage in BCL, CEF or MRC-5 cells (Table 3.6).
No NA activity was detected either for Rubini derived from passage in BCL cells. 
However, NA activity was detected for Rubini, after the second passage in CEF cells only 
and after the second and third passage in MRC-5 cells only but thereafter was not detected 
(Table 3.6). The detected activity was likely remaining from input virus.
3.3.6 The RELATIONSHIP BETWEEN TCID50 and NA ACTIVITY
A TCID50/NA ratio was calculated to determine if, over the five passages, there was any 
significant difference in the amount of TCID50 units per NA unit. The ratio of TCID50/NA 
was calculated for each virus grown in B95a and HeLa cells by dividing the TCIDso/ml 
(Table 3.2) by the NA titre (Table 3.6).
The value of the ratio for the parental viruses was incalculable due to the absence of NA 
activity, with the exception of Enders and Rubini (Table 3.7A and B). After five passages 
in B95a and HeLa cells, the amount of TCID50 units per NA unit for each of the MuVs 
ranged from 5.15 logio to 6.51 logio in B95a cells and from 4.53 logio to 6.63 logio in HeLa 
cells (Table 3.7A and B), with the exception of Pol5/t grown in HeLa cells, where the ratio 
was incalculable due to an absence of NA activity.
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Table 3.7A: Ratio of TCID50/NA for each virus passaged in B95a cells. Values are
expressed in Logio-
VIRUS PASSAGE LEVEL
P0l PI P2 P3 P4 P5
JL-2 - - 6.46 6.34 5.86
JL-5 - - - 5.26 5.20 6.04
U rPTl - - 6.28 5.49 6.52 6.52
UrPT3 - 5.43 5.43 4.23 4.38 6.15
Enders 4.20 4.78 3.56 4.18 5.08 5.62
Rubini 3.41 3.81 4.00 3.57 5.68 5.15
Pol5/t - - - 6.70 6.28 5.68
1 PO, Vero-grown parental virus
2 -, Incalculable due to absence of neuram inidase activity
Table 3.7B: Ratio of TCID50/NA for each virus passaged in HeLa cells. Values are 
expressed in Logio.
VIRUS PASSAGE LEVEL
P01 PI P2 P3 P4 P5
JL-2 - - 3.93 4.65 4.53
JL-5 - - - - 5.08 5.32
U rPTl - - - - 5.68 6.64
UrPT3 - - - 5.80 6.46 5.98
Enders 4.20 - - 4.00 5.34 5.08
Rubini 3.41 - - 3.52 4.72 5.15
Pol5/t - - - 5.98 - -
1 PO, Vero-grown parental virus
2 -, Incalculable due to absence o f neuram inidase activity
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3.4 DISCUSSION
In this study, seven MuV strains have been passaged five times in five different cell lines 
to increase our understanding of the effect of host cell passage on MuVs. The infectivity 
of the progeny from these passages was determined using the TCID50 assay. The HA and 
the NA assays were used to determine whether non-infectious virus particles were present, 
which were not detected by the TCID50 assay.
3.4.1 CHOICE OF CELL LINE
To increase the understanding of host cell passage, MuVs Were grown in a variety of 
different cell substrates. The cell lines chosen for use in this study were B95a, BCL, CEF, 
HeLa and MRC-5 cells.
B95a cells are a marmoset lymphoid cell line transformed with EBV and have previously 
been shown to support the growth of other paramyxoviruses, such as measles virus (MV) 
(Kobune et al.9 1990). Indeed, MV grown in B95a cells was more representative of MV 
circulating among humans than MV grown in Vero cells (Kobune et al., 1990). Rinderpest 
virus (RPV) and canine distemper virus (CDV), other paramyxoviruses of the morbillivirus 
genus, have also been grown in B95a cells (Kobune et al., 1991; Kai et al., 1993); again, 
the B95a-derived virus was more representative of the parental population than Vero- 
derived virus. Measles virus, RPV and CDV grown in B95a cells retained virulence for 
monkeys, rabbits and dogs respectively, whereas Vero grown virus became less virulent. 
Hence, growth of MuV in these cells was investigated to determine if  B95a-derived virus 
differed from Vero-derived virus. '
BCL cells are a murine lymphocytic cell line. Studies of the replication of MuV in murine 
cells (Tsurudome et al., 1984) showed that full replication of MuV was possible despite 
other reports that propagation o f MuV in murine cells led to abortive infections (Cantell et 
al., 1961). The study by Tsurudome et al (1984) also suggested that murine cells of
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lymphoid origin supported growth better than other murine derived cells. The BCL cells 
used in this project were interferon (TFN) negative (A. Meager, personal communication); 
this property possibly increased the potential for productive replication of MuVs in these 
cells because IFN, produced by cells in response to a virus infection, acts to eliminate 
virus.
Chicken embryo fibroblast (CEF) cells were used in this project because JL-2, JL-5, Ur 
PT1 and Ur PT3 had previously been exposed to these cell lines in the original production 
of the JL and Urabe live attenuated vaccine strains. Hence, it was likely that these viruses 
and the other MuVs would propagate on these cells. Also, growth of Urabe in these cells 
affected its phenotypiu and genotypic characteristics (Afzal et al., 1998); therefore, it was
of interest to determine if growth in CEF cells affected the various other MuV strains.
)
HeLa cells are of human tumour origin and were originally epithelial cells. Epithelial cells 
are the sites of MuV infection of humans (Feldman et al., 1989) and potentially the viruses 
could propagate efficiently in this cell line.
MRC-5 cells are diploid cells of foetal human lung origin and were used in this project 
because the Rubini strain had been propagated on these cells to produce the vaccine, and it 
was hoped that other MuVs might also grow in these cells.
3.4.2 CYTOPATHIC EFFECT
Cytopathic effect is defined as the histological appearance of damage produced in cultured 
cells by an infecting virus and is an indication of virus infectivity for the cell line. CPE 
manifested itself as cell death and cell fusion; enlarged cell formations with many nuclei, 
known as syncytia after passage in B95a and HeLa cells. CPE was not observed in BCL, 
CEF or MRC-5 cells infected with MuV, suggesting that no active replication was 
occurring. CPE could have developed in these cell lines after further passage and 
adaptation of the viruses to the cells. The extent of CPE differed with less cell fusion and
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no production of spindle cells occurring in B95a or HeLa cells infected with Ur PT1 or Ur 
PT3, unlike infection with the other viruses. The protein most likely to manifest these 
observations is the F protein, which is responsible for virus-to-cell fusion (fusion from 
without) and cell-to-cell fusion (fusion from within). It is also likely that the HN protein 
plays an equal role in cell fusion.
3.4.3 PROPAGATION of MuV in ALTERNATE CELL LINES
One measure of virus infectivity is the TCID50 assay. TCID50 assays were performed using 
Vero cells; hence, if viruses were produced after passage, which were not infectious for 
Vero cells, they would not be detected in the assay. Therefore, HA and NA assays were 
used in addition to determine if such virus was present. The results of this chapter are 
summarised in Table 3.8.
The TCID50 results indicate three outcomes from propagating MuV in alternate cell lines:
• A decrease in infectivity, followed by an increase, suggesting an adaptation event (JL- 
5 in B95a cells, all MuVs in HeLa cells and Ur PT3 in MKC5 cells).
• An increase in virus infectivity with no prior decrease (all viruses in B95a cells, except 
JL-5), suggesting an increasing fitness for the cell line.
• A decrease in virus infectivity (MuVs in BCL, CEF and MRC-5 cells (except Ur 
PT3)).
For yow th of JL-5 in B95a cells (Figure 3.4A), all the MuVs in HeLa cells (Figure 3.4D) 
and Ur PT3 in MRC-5 cells (Figure 3.4E), an apparent period of adaptation was required. 
Adapted viruses possibly contain a change in a viral protein giving them an advantage to 
replicate better than the parent in the selecting cell substrate. This change could be located 
within either of the two envelope glycoproteins because these proteins play a crucial role in 
virus attachment and entry to the cell. It is also possible that a change could be located 
within any of the other proteins.
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Table 3.8: Summary of the results of Chapter m. Presented are the significant differences 
observed between Vero-grown parental viruses and their progeny after five passages in 
alternate cell lines.
CELL Virus Logio
T c ro 5o
HA NA TCED/HA TCDD/NA
B95a JL-2 + 1 + + + +
JL-5 + + + + +
U rPTl + + + = +
UrPT3 + _3 + + +
Enders + = + + +
Rubini + = = + +
Pol5/t + = + + +
BCL JL-2 2 = =
JL-5 - - —
UrPTl - - = NA4
UrPT3 - - =
Enders - - -
Rubini - - -
Pol5/t - - =
CEF JL-2 - = =
JL-5 - - =
U rPTl - - = NA
UrPT3 - - =
Enders - - -
Rubini - - -
Pol5/t - - =
HeLa JL-2 + + + + +
JL-5 + = + + +
U rPTl + = + = +
UrPT3 = = + = +
Enders + + + + =
Rubini + = = + +
Pol5/t = = + + +
MRC-5 JL-2 - = —
JL-5 - - —
U rPTl - - = NA
UrPT3 = - =
Enders - - -
Rubini - - -
Pol5/t - =
1 +, Significant increase in comparison to Vero-grown parental virus
2 -, Significant decrease in comparison to Vero-grown parental virus
3 =, No significant change in comparison to the Vero-grown parental virus
4 NA, Not applicable
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Growth of all MuVs, except for JL-5, in B95a cells did not require an adaptation period 
and progeny virus increased in infectivity after passage in B95a cells in comparison to the 
Vero-grown parent, implying that growth of MuVs in B95a cells enhances virus 
infectivity, likely due to host cell factors. The ability of a virus to replicate in a host cell is 
known as viral fitness and results from this Chapter suggest an increase in viral fitness after 
passage in B95a and HeLa cells.
Although different inoculum volumes and adsorption periods were used to try to improve 
virus growth in BCL, CEF or MRC-5 cells, in most cases little infectious virus was 
produced. It is likely that the minimal virus activity detected was remaining inoculum, due 
to the method used to harvest the virus, which was freeze-thawing as opposed to collecting 
the supernatant. Whilst growing MuVs in these cell lines it may have been beneficial, not 
only to increase the MOI further, but to treat the cells prior to inoculation with substances 
such as polybrene, which disturb the charge on the cell membrane, disrupting the 
permeability of the membrane and allowing greater opportunity for virus entry to cell. For 
active replication of MuV to occur the F protein has to be cleaved by a protease into its 
fusogenic form. Therefore, it is possible that these cells did not contain the protease 
enzyme necessary for cleavage of the F protein into its active form; thus, virus progeny 
would only be capable of one round of infection. The addition of a protease in the 
inoculum could ensure cleavage of the F protein into its fusogenic form, possibly enabling 
further rounds of replication. Influenza virus is another example of a virus, which also 
requires a protease to enable productive replication in vivo or in vitro. Reports, regarding 
the growth of influenza virus in MRC-5 cells, have indicated that optimal growth 
conditions include the addition of trypsin into the medium, during the inoculation period 
(Reina et al., 1997 & Herrero-Uribe et al., 1983), hence, the addition of trypsin, whilst 
trying to grow MuV in the different host cells may have been valuable.
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For productive replication to occur, influenza virus requires proteolytic cleavage of its HA 
by a cellular protease, of which furin is one example (Rott et al., 1995). Furin, a member 
of the subtilisin family, recognises a multibasic cleavage signal on the HA of influenza 
viruses, where it cleaves the HA into its fusogenic form, thus enabling active replication to 
occur. Serine proteases, which are only secreted from a restricted number of cell types, 
recognise a monobasic cleavage signal (Rott et al., 1995) and lead to only a localised 
infection. However, serine proteases have been observed to have multiple activities in 
HIV-1 infection of macrophages and increase macrophage susceptibility to acute infection 
by HIV-l (Moriuchi et al., 2000).
In general, reactivity of the viruses with equine RBCs was lower than with the other RBCs, 
to the extent that neither Ur PT1, Pol5/t nor their cell-derived progeny were able to 
agglutinate horse erythrocytes, except for Vero-derived parental U rP T l, which only had a 
titre o f 2. This suggested some common feature between the HN proteins of these two 
strains which differed from the others. Erythrocytes from chickens, humans and sheep 
contain both SAa2,3Gal- and SAa2?6Gal-specific lectin-reactive oligosaccharides. In 
contrast, horse erythrocytes contain virtually 100% SAa2,3Gal linkages (Ito et al., 1997) 
and lack of haemagglutination of horse RBCs by Ur PT1 and Pol5/t could be caused by 
their inability to recognise the SAa2,3Gal linkage. While JL-2, JL-5, Ur PT3, Enders and 
Rubini mainly recognise erythrocytes containing the SAa2,6Gal linkage, they can also 
recognise the SA<x2,3Gal linkage. This difference in recognition of erythrocytes is likely 
to be due to differences in the receptor-binding site within the HN protein in the different 
viruses.
Increases in HA litre were observed for MuVs grown in B95a and HeLa cells and 
correspond to an increase in TCID50. In contrast, virus derived from passage in BCL, CEF 
or MRC-5 cells could not haemagglutinate. By comparing TCID50/HA ratios, significant 
differences indicate changes in the ability of a virus to grow in B95a or HeLa cells could
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be detected. A low ratio could indicate the presence of non-infectious particles (TCID50 
value low but HA detectable), whereas high ratios imply a relative lack of non-infectious 
particles in the virus strains. The TCID50/HA ratios suggest B95a and HeLa cells are 
suitable cell lines for growing MuVs since after five passages, high TCID50 titres and 
TCID50/HA ratios were obtained (Tables 3.2 and 3.4). The process by which passage of 
MuV in B95a or HeLa cells selected for a fitter virus is unknown. However, these higher 
ratios obtained after five passages of MuV in B95a or HeLa cells indicate that more 
efficient replication is occurring in later passages.
Results obtained in this study regarding the TCID50/HA ratio are in agreement with a 
previous study by Isaacs & Donald (1955). Isaacs and Donald showed the ratio of egg 
infective dose 50 (ID 50) to agglutinating dose for MuV ranged from 4.5 logio to 6.3 logio. 
Results from this study show nearly identical results where the TCID50/HA ratios for MuV 
growth in B95a and HeLa cells ranged from 4.08 logio to 5.91 logio. Isaacs and Donald 
also presented data indicating that MuV has a low efficiency of initiating infection, needing 
some hundreds of particles/ID 50, in comparison to other haemagglutinating animal 
viruses, which require approximately 10 particles/TDso. The authors suggested that the low 
efficiency of replication observed by MuVs was because this virus was not readily 
absorbed by the RBCs and therefore at the agglutination end point only a small fraction of 
MuV was absorbed to the RBCs. A study by Desselberger (1975), produced similar results 
to the study by Isaacs and Donald, where approximately 20 influenza A virus particles 
were observed to correspond to one egg ID 50.
The HN glycoprotein of MuV not only allows the virus to bind to and agglutinate 
erythrocytes from certain species but also possesses neuraminidase activity, which removes 
the terminal sialic acid from glycoproteins and glycolipids present on the surface of cells, 
thus allowing efficient budding of the virus from the cell and preventing self-aggregation 
of the budded virus particles. Neuraminidase activity was detected only for parental
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MuVs, Enders and Rubini. It is likely that Enders and Rubini have a genetic difference in 
the neuraminidase active site within the HN gene, which accounts for their NA activity in 
comparison to the other viruses. The level of neuraminidase activity of each parental virus 
and its cell-derived progeny were investigated and differences were observed. After 
passage in B95a and HeLa cells, the NA activity became detectable for all viruses, 
increasing as infectivity titres increased.
It has been previously proposed that the level of NA activity affected MuV cell fusion 
(Merz and Wolinsky, 1981) and this could affect plaque morphology. Since neuraminidase 
activity is necessary to release virus effectively from the infected cell, a higher level of NA 
could lead to a greater release rate, leading to a larger plaque morphology. It is also 
possible that the NA activities are not at a high enough level to affect plaque morphology 
alone and that other factors are involved such as the F protein, which affects cell fusion or 
HA activity which could also affect plaque, morphology.
3.4.4 CONCLUSION
The highest infectivity, HA and NA titres were observed for B95a or HeLa-derived MuVs. 
MuV growth in B95a cells resulted in the production of higher quality virus without any 
apparent need for adaptation, except for JL-5. In contrast, virus growth in HeLa cells did 
not produce virus of such high quality and there was a more obvious period of adaptation. 
It is likely that viruses, which showed an adaptation period, will contain a difference in 
genotype and/or phenotype. Virus, which grew without a period of adaptation, is less 
likely not to contain a difference in genotype or phenotype.
Since the data suggests that variants of the original MuV population were possibly 
propagated after the passage of MuV in HeLa cells, and that B95a-derived virus may be 
identical to the parent virus, changes in other phenotypic properties of the viruses may also
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be apparent. Therefore, the progeny viruses were analysed further by investigating plaque 
morphology and antigenic profiles using a panel of MAbs.
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CHAPTER IV 
PHENOTYPIC CHARACTERISATION OF MuV
no
4.1 INTRODUCTION
Results from the previous chapter indicate that B95a- or HeLa-derived MuV is of higher 
fitness, identified by an increase in infectivity titre, compared to the Vero-grown parental 
virus. Therefore, B95a and HeLa cell lines appear to be suitable alternatives to Vero cells 
as a source of infectious MuV. To characterise further the viruses derived from the 
alternate cell lines, the phenotypic properties of plaque morphology and antigenic profile 
were compared to those of the Vero-grown parental virus.
The plaque morphology of a virus is directly related to its replicative ability. The results 
from Chapter HI indicate an increasing ability to produce infectious progeny after passage 
in B95a or HeLa cells. Therefore, plaque morphology was assessed to investigate if 
changes occurred due to passage in alternate cell lines. Plaque assays for MuV have 
previously been and are routinely performed in laboratories at NIBSC using Vero cells and 
a further aim was to investigate alternative cell lines for use in these assays.
In this instance, virus antigenic profiles are related to the properties of the HN protein 
because the monoclonal antibodies used were raised against this protein. Results from 
Chapter m  indicate increases in the ability of the viruses to cause haemagglutination and 
increases in neuraminidase activity. These increases in activity could be caused by changes 
in the HN protein, which could, therefore, affect the antigenic properties of the HN protein.
4.2 EXPERIM ENTAL PROCEDURES
Initially, plaque assays were performed on the parental Vero-adapted MuVs using either 
B95a, CEF, HeLa, MRC-5 or Vero cells (as described in Chapter II) to determine the cell 
line of choice for use in further plaque assays. BCL cells grow in suspension and do not 
form monolayers, hence, by definition they were excluded from this particular study. Once 
the cell substrate for use in plaque assays had been determined, the plaque morphology of
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parental viruses was examined and used as a basis for the comparison of those formed by 
virus derived from passage in the alternate cell lines.
To determine virus antigenic profiles, neutralisation assays (as described in Chapter II) 
were performed with a panel of anti-HN monoclonal antibodies (MAbs). The MAbs used 
had previously been characterised for neutralisation activity, neuraminidase inhibitory and 
haemagglutination inhibitory activities at NIBSC (Yates et al.9 1996) and were known as 
MAbs 1637, 1641, 1648, 1689, 1721, 1726 and 1970 (Table 4.1). Neutralisation assays 
were performed by incubating each MAb (at a dilution of 1 in 100 from the stock) with 
500 TCIDso/ml of virus (or virus was used neat if  its titre was lower than 500 TCIDso/ml) 
at 4°C for 90 minutes and then incubating 50pl of this virus/MAb mixture on Vero cells 
for 1-2 hours in a 24 well plate, when the medium was replaced with CMC containing 
MAb. The plates were then incubated at 35°C for 7 days (See Chapter II for further 
details).
Table 4.1: Characterisation of monoclonal antibodies: biological activity with the Urabe 
strain of mumps (Yates et al., 1996).
MAB NEUTRALISATION
TITRE
HI TITRE NI TITRE
1637 100 000 <20 500
1641 1 000 <20 500
. 1648 10 000 <20 1 000
1689 100 000 >2560 100
1721 100 000 5 000 >100
1726 10 000 1 280 >100
1970 100 000 >20 480 >100
Using these MAbs, the antigenic profiles of Vero-grown parental viruses and viruses 
derived from passage in the alternate cells lines were studied and compared, as described 
in Chapter H.
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4.3 RESULTS
4.3.1 PLAQUE ASSAYS
Cell substrate for use in plaque assays
Initially, the plaque morphologies of the Vero-grown parental MuVs were investigated 
using Vero, B95a, CEF, HeLa and MRC-5 cells under a CMC overlay (as described in 
Chapter II) to determine the most suitable cell line for use in future assays. After a 7 day 
incubation period, no plaques were observed in the assays using CEF or MRC-5 cells. 
Although faint plaques were observed in assays using B95a and HeLa cells, the cells did 
not survive under CMC or agar overlay for the 7 days required for a MuV plaque assay. 
Plaques were observed with the use of Vero cells and the cell monolayer survived intact. It 
was concluded that Vero cells were the most appropriate cell substrate with which to 
perform subsequent plaque assays.
Plaque morphology of parental MuV in Vero cells.
The plaque morphology of each virus was assessed by measuring the diameter of the 
plaque.
It has previously been established that JL-2 and JL-5 strains are distinguishable from one 
another by their plaque morphology in Vero cells (Afzal et a i, 1997). In this study, JL-2 
formed smaller plaques when compared to those of JL-5 (Figure 4.1), in agreement with 
this previous study. Ur PT1 and Ur PT3 are also distinguishable by their plaque 
morphology upon infection of Vero cells; Ur PT1 plaques are larger and clearer than those 
of Ur PT3 (Afzal et a l, 1998), and identical results were obtained in this study (Figure
4.2). Results from this study also indicated that Enders and Rubini had distinguishable 
plaque morphology; Enders formed larger and clearer plaques than those of Rubini (Figure
4.3). Plaques formed by Pol5/t were intermittent in size between those of JL-5 and Ur 
PT3 (Figure 4.4).
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Figure 4.1: The different plaque morphologies of a) JL-2 and b) JL-5. Plaques formed by 
JL-2 are smaller than those formed by JL-5
a)
* P
Figure 4.2: The different plaque morphologies of a) Ur PT1 and b) Ur PT3. Plaques 
formed by Ur PT1 are larger and clearer than those formed by Ur PT3. 
a)
b)
Figure 4.3: The different plaque morphologies of a) Enders and b) Rubini. Plaques formed 
by Enders were slightly larger and clearer than those formed by Rubini. 
a)
Figure 4.4: The plaque morphology of Pol 5/t.
Effect of host cell passage on plaque formation
Differences in plaque morphology were observed for JL-2, derived by one or more 
passages in B95a cells, where smaller plaques were formed in comparison to those formed 
by its Vero-grown parental virus (Figures 4.1 A and 4.5). A difference in plaque 
morphology for Ur PT3 in HeLa cells was observed only after the fifth passage when 
larger and clearer plaques were formed (Figures 4.6 and 4.2B). A difference in plaque 
morphology for Enders in HeLa cells was only observed after the second passage when 
smaller plaques were formed when compared to those of the Vero-grown parental virus 
(Figures 4.7 and 4.3A). A change in plaque morphology was only observed for Rubini in 
B95a cells after the fifth passage when clearer plaques were formed in comparison to those 
of lesser-passaged virus (Figures 4.8 and 4.3B).
The plaques formed by MuVs after passage in all the other cell lines were identical in 
morphology to those of the Vero-grown parental virus.
Table 4.2 summarises the different plaque morphologies.
Table 4.2: Summary of the different plaque morphologies of MuV.
VIRUS CELL LINE
Vero1 B95a BCL CEF HeLa MRC-5
JL-2 Clear,
1mm2
Clear,
0.5mm
- - -
JL-5 Clear,
1.5mm
_3
- - - -
UrPTl Clear
1mm
- - - - -
Ur PT3 Cloudy,
0.5mm
- - - Cloudy,
1mm
-
ENDERS Clear,
0.5mm
- - - Clear,
<0.5mm
-
RUBINI Cloudy,
0.5mm
Clear,
0.5mm
- - - -
Pol5/t Clear,
1mm
- - -
1 = Cell line in which the viruses were grown to produce the Vero-grown parental viruses
2 = Plaque diameter
3 = Plaque morphology is identical to that formed by the parental virus
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Figure 4.5: The plaque morphology of JL-2 passaged in B95a cells. The plaques formed 
were smaller than the parental JL-2 plaques.
Figure 4.6: The plaque morphology of UrPT3 passaged in HeLa cells. The plaques formed
were less cloudy than the parental Ur PT3 plaques.
Figure 4.7: The plaque morphology of Enders passaged in HeLa cells. The plaques formed 
were smaller than the parental Enders plaques.
Figure 4.8: The plaque morphology of Rubini passaged in B95a cells. The plaques formed
were slightly clearer than the parental Rubini plaques.
To investigate reversion of plaque morphology, JL-2, derived by two passages in B95a 
cells, was passaged four times in Vero cells. This virus also formed smaller plaques than 
the Vero-grown parental JL-2 virus (data not shown); therefore no reversion was detected.
4.3.2 ANALYSIS of the ANTIGENIC PROFILE of MuV
The antigenic profiles of MuVs were assessed by determining the ability of a panel of 
MAbs to neutralise virus infectivity (Table 4.1). Virus neutralisation (sensitivity) was 
observed by a complete absence of plaque formation, whereas resistance is indicated by the 
formation of plaques.
Results of the neutralisation assays using 7 MAbs (Table 4.3) indicated that two of the 
MAbs (1637 and 1648) were active against the Vero-grown parental JL-2 and three against 
parental JL-5 (1637, 1648 and 1970). Vero-grown parental Ur PT1 and Ur PT3 were 
neutralised by six of the MAbs but not by MAb 1637 (Table 4.3). Vero-grown parental 
Enders, Rubini and Pol5/t were also neutralised by six MAbs but were resistant to MAb 
1970 (Table 4.3).
To investigate differences in antigenic profile between Vero-grown parental virus and the 
altemate-cell-derived viruses, neutralisation assays were performed on viruses derived by 
five passages in each cell type and the results compared to the antigenic profile of the 
Vero-grown parental virus.
JL-2 (sensitive to MAb 1648) became resistant to MAb 1648 after five passages in B95a 
cells. The results of the neutralisation assay also revealed that B95a-derived JL-2, 
although retaining resistance to MAbs 1689, 1726 and 1970, formed smaller plaques in the 
presence of the MAbs compared to in their absence (Table 4.3). The formation of smaller 
plaques in the presence of a MAb was also observed with HeLa-derived JL-2 with MAb 
1970 (Table 4.3). JL-5 (sensitive to 1648) became resistant to MAb 1648 after five
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Table 4.3: Reactivity of a panel of MAbs with the parental viruses, JL-2, JL-5, Ur PT1, Ur 
PT3, Enders, Rubini and Pol5/t and their progeny after five passages in the cell line 
indicated. The neutralisation titres of the MAbs are presented in Table 4.1.
VIRUS CELL MONOCLONAL ANTIBODY
1637 1641 1648 1689 1721 1726 1970
JL-2 Vero1 S2 R3 S R R R R
B95a 4 - R *5 - * *
BCL - - - - - - -
CEF - - - - - - -
HeLa - - - - - - *
MRC-5 - - - - - - -
JL-5 Vero s R S R R R S
B95a - - - - - - -
BCL - - - - - - -
CEF - - - - - - -
HeLa . - R - * * -
MRC-5 - - - - - - -
Ur PT1 Vero R S S S S S s
B95a - - - - - - -
BCL - - - - - - -
CEF - - - - - - -
HeLa - * R - R R -
MRC-5 - - - - - - -
Ur PT3 Vero R s S s S S s
B95a - - - - - - -
BCL - - - - - - -
CEF - - - - - - -
HeLa - - - - - - - -
MRC-5 - - - - - - -
Enders Vero S s s s s s R
B95a - - - R - - -
BCL - - - - - - -
CEF - - - - - - -
HeLa - - - R - - -
MRC-5 - - - - - - -
Rubini Vero s s s S s s R
B95a - R - - R - -
BCL - - - - - - -
CEF - - - - - - -
HeLa - - - - - - -
MRC-5 - - - - - - -
Pol5/t Vero s s s s s s R
B95a - - - - - - -
BCL - - - - - - -
CEF - - - - - - -
HeLa - - - - - - -
MRC-5 - - - - - - -
1 = Vero-grown parental viruses
2 S = Sensitive to MAb (no plaques observed)
3 R = Resistant to MAb (plaques observed)
4 - = Identical antigenic profile to the Vero-grown parental virus
5 * = Resistant to MAb but smaller plaques observed
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passages in HeLa cells (Table 4.3) and in the presence of MAbs 1721 and 1726 smaller 
plaques were formed, compared to in their absence.
Ur PT1 (sensitive to MAbs 1641, 1648, 1721 and 1726) became resistant to these MAbs 
after five passages in HeLa cells (Table 4.3). In addition, HeLa-derived virus formed 
smaller plaques in the presence of MAb 1641 compared to in its absence. No differences 
in antigenic profiles were observed between Ur PT3 and its various cell-derived virus 
progeny (Table 4.3).
B95a- and HeLa-derived Enders viruses were resistant to MAb 1689 in comparison to the 
sensitivity shown by the Vero-grown parental virus (Table 4.3). Rubini (sensitive to Mab 
1641 and 1721) became resistant to these after five passages in B95a cells.
Viruses, derived by passage of Pol5/t in different host cells, have identical antigenic 
profiles to the Vero-grown parental virus.
No changes in antigenic profile were detected for BCL, CEF or MRC-5 derived viruses, 
supporting the previous suggestion that no productive replication of MuV occurred during 
passage in these cells (see the section entitled, 'Growth of MuV in BCL, CEF or MRC-5 
cells' in Chapter 3).
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4.4 DISCUSSION
Seven MuV strains have been passaged five times in five different cell lines to investigate 
the effect of host cell passage on MuV. In this chapter, the virus progeny derived from 
these five passages have been investigated by comparison of plaque morphology and 
antigenic profile to determine whether host cell passage has generated phenotypic variants 
of their parents.
Table 4.4 summarises the results of Chapter IV and shows changes in plaque morphology 
were observed for two of the MuVs after passage in B95a cells (JL-2 and Rubini) and for 
two of the MuVs after passage in HeLa cells (Ur PT3 and Enders). Changes in antigenic 
profile were observed for three of the MuVs after passage in B95a cells (JL-2, Enders and 
Rubini) and for three of the MuVs after passage in HeLa cells (JL-5, Ur PT1 and Enders).
Plaque morphology may be influenced by several factors that affect viral replication and 
any difference in one of these factors could lead to alteration of plaque morphology. Such 
factors include the rate at which MuV attaches to and buds effectively from the host cell 
and the rate at which fusion of the viral and host cell membranes occurs. The HN protein 
is responsible for virus attachment and budding and the F protein is implicated in virus and 
cell fusion. A difference in these proteins could decrease or increase the rate at which 
virus enters and replicates in the host cell. Neuraminidase activity is also likely to affect 
plaque morphology, with a higher level leading to a quicker virus release rate and hence a 
larger plaque morphology because the released virus progeny infect the surrounding cells. 
Therefore, the neuraminidase activities of the different parental MuVs and of parental 
viruses and their respective cell-derived virus progeny, where plaque morphology changes 
are observed, might differ. It is also possible that other virus-encoded proteins are 
involved, for example, a change in the matrix (M) protein could lead to inefficient 
packaging and budding of mature virions.
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Table 4.4: Summary of the results of Chapter IV.
VIRUS CELL PLAQUE SIZE2 ANTIGENIC PROFILE4
JL-2 Vero1 Clear, 1mm 1648 (S)
B95a 0.5mm R
BCL _3 =
CEF = =
HeLa = =
MRC-5 = =
JL-5 Vero Clear, 1.5mm 1648 (S) [
B95a = =
BCL = =
CEF = =
HeLa = R
MRC-5 = =
UrPTl Vero Clear, 1mm 1641 (S),1648 (S), 1721(S), 1726 (S)
B95a = =  i
BCL = =
CEF = =
HeLa = R
MRC-5 = =
Ur PT3 Vero Cloudy 0.5mm NA
B95a = =
BCL = =
CEF = =
HeLa 1mm =
MRC-5 = =
1 Enders Vero Clear, 0.5mm 1689 (S)
B95a = R
BCL = = 1
CEF = =
HeLa <0.5mm R
MRC-5 = =
Rubini Vero Cloudy, 0.5mm 1641 (S), 1721 (S)
B95a Clear R
BCL = =
CEF = =
HeLa = =
MRC-5 = =
Pol5/t Vero Clear, 1mm NA
B95a = =
BCL = =
CEF = =
HeLa = = ,
MRC-5 = : =
1 Vero-grown parental virus
2 Plaque diameter
3 = No change from parental
4 Presented are the MAbs for which changes were observed between parental and progeny viruses. S = 
sensitive; R = resistant
NA = Not applicable
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A plaque morphology difference can, therefore, be due to a multitude of factors; a change 
in any part of the viral replication cycle, from genome replication to protein synthesis to 
changes in cellular factors such as protein synthesis of cellular components necessary for 
viral replication.
Previously published results have shown that after passage of the wild type Matti strain of 
MuV in cells derived from normal human joint tissue, the viruses produced formed cloudy 
plaques in Vero cells when compared to the original parent (Huppertz and Chantier, 1991). 
Hence, it appears that passage of MuV in different host cells could affect virus replication 
and therefore plaque formation.
The results of this chapter indicate that passage of some MuVs in B95a or HeLa cells can 
produce progeny viruses with changes in their plaque morphology (Table 4.2). No 
consistent relationship is observed between the cell line from which virus was derived and 
a change in plaque morphology. The differences observed in plaque morphology are likely 
due to the differing ability of the viruses to infect Vero cells, after passage in B95a or 
HeLa cells and possibly due to host cell interactions.
There were some differences in the antigenic profiles of MuV determined in this study 
compared to a previous study (Yates et al., 1996). Results from the study by Yates et al 
(1996) indicated that JL-2 and JL-5 were sensitive to 1641, rather than resistant, as was 
observed in this study and that the Urabe vaccine virus was sensitive to 1637, rather than 
resistant, as was observed for Ur PT1 and Ur PT3 in this study. The antigenic profiles of 
Enders and Rubini were identical between the two studies and the antigenic profile of 
Pol5/t was not investigated by Yates et al (1996). It is possible that the differences were 
due to the different level of passage of the Vero-grown parental viruses used but 
differences could also have been detected due to technical error in either study. The plaque 
purification of Ur PT1 and Ur PT3 from the Urabe vaccine involved extra passages in Vero
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cells and the JL-2 and JL-5 viruses used in this study have been passaged one extra time in 
Vero cells compared to the JL-2 and JL-5 used in the study by Yates et al (1996).
Neutralisation of virus results when antibody binds to a virus preventing replication and 
generally occurs by inhibition of virus binding to the cell receptor. In comparing the 
antigenic profiles of different cell-derived viruses with the parental (Vero-grown) virus, 
B95a-derived JL-2, HeLa-derived JL-5, HeLa-derived Ur PT1, B95a-derived Enders, 
HeLa-derived Enders and B95a-derived Rubini are different (Table 4.3). Some altemate- 
cell-derived viruses formed smaller plaques in neutralisation assays when compared to the 
Vero-derived control viruses. This suggested that there was some inhibition of replication 
by the MAh, insufficient to neutralise the virus completely.
The MAbs used in this project were raised against the Urabe strain of MuV and were 
reactive against the HN protein (Table 4.1; Yates et al, 1996). Therefore, differences in 
antigenic profile between parent and progeny were assumed to be due to a difference in a 
particular antibody-binding site within the HN protein. JL-2, JL-5, Ur PT1 and Rubini 
progeny, after passage in either B95a or HeLa cells, showed resistance to MAbs 1641 
and/or 1648. These MAbs are reactive against the neuraminidase active site (Table 4.1) 
and resistance to these MAbs indicates a possible genotypic change in the neuraminidase 
active site, within the HN protein. The neutralisation titre of MAb 1641 is low (Table 4.1) 
and hence virus resistance, by Ur PT1 and Rubini progeny, to this MAb is likely to be due 
to breakthrough virus and therefore, does not indicate a significant change in the 
neuraminidase active site. Breakthrough virus, or virus which has escaped neutralisation, 
can occur when the neutralisation titre of the antibody is low and the titre of the virus is 
high, therefore the amount of virus present is to high to be fully neutralised by the amount 
of antibody present.
Ur PT1, Enders and Rubini progeny, after passage in B95a or HeLa cells, showed 
resistance to MAbs 1689, 1721 and/ or 1726. These MAbs are reactive against the
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haemagglutinin active site (Table 4.1) and resistance to these MAbs indicates a possible 
genotypic change within the active site for haemagglutination.
4.4.1 CONCLUSION
Results from this chapter indicate that passage of some MuVs in B95a or HeLa cells 
produces progeny virus with altered phenotypic characteristics. The production of altered 
phenotypes appears to be a chance association rather than dependant on the virus or the 
cell line because no correlation was detected between cell line, plaque morphology or 
antigenic profile. Investigation into whether these phenotypic changes correspond to 
genotypic changes, by sequence analysis of the HN and F proteins, was deemed necessary.
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CHAPTER V
GENOTYPIC CHARACTERISATION OF THE HN PROTEIN
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5.1 INTRODUCTION
Results of Chapters III and IV indicate the production of high quality MuV after passage in 
B95a or HeLa cells. Some of the viruses were plaque morphology and/or antigenic 
variants of their respective Vero-grown parental virus. Plaque morphology is affected by 
the rate of virus replication, possibly due to alterations in the virus attachment glycoprotein 
(HN). This protein is also the one against which the monoclonal antibodies used in this 
project are reactive. The 3D structure of the HN protein has not been deduced, and the 
structure of the receptor-binding pocket and the NA active site remains unidentified.
The aim of this chapter is to analyse the nucleotide and deduced amino acid sequences of 
the HN gene of Vero-grown parental viruses and their respective progeny after passage in 
5 different cell lines in a comparison to determine whether genotypic differences were 
present. A second aim of this chapter was to compare the HN amino acid sequence of the 
Enders and Rubini strains.
5.2 EXPERIMENTAL PROCEDURES
The nucleotide sequence of the HN gene of the mumps vaccine virus strains JL-2, JL-5, Ur 
PT1, Ur PT3, Enders, Rubini and the wild type strain Pol5/t was determined. Their 
respective amino acid sequences were deduced using start codon sequences of the standard 
triplet genetic code (Appendix I). To investigate the presence of genetic variants, the 
nucleotide sequences of the HN gene of MuVs after passages two and five in each different 
cell line were also determined, the respective amino acid sequences deduced and compared 
to that of their respective Vero-grown parent.
To analyse the nucleotide sequence of the HN gene, viral RNA was extracted from 
infectious tissue culture fluid, cDNA synthesized and the DNA amplified by PCR, as 
described in Chapter II. For each virus, the HN gene was amplified in three overlapping 
fragments (Figure 5.1 A). Primers SH-7 and HN-2 were used to amplify the 5’ fragment of
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the HN gene. The middle fragment was amplified using HN-3 and HN-5 and the 3’ 
fragment of the HN gene was amplified using HN-7 and L-19 (Figure 5.IB). The PCR 
products were purified for use in sequencing reactions performed using the aforementioned 
primers giving complementary data, one of forward sense and the second of reverse sense, 
and the products analysed using an ABI Prism 310 Genetic Analyzer. The resultant 
chromatograms were analyzed using the computer programs Chromas and GCG 
(Wisconsin Package Version 9.1).
Any nucleotide differences observed between a progeny virus and a parental virus were 
confirmed by repetition of the sequence analysis.
5.3 RESULTS
5.3.1 MOLECULAR CHARACTERISATION of the MuV HN PROTEIN 
The HN nucleotide and deduced amino acid sequence has previously been determined for 
JL-2, JL-5, Urabe (vaccine), Enders and Rubini (Yates et aL, 1996). Nucleotide sequence 
analysis of the HN gene of these viruses was repeated (Appendix II) in this project because 
the Vero-grown parental viruses were at higher passage level to those used in the study by 
Yates et al (1996). JL-2, JL-5 and Enders were passaged once more in this study, Ur PT1 
and Ur PT3 had been passaged three further times and Rubini was passaged five further 
times in Vero cells, in comparison to the viruses analysed by Yates et al (1996). The 
Rubini analysed by Yates et al (1996) was unpassaged commercial vaccine. Some 
discrepancies were observed between data being derived in this project and the published 
data (Table 5.1), possibly due to the different passage levels of the viruses analysed. It is 
believed that the data determined in this project is accurate because of the numerous 
repetitions performed, the accuracy of previous data could be questioned. Ur PT1 and Ur 
PT3 analysed in this study were at the same passage level to the viruses analysed by Afzal 
et al (1998) but had been plaque purified three times in Vero cells in relation to the CEF- 
derived Urabe analysed by Yates et al (1996).
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Figure 5.1 A: Agarose gel electrophoresis of the PCR products after amplification of the 
HN gene in three overlapping fragments. Primer sequences are listed in Chapter II.
1 2  3 4
2176bp 
1766bp
1230bp
1033bp
653bp
517bp
453bp
394bp
298bp
234bp
1168bp 
862bp
384bp
Lane 1 : Molecular weight markers
Lane 2: PCR product amplified using primers SH-7 and HN-2 (1168bp) 
Lane 3: PCR product amplified using primers HN-3 and HN-5 (384 bp) 
Lane 4: PCR product amplified using primers HN-7 and L-19 (862 bp)
Figure 5. IB: Schematic diagram showing the positions of the primers, within mRNA 
sense RNA, used for amplifying and sequencing the HN gene.
HN-7 862bp L-19
HN-3
384bp
HN-5
1899
5' 3 '
SH-7
1168bp
HN-2
1 11 Ibp o f L gene and 751bp o f HN gene
2 109 of SH gene and 1059bp of HN gene
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Table 5.1: The differences in the HN gene between previously published data (Yates et al., 
1996) and data determined in this project.
Virus Nucleotide Yates et 
al
This
project
Amino
acid
Yates et 
al
This 1 
project i
JL-2 692 G G/A 205 Arg Arg/His
719 C T 214 Met Met
1733 T C 552 Ala Ala
JL-5 209 C T 44 Thr He
1587 C T 503 Gly Gly
! Urabe1 3432 A G 89 Met Val
10813 G A 335 Glu Lys |
17273 A G 550 Asp Gly
Enders 96 C A 6 Leu Leu
795 T G 239 Leu Leu
1587 C T 503 Gly Gly !
Rubini 96 C A 6 Leu Leu
332 C A 85 Ala Asp
460 T C 128 Cys Arg
552 C T 159 He He
795 T G 239 Leu Leu
1587 C T 503 Gly Gly
1611 T C 511 Thr Thr
1 The HN gene o f Urabe was analysed by Yates et al (1996). In this project the HN gene o f Ur PT1 and Ur 
PT3 were analysed.
2 This difference was only observed in Ur PT3.
3 These differences were observed in Ur PT1 and Ur PT3.
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The nucleotide sequence of the HN gene of Pol5/t has not previously been determined and 
so no comparison could be made. The nucleotide and deduced amino acid sequences of 
the Pol5/t HN gene have been submitted to the EMBL genetic database (accession number 
AJ238210).
Figure 5.2 shows the deduced amino acid sequence of the seven parental MuVs used in 
this study and includes a consensus sequence, obtained via comparison of the seven amino 
acid sequences; the amino acid residues in the consensus sequence are the most frequently 
observed at a particular position. The coding region of the HN gene is 1734 nucleotides in 
length and codes for 582 amino acids. The HN protein of the seven MuVs contains 7 
conserved potential N-linked glycosylation sites (underlined in Figure 5.2). It is not known 
which, if any, are glycosylated but it is presumed that all are except one. The exception is 
considered to be the site located at residues 514-516 (N-P-T) because it contains a proline 
residue as the X amino acid (N-X-T/S), which is considered to inhibit glycosylation, 
possibly because of its structure. The HN protein also contains two heptad repeat regions; 
both located between amino acids 93 to 124, which can form coiled coil structures of ex- 
helices. The amino acid sequence comprising these heptad repeat regions is conserved 
between the MuVs in this project, with the exception of 3 residues in Ur PT1, Ur PT3 and 
Pol5/t, 1 in Enders, 2 in Rubini.
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Figure 5.2: The deduced amino acid sequence of the HN protein from the seven MuVs 
analysed in this project. Potential N-linked glycosylation sites are underlined.
JL-2 
JL-5 
Ur PT1 
Ur PT3 
ENDERS 
RUBINI 
Pol5t 
CONSENSUS
1
-----------------        - - - I
— — — — — — — ^ — — — — — — — — — — — J  — — — D — — — — — — — — — — — — — — — — — — —
— — — — — — — ^  — — — — — — — — — — —^ J — — —D— — — — — — — — — — — — — — — — — — —
50
MEPSKLFIMS DNATFAPGPV VNAAGKKTFR TCFRILVLSV QAVTLILVIV
51 100
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ----------  ---------- V ----------  ----------
Ur PT1  V ---------------- -A------ T ------------ ----------
ENDERS ----------  ----------  ---------- V ----------  ----------
RUBINI ----------  ----------  ---------- V---D------ ------------
Pol5/t-----------------  ----------  ----------  ----------  ----------
CONSENSUS TLGELIRMIN DQGLSNQLSS ITDKIRESAA MIASAVGVMN QVIHGVTVSL
101 150
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5       1----- ------------
Ur PT1    GKK-------  ----------  ----------
Ur PT3    GKK-------  ----------  ----------
ENDERS  R ---------------- ----------  ----------  ----------
RUBINI  R------   R- - ----------  ----------
Pol5/t    SKK-------  ----------  ----------
CONSENSUS PLQIEGNQNQ LLSTLATICT NRNQVSNCST NIPLVNDLRF INGINKFIIE
JL-2 
JL-5 
Ur PT1 
Ur PT3 
ENDERS 
RUBINI 
Pol5/t 
CONSENSUS
151 2 0 0
DYATHDFSIG HPLNMPSFIP TATSPNGCTR IPSFSLGKTH WCYTHNVINA
JL-2 
JL-5 
Ur PT1 
Ur PT3 
ENDERS 
RUBINI 
Pol5/t 
CONSENSUS
JL-2 
JL-5 
Ur PT1 
Ur PT3 
ENDERS 
RUBINI 
Pol5/t 
CONSENSUS
2 0 1
-------------------- A
---------- -I------
---------- -I------
250
NCKDHTSSNQ YVSMGILVQT ASGYPMFKTL KIQYLSDGLN
----------V ---
RKSCSIATVP
251
-------- v ----
-------- v ----
------ T--------
------T-------
------ E----- ---------------- -------- v----
DGCAMYCYVS TQLETDDYAG SSPPTQKLTL LFYNDTITER TISPSGLEGN
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Figure 5.2 continued :
301 350
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5       L--------
Ur PT1 ----------  ----------  ----------  ----------  ----------
UR PT3 ----------  ----------  ----------  ----------  ----------
ENDERS         --
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/1       L--------
CONSENSUS WATLVPGVGS GIYFENKLIF PAYGGVLPNS TLGVKSAREF FRPVNPYNPC
351 400
JL-2  P---- ------------ ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
Ur PT1  D------------- -N--------  ----------  ----------
Ur PT3  D------------- -N-------- ------------ ----------
ENDERS  P---- ------------ ----------  ----------  ----------
RUBINI  P---- ------------ ----------  ----------  ----------
CONSENSUS SGPQQELDQR ALRSYFPSTF SSRRVQSAFL VCAWNQILVT NCELWPSNN
401 450
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  -Y--------
Ur PT1 ---------- ------------ ----------  ----------  ----------
Ur PT3 ----------  ----------  ----------  ----------  ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t-----------------  ----------  ----------  ----------  ----------
CONSENSUS QTLMGAEGRV LLINNRLLYY QRSTSWWPYE LLYEISFTFT NSGQSSVNMS
451 500
JL-2    1 ----------  ----------  ----------
JL-5 ----------  ----------  - I-------  ----------  ----------
ENDERS     T ----- ------  -----
RUBINI         1-
Pol5/t    M ----A ------ ------------ ----------
CONSENSUS WIPIYSFTRP GLGNCRGENV CPTVCVSGVY LDPWPLTPYS HQSGINRNFY
501 550
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
Ur PT1 ----------  ----------  ----------  - -N------- ------------
Ur PT3 ----------  ----------  ----------  - -N------- ------------
ENDERS-----------------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t-----------------  ----------  ----------  ----------  ----------
CONSENSUS FTGALLNSST TRVNPTLYVS ALNNLKVLAP YGTQGLFASY TTTTCFQDTG
551 583
JL-2       --*
JL-5       --*
Ur PT1     T -----*
Ur PT3     T -----*
ENDERS       --*
RUBINI       --*
Pol5/t     T -----*
CONSENSUS DASVYCVYIM ELASNIVGEF QILPVLARLT IT*
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The HN gene is highly conserved between the related MuV strains sequenced in this study 
(Table 5.2).
TABLE 5.2: Percentage differences in the HN gene and protein sequences between seven 
parental MuV strains sequenced. The bottom left of the table depicts percentage 
differences in nucleotide sequence and the top right of the table depicts percentage 
differences in amino acid sequence.
Virus
UrPTl
Ur PT3
Enders
Rubini
Pol5/t
UrPTl Ur PT3 Enders Rubini Pol5/t
1.03 1.37 3.61
1.89 2.06 3.95
4.30 4.64 2.92
4.47 4.81 3.09
0.69 3.95
0.29 I 4.30
6.74 6.74
5.3.2 MOLECULAR COMPARISON of the ENDERS and RUBINI HN GENE
Rubini is considered to have arisen by a laboratory contamination with Enders and it was 
of interest to compare their HN gene nucleotide sequence to investigate if this theory can 
be substantiated. Comparison of the previously published HN nucleotide sequence of 
Enders and Rubini (Yates et al, 1996) revealed three differences between the two strains, 
coding for two amino acid differences at positions 477 and 497 (Table 5.3). Comparison 
of the HN nucleotide sequences, determined in this project, indicate five differences 
between the two strains (Tables 5.2 and 5.3), coding for four amino acid differences at 
position 85, 128, 477, 497.
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Table 5.3: The differences between the HN genes of Enders and Rubini.
Nucleotide / 
amino acid
Yates et a l, 1996 This project
Enders Rubini Enders Rubini
332/85 C/A la C /A la C /A la A/Asp
460/ 128 T/Cys T/C ys T /C ys C / Arg
1507/477 A / Thr T /Ser A / Thr T /S er
1558/497 G / Arg T /Ile G /Arg T / lie
1611/511 C / Thr T / Thr C / Thr C /T hr ,
5.3.3 EFFECT of HOST CELL PASSAGE on MuV GENOTYPE
The nucleotide sequences of the HN gene of MuVs were determined after the second and 
fifth passages in each cell line and together with the deduced amino acid sequence, were 
compared with the respective sequences of the HN gene and its protein of the Vero-grown 
parental viruses. Original data showing coding nucleotide sequence differences are 
presented in Figure 5.3 and the results are summarised in Table 5.4. Nucleotide 
differences were detected for all of the viruses after passage in at least one cell line with 
one exception, Pol5/t (no differences were detected between this Vero-grown parental 
virus and its progeny derived from passage in any of the cell lines). Where differences in 
nucleotide sequence were detected, the sequence analysis was repeated to confirm the 
results.
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Figure 5.3: Chromatograms, depicting the amino acid substitutions between parental 
viruses and their progeny in the HN protein. A) JL-2, B) Ur PT1, C) Ur PT3, D) Enders 
and E) Rubini.
A) Vero-grown parental JL-2
nt 692, a/g; Arg/His 
!
IC R À C  T S c a a G G  A 7 C H T ,A j£  T 1 C A T C C :
JL-2 passaged on B95a cells
nt 692, a; His
i
i u a a l ; t  u i ^ a i j 'U A T C A T A C  1  r G rt T  C V A A C
B) Vero-grown parental Ur PT1
nt 1655, a; Lys
I
Ur PT1 passaged on HeLa cells 
nt 1655, c; Thr
V
i v t bctc itji a re I m e  a  gy 7c re i y c e c i  ta.hi aa re t  t a  a a y
Figure 5.3 continued:
C) Ur PT3
Vero grown parental Ur PT3
nt 841, a; Met
aC&A.tAGTCC'C QCAAT^ÎftÇ
Ur PT3 passaged on HeLa cells 
nt 841, c; Leu
i
iCAsi£AGT.cct v'Gxz ggat-sc-og acK  me
Vero grown parental Ur PT3
nt 1369, c; Leu
i
rççîG<K c Sï&'iGAAC icc ic
Ur PT3 passaged on MRC-5 cells 
nt 1369, a; Ile
4
IG G IG G C  C 6T A T  Q ftA A fÇ Ç  K  l A îG A G A m l
Figure 5.3 continued:
D) Enders
Vero-grown parental Enders Enders passaged on B95a cells
nt 353, t; Val nt 353, g; Gly
.'GRAfCA A132
/i
iM M Jl
Vero-grown parental Enders
nt 1117, t; Tyr
4
Enders passaged on HeLa cells
nt 1117, g; Asn
4
f«r£ A fSA.TAATfeg A .fe rf ic  &,
Figure 5.3 continued:
E) Vero-grown parental Rubini Rubini passaged on B95a cells
nt 1252, t; Cys nt 1252, c; Arg
\]\ I Il .i l  1
Table 5.4: Nucleotide and deduced amino acid substitutions detected in the HN gene of
progeny viruses after passage in different host cells.
Virus Cell line Passage level Nucleotide Amino acid
Difference Difference
JL-2 B95a 2 and 5 692, A/G -» A 205, R/H -> H
B95a 2 and 5 729, T -> C Silent
HeLa 2 and 5 729, T -» C Silent
B95a + Vero1 2 and 4 692, A/G -> A 205, R/H -> H
B95a + Vero1 2 and 4 729, T -> C Silent
JL-5 B95a 2 and 5 1515,T -> C Silent
UrPTl B95a 5 1269, C T Silent
HeLa 5 1655, A ^ C 526, K -> T
Ur PT3 HeLa 5 841, A ^ C 255, M —> L
MRC-5 5 1369, C ^  A 431, L —» I
Enders B95a 2 and 5 353, T -^  G 92 V ,-»  G
HeLa 2 and 5 1117,T -> G 347 Y , - »N
Rubini B95a 5 1252,T -> C 392 C, -» R
1 JL-2 derived from two passages in B95a cells was passaged in Vero cells four times to investigate 
reversion.
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Summary
• B95a-derived JL-2, Enders and Rubini are genetic variants, when compared to their 
Vero-grown parental viruses.
• HeLa-derived Ur PT1, Ur PT3 and Enders virus progeny are genetic variants, when 
compared to their Vero-grown parental viruses.
• No genotypic differences in the HN gene were detected between Pol5/t and its cell- 
derived progeny.
• MRC-5-derived Ur PT3 is a genetic variant, when compared to its Vero-grown parental 
virus.
• Silent mutations were observed in viruses derived from B95a or HeLa cells.
• No genotypic differences were detected between BCL or CEF-derived viruses and their 
Vero-grown parental viruses.
5.4 DISCUSSION
The HN protein is involved in virus attachment to cells and also partly in effective virus 
budding. Sequence analysis of the HN gene was performed for viruses passaged in a 
variety of different host cells to investigate its involvement in host cell adaptation. Where 
differences in the molecular structure of the HN protein were detected, sequence analysis 
was repeated to confirm the result.
Initially nucleotide analysis of the HN gene was performed for the parental viruses. The 
percentage difference of nucleotide and amino acid residues within the HN protein of the 
strains sequenced is relatively low (Table 5.2) when compared to the SH gene. The SH 
gene is highly variable between strains (Afzal et al., 1997, Wu et al., 1998), showing 2.3% 
to 13.4% nucleotide sequence variation between the isolates analysed and the consensus 
sequence (Afzal et al., 1997). The HN genes of the MuVs analysed in this study show 
upto 7.95% nucleotide sequence variation.
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The data presented here indicate that passage of some MuVs in certain cell lines (B95a, 
HeLa and MRC-5) produces viruses with genotypic differences when compared to their 
Vero-grown parents. Genetic changes were observed in the form of nucleotide differences, 
several of which resulted in amino acid changes at residues 92, 205, 255, 347, 392, 431 
and 526. In addition to coding differences, silent substitutions were also detected. Silent 
differences arise due to random mutation during virus replication but it is also possible but 
unlikely that a nucleotide difference could have been introduced, in error, by the Taq 
polymerase used in the amplification of DNA from viral cDNA prior to sequencing.
Nucleotide analysis of the JL-2 HN gene indicated cross-banding between two nucleotides 
at position 692 (A/G, coding for amino acids His/Arg at residue 205 (Figure 5.3A)), 
suggesting that the Vero-grown parental virus is a mixed population. After the second 
passage in B95a cells this cross-banding was not observed; nucleotide A was detected 
(coding for amino acid His) but not nucleotide G (Figure 5.3A). Nucleotide 692 was a G 
in the data determined by Yates et al (1996) (Table 5.1). Therefore, it appears that the 
parental population has evolved to adapt to growth in its various environments; changing at 
amino acid 205 from an Arg, in virus passaged twice in Vero cells (Yates et al., 1996) to 
Arg/His, in virus passaged three times in Vero cells (JL-2 parental virus used in this 
project) to a His, in virus passaged in B95a cells. No reversion is observed in the HN gene 
of B95a-derived virus after further passage in Vero cells.
The Enders and Rubini strains of MuV have been observed to be genetically closely 
related, with few differences previously detected in their HN gene (Yates et al., 1996). 
Sequence data, determined in this project, support previous results that Enders and Rubini 
are very closely related to one another and, therefore, previous suggestions that one of 
these viruses arose as a laboratory contaminant of the other appear possible. The Enders 
and Rubini strains sequenced in this project had different passage histories, which could 
account for the few amino acid differences. Passage of these two strains in the same cell
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substrate did not select for the same mutations. This either suggests that, for Enders and 
Rubini to grow in B95a or HeLa cells, these amino acid differences were not necessary or 
were necessary to compensate for the differences already observed between the two 
strains.
Passage of MuV in Vero cell lines had previously been observed to select for genetic 
variants with amino acid substitutions in their HN protein at positions 335 and 464 (Yates, 
1995). It called into question the suitability of Vero cells for the propagation and assaying 
of MuV because certain viruses after passage in Vero cells were different from the original 
vaccine virus.
The MuVs, which contain amino acid differences in their HN gene, possibly contain 
differences in HN protein structure and/or function, enabling them to propagate on the 
B95a, HeLa or MRC-5 cell line to a greater extent than their Vero-grown parental virus. 
However, the observed mutations could be random mutations with no deleterious effect 
and mutations, responsible for adaptation, could be present elsewhere in the genome.
Viruses identified in this study with genetic differences were probably present in the 
original Vero-grown virus population but at a level too low to be detected by sequence 
analysis. The viruses, containing the amino acid differences, then outgrew the Vero-grown 
parental viruses and sequence differences were detected.
To complement the data determined in this chapter, where only a few of the progeny 
viruses contained changes in their HN genes when compared to the Vero-grown parents, 
analysis of the nucleotide sequence of the second glycoprotein, the F protein, was 
performed. It was also of interest to sequence the F gene of Enders and Rubini to observe 
the similarity between the two strains.
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CHAPTER VI
GENOTYPIC CHARACTERISATION OF THE F PROTEIN
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6.1 INTRODUCTION
Results from the previous three chapters indicate that growth of MuV in B95a or HeLa 
cells produces progeny of improved fitness. Some of the progeny are plaque morphology 
and/or antigenic variants of their parent and nucleotide differences within some of their HN 
genes have been detected, which could account for the observed phenotypic differences. It 
was also of interest to analyse the nucleotide sequence of the F gene of the progeny viruses 
to determine if any of the phenotypic variants were also genetic variants with respect to 
their F gene. In addition, this would extend available information on the MuV F protein 
structure, providing more information about its function.
6.2 EXPERIMENTAL PROCEDURES
The nucleotide sequence of the F gene of the Vero-derived parental viruses JL-2, JL-5, Ur 
PT1, Ur PT3, Enders, Rubini and Pol5/t was determined. Their respective amino acid 
sequences were deduced using the start codon of the standard triplet genetic code 
(Appendix I). The nucleotide sequence of the F gene of Mu Vs after passages two and five 
in each different cell line was also determined and the respective amino acid sequences 
deduced. The nucleotide and amino acid sequence of the F gene from the progeny viruses 
were then compared with that of their respective parental virus to determine the presence of 
genetic variants.
To analyse the nucleotide sequence of the F gene, viral RNA was extracted from infectious 
tissue culture fluid, cDNA synthesized and the DNA amplified by PCR as described in 
Chapter II. For each virus, the F gene was amplified in three overlapping fragments. 
Primers M-4 and F-4 were used to amplify the 5’ fragment of the F gene. The middle 
fragment was amplified using F-10 and F-12 and the 3’ fragment of the F protein gene was 
amplified using F-6 and F-2 (Figure 6. IB). Figure 6.1 A shows gel electrophoresis of the 
three DNA fragments after amplification. The PCR products were purified for use in
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Figure 6.1A: Agarose gel electrophoresis of the three overlapping fragments of DNA after 
PCR amplification of the MuV F gene.
2176bp 
1766bp 
1230bp 
1033bp
653bp
517bp
453bp
394bp
298bp
1178bp
*  2 , m Pl 12„ bp,
Lane 2 : Product of PCR amplification using primers M-4 and F-4 (1178 base pairs).
Lane 3: Product of PCR amplification using primers F-10 and F-12 (617 base pairs).
Lane 4: Product of PCR amplification using primers F-6 and F-2 (638 base pairs).
Lane 5: Negative control.
sequencing reactions, which were performed using the aforementioned primers giving 
complementary data, and the resultant chromatograms were analyzed as described in 
Chapter IV.
6.3 RESULTS
6.3.1 MOLECULAR CHARACTERISATION of the MuV F PROTEIN
The nucleotide and deduced amino acid sequences of the JL-2, JL-5, Enders, Rubini and 
Pol5/t F proteins were determined as described above and in Chapter II and have been 
submitted to the EMBL genetic database (accession numbers AJ010821, AJ133694, 
AJ133694, AJ009685 and AJO10300 respectively). The nucleotide and deduced amino 
acid sequences of Ur PT1 and Ur PT3, although determined, were not submitted because 
Ur Am9, the original Urabe vaccine strain, was submitted previously (Cusi et al., 1995).
The F gene sequence contains 1721 nucleotides (Appendix III) with the first start codon
located at nucleotide position 64. The coding region was 1614 nucleotides in length, from
nucleotide 64 to 1677 inclusive (the first stop codon was from 1678 to 1680), coding for
538 amino acids. Figure 6.2 shows the deduced amino acid sequence of the virus strains
analysed and also includes the amino acid sequence for SBL-1, RW and Ur Am9 viruses
and a consensus sequence, obtained via comparison of the amino acid sequences; the
amino acid residues used in the consensus sequence are the most frequently observed at a
particular position.. The inactive form of the F protein (F0) is cleaved into two subunits to
form the fusogenic form, which consists of two subunits, F2, from amino acid 1 to 102 and
FI, from amino acid 103 to 538 inclusive (436 amino acids in length). The signal peptide
at position 1 to 19 is underlined and shows high variation amongst the strains sequenced;
this high variation indicates the signal sequence is not a major determinant of infectivity.
Potential N-linked glycosylation sites are depicted in dark blue. All the F proteins of the
virus strains sequenced in this study contain a potential N-linked glycosylation site in the
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FIGURE 6.2: Deduced amino-acid sequence of the F protein of MuVs. Possible N-linked 
glycosylation sites are in blue, the cysteine residues are in green, the F protein cleavage 
site is shown in red, the fusion peptide is shown in light blue, the signal sequence is 
underlined and the transmembrane domain is shown in pink. The figure includes a 
consensus sequence and the sequences of the SBL-1 (Elango et al, 1989), RW (Waxham 
etal., 1987) and UrAm9 (Cusi etal., 1995) strains of MuV.
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Figure 6.2 continued:
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Figure 6.3: Chromatograms obtained by nucleotide sequencing of the F gene depicting the 
nucleotide difference in both Enders and Rubini, which translates to an amino acid 
substitution resulting in the addition of an extra possible N-linked glycosylation site.
a) JL-2, JL-5, Ur PT1, Ur PT3 and Pol5/t
nt 334
I
G A m  C À T m  C A A T  A T T G C A T C GC C C T C
AATATTG CA
Asn lie Ala
b) Enders and Rubini
nt 334
I
G A . À A  AC A T  A A A C  A A T  A T  T  A C  A T C G  C C  C T C
AATATTACA
Asn He Thr
F2 subunit at residues 73 to 75 (NKT); however, the Enders, Rubini and SBL-1 strains 
contain an additional site at residues 89-91 (NIT). Figure 6.4 shows an example of a 
chromatogram, obtained from nucleotide sequencing of the F gene at the site of the extra 
N-linked glycosylation site. In the FI subunit, all strains contain five potential N-linked 
glycosylation sites at amino acid residues 182-184 (NMS), 352-354 (NIS), 427-429 (NIT), 
433-435 (NLT) and 457-459 (NAS).
The cleavage site within the F protein between F2 and FI, between amino acids 102 and 
103, is highlighted in red and underlined and consists of the amino acid sequence Arg-Arg- 
His-Lys-Arg (Waxham et al., 1987). A protease is responsible for cleavage immediately 
after this sequence, between residues 102 and 103, forming a mature fusogenic protein with 
a fusion peptide at the N-terminus of FI consisting of residues 103 to 128, depicted in light 
blue (Figure 6.2). This domain is completely conserved amongst the Mu Vs sequenced to 
date. Adjacent to the fusion peptide is heptad repeat A (HRA), from position 130 to 178. 
A cysteine rich region, containing eight conserved cysteine residues (depicted in green), is 
located from amino acid 324 to 410. Heptad repeat B (HRB) is located between positions 
453 and 477. The transmembrane region is underlined and highlighted in pink at positions 
485-509. Conservation of the residues within HRA is observed for all seven mumps virus 
strains sequenced except for JL-5, which contained a Ser at position 177 (position f within 
HRA) instead of an Asn. Conservation of HRB was observed except for JL-5, which had a 
Phe at position 477 (position d in HRB) instead of a Val as observed in all other F proteins 
sequenced.
The percentage difference of nucleotide and amino acid residues between the F gene and 
protein of the strains sequenced is relatively low (Table 6.1). Percentage nucleotide 
differences were calculated as a percentage of the whole gene, including non-coding 
regions. The most variable region of the F protein is the signal sequence (Figure 6.2).
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TABLE 6.1: Percentage differences in the F protein between the seven MuV strains 
sequenced. The bottom left of the table depicts percentage differences in nucleotide 
sequence and the top right of the table depicts percentage differences in amino acid 
sequence. Values were rounded up to 2 decimal places.
VIRUS JL-2 JL-5 PT1 PT3 ENDERS RUBINI Pol5/t
JL-2
JL-5
PT1
PT3
ENDERS
RUBINI
Pol5/t
2.23
3.00
5.64
5.58
1.53
5.93
5.87
2.44
1.39 2.21
5.52 5.70
3.34
4.08
0.58
5.23
5.29
3.78
3.34 1.30 0.74
4.08 2.41 2.04
0.00 153 3.15
153 3.15
5 T 7 | I 0.37
5.23
3.72
0.35
5.17
3.15 
3.71
2.23
2.23
3.15 
2.97
5.17
The relationship between the nucleotide sequences was illustrated by constructing a tree 
diagram using a distance matrix approach (Figure 6.5). This is intended to show groupings 
of similar sequences and is not intended to imply any evolutionary relationship. In this 
sense, it is strictly a phenogram (Nei et a l, 1987). The distance between each pair of 
aligned sequences was calculated as the number of mismatched nucleotide bases, as a 
percentage of the sequence length and does not include nucleotides from the non-coding 
region. All sequences covered identical regions, and there were no gaps. The sequence 
alignment and calculation of distances was performed using the GCG software package 
(Wisconsin Package Version 9.1). The sequences were grouped using the average distance 
method (UPGMA) (Wisconsin Package Version 9.1) using an in-house program based on 
the SAS statistical package clustering procedure (SAS/STAT Users Guide, 1989). The 
phenogram includes data for the SBL-1, RW, Odate, Miyahara and Ur Am9 strains of 
MuVs. The relationship between the nucleotide sequence of the F gene of MuVs 
determined in this project and of other MuV strains that had previously been sequenced 
shows three clear groupings of MuVs (Figure 6.5). JL-2, JL-5, Enders and Rubini were 
grouped together with SBL-1. Ur PT1 and Ur PT3 were grouped together with the Ur
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Figure 6.4: Phenogram showing the relationship between the nucleotide sequences of the F 
genes of different MuV strains.
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Am9 strain, the Miyahara strain and the Odate strain. The wild-type Pol5/t was grouped 
separately with the RW strain.
The F proteins of JL-2 and of JL-5 differ by ten amino acids (2.23%), which are located in 
the signal peptide at positions 2, 4 and 11 and at positions 24, 70, 95, 177, 326, 331, 477, 
480 and 489. The two Urabe strains, Ur PT1 and Ur PT3 are grouped together and their F 
genes appear the closest, with a percentage nucleotide difference of 0.58 and no amino acid 
differences, showing full conservation of the secondary structure of the F protein between 
these two MuV strains. Enders and Rubini are also very closely related with two amino 
acid differences (0.37%) in the F protein, which are at position 443, a Thr in Enders and an 
Asn in Rubini and the second at position 533, a Gly in Enders and an Asp in Rubini. The 
wild type isolate included in this study, Pol5/t, was isolated from the throat of a patient 
with mumps in Portugal in 1996 in Vero cells. The F gene of Pol5/t has a percentage 
nucleotide difference of between 3.72 to 5.70% (Table 6.1) when compared to the F genes 
of the other MuVs sequenced and a 2.23 to 3.71% difference in the deduced amino acid 
sequence (Table 6.1). The F protein of Pol5/t is observed to be more closely related to the 
F proteins of the two Urabe viruses than the Jeryl Lynn, Enders or Rubini strains (Table
6.1). This wild type virus has a conserved fusion peptide domain and other structurally 
important amino acids, such as cysteines and prolines, are also conserved. If percentage 
amino acid differences are calculated omitting the signal peptide sequence, the values are 
lower (considerably in some cases) but the pattern of relationship between the viruses 
remains the same.
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6.3.2 EFFECT of HOST CELL PASSAGE on MuV GENOTYPE
After two and five passages in the various different cell lines, the F gene of the seven 
different strains was sequenced and compared with that of the parental Vero-grown viral 
sequence. No differences were observed between any virus passaged in any cell line, when 
compared to the Vero-grown parental virus, except for JL-2. The F gene of JL-2, derived 
by five passages in B95a cells, contained a difference at nucleotide 751 (A —► G), which 
coded for an amino acid change at position 230 (Ser —> Gly) (Figure 6.5). No other 
nucleotide and hence amino acid substitutions were observed in the F gene of virus derived 
from passage in different cell lines.
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Figure 6.5: The chromatograms showing the results of nucleotide analysis of the F gene; 
the mutation between JL-2 and its B95a-derived progeny is shown.
JL-2 JL-2 passaged on B95a cells
nt 751, a; Ser nt 751, g; Gly
4
6.4 DISCUSSION
6.4.1 F PROTEIN STRUCTURE
The fusion gene of seven MuV strains was sequenced. The length of the nucleotide and 
deduced amino acid sequences were identical to those reported for other MuV strains 
(Elango et al., 1989; Waxham et al., 1987; Takeuchi et al., 1989; Cusi et al., 1995) at 1721 
nucleotides and 538 amino acids.
The amino acid sequence of the F gene shows high conservation with the exception of the 
signal sequence. Full conservation of the residues within HRA and HRB is observed with 
the exception of JL-5, which contained a Ser at position 177 (position f within HRA) 
instead of an Asn and a Phe at position 477 (position d in HRB) in place of a Val. These 
substituted amino acids retained the hydrophobicity of the HR regions. The F protein of 
Enders and Rubini contains an extra potential N-linked glycosylation site in the F2 peptide 
when compared to the other viruses studied. The SBL-1 strain of MuV also contains this 
extra potential N-linked glycosylation site and the phenogram (Figure 6.4) indicates that 
the F proteins of Enders, Rubini and SBL-1 are closely related. The glycosylation status of 
this or any other site is unknown but is highly likely because N-X-T/S sites are usually 
glycosylated, especially for virus glycoproteins.
Critical amino acids, such as cysteine, are important for the biological activity of proteins. 
Cysteine residues are important for structure and conformation and are also involved in 
linking FI and F2, the two subunits of the mature F protein. The cysteine residues in the F 
protein are highly conserved. Other structurally important amino acids such as proline, 
glycine and alanine also show a high level of conservation.
The cytoplasmic domain of the F protein also appears important for syncytia formation, by
comparison to NOV. Mutational analysis implicated a region of ten amino acids at
position 540 to 550, important for syncytia formation by NDV (Sergei and Morrison,
1995). The cytoplasmic domains of the F protein of the MuV strains studied here show
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high conservation of residues, implicating the importance of this region. It is possible that 
the cytoplasmic domain interacts with cellular proteins such as cytoskeletal components 
that participate in syncytia formation.
The phenogram, generated from the nucleotide sequence of the F gene indicates three 
groups. JL-2, JL-5, SBL-1, Enders and Rubini constitute one group, RW and Pol5/t 
constitute a second group and Odate-1, Miyahara, Ur PT1, Ur PT3 and Ur Am9 constitute 
the third group. These results uphold a recent study of the relationship between the SH 
protein genes of mumps viruses (Wu et a l, 1998). The first group corresponds to group A, 
European and North American isolates, the second group corresponds to group D, also 
European and North American isolates and the third group corresponds to group B, 
Japanese isolates plus a few UK isolates. The percentage difference of nucleotide and 
amino acid residues within the F protein of the strains sequenced is relatively low (Table
6.1) when compared to other genes, such as the SH gene. The SH gene is highly variable 
between strains (Afzal et a i, 1997; Wu et al., 1998), where upto 13.4% nucleotide 
differences are detected between strains (Afzal et al., 1997). The phenogram showing the 
relationship between the various MuV strains, with respect to their F protein, shows 
comparable grouping to a phenogram presented by Yates et al (1996), with respect to the 
HN protein of MuVs. The high level of conservation between the F genes suggests that the 
function of this protein is important and that there is little room for variability.
The F protein of the MuV strains included in this study contain two heptad repeat regions 
that are highly conserved and contain hydrophobic residues at their a and d positions 
(Figure 6.6). The MuV protein sequences described here are consistent with the structures 
reported for HIV and influenza fusion proteins, gp41 and HA respectively.
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6.4.2 EFFECT of HOST CELL SELECTION on the GENETIC PROPERTIES of MuV. 
The F protein was completely conserved between viruses derived after passage in five 
alternate cell lines and their Vero-grown parental strain except for JL-2, passaged five 
times in B95a cells, where a nucleotide difference at position 751 (A —» G) resulted in a 
coding difference (Ser —» Gly).
A previous study selected genetic variants of MuV by passage, which has altered structure 
and pathogenicity. Borskin et al (1992) observed that the Leningrad-3 strain of MuV, 
when passaged in QEF cells, after either 8 or 38 passages, differed at nucleotide 501 in the 
F protein, an A residue after 8 passages and a G residue after 38 passages. The virus 
passaged 8 times was also observed to contain several regions of cross banding, suggesting 
that this virus consisted of more than one variant. The authors found no change in the P 
gene and did not examine the HN or any other viral gene.
6.4.3 CONCLUSION
The high conservation of the F protein between MuVs suggests that the function of this 
protein is completely defined and the role it performs does not allow for much change in 
primary or secondary structure and the selection of only one F protein variant from all the 
MuVs passaged on all the different cell lines confirms this. The MuV F protein resembles 
the F protein of other paramyxoviruses and of other RNA viruses suggesting that the role it 
performs and the method it uses to perform these roles is similar.
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Figure 6.6: Amino acid sequence of the two HR regions located within the FI subunit of 
the F protein of the seven MuV strains analysed in this study. Underlined residues were 
not completely conserved between the strains sequenced. Includes sequences for other 
paramyxoviruses : MV (Richarson et al., 1986), NDV (Chambers et al., 1986) and Sendai 
Virus (Blumberg et al., 1985). Residues at positions a and d are capitalised and 
highlighted. The conservation of hydrophobic amino acids within these HR regions is 
clear.
A) HRA
MuV AqtNaralaaMknsIqaTnraVfeVkegTqqLaiaVqalqdhlntlmntQ 
MV SmlNsqaldnLrasLetTnqaleaGqemllaVqgvQdylnneLipSmnqL 
NDV AkqNaanllrLkesIaaTneaVheVtdgLsqLavaVgkMqqfVndQfnkT 
SeV  AreAkrdlallkesMtkThksVelLqnaVgeQilaLktLqdfVndEikpA
B) HRB (leucine zipper motif)
MuV LskVnasLqnAvkylkeSnhqLqsVsvs 
MV LgnAiakLedAkelLesSdqiLrsMkgl 
NDV LgnVnnsIsnAldkLeeSnskLdkVnvk 
SeV  LadAtnfLqdSkaeLekArkiLseVgrw
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CHAPTER VII 
GENERAL DISCUSSION
167
7.1 INTRODUCTION
Tissue culture is an invaluable tool in the study of MuV infection because, to date, no 
optimal animal model has been identified. Vero cells are currently used for isolation, 
propagation and assaying of MuVs; however, the appropriateness of this is under question 
after a previous study concluded that growth of MuV in Vero cells produces virus 
populations that are different from the original isolate (Yates., 1995). Yates (1995) 
passaged MuVs on Vero and CEF cells, and observed that variants were selected with a 
different antigenic pattern compared to the previous, predominant population. The Vero 
adapted Urabe vaccine strain of MuV was neutralised by a panel of anti-HN MAbs, 
whereas the commercial bulk Urabe vaccine, adapted to CEF cells, was not neutralised by 
one of the MAbs. Sequencing of the HN gene revealed one amino acid difference between 
the two at position 335. In the CEF isolate, no selection occurred and the amino acid at 
335 was a Lys. In the Vero adapted virus, selection occurred and the amino acid at 335 
was a Glu. The author also observed that passage in Vero cells appeared to select either a 
virus with a Lys, instead of an Asn, at position 464 or a Glu, instead of a Lys, at position 
335, but not both. The study by Yates (1995) called into question the suitability of using 
Vero cells for MuV propagation and especially for wild type MuV isolation from patients.
During the period of study leading to this thesis, several cell lines were investigated to 
increase our understanding of the mechanisms involved in host cell passage of MuV and to 
move towards an optimum host cell with which to study MuV replication in vitro. This 
thesis describes the phenotypic and genotypic analysis of MuV after passage in a variety of 
host cells by the application of virological and molecular techniques. Tables 7.1 A and B 
provide a brief summary of the results of passaging MuVs in B95a or HeLa cells and 
indicate increased viral infectivity, with occasional phenotype or genotype alterations in 
comparison to the Vero-adapted parental virus.
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Table 7.1 A: Summary of the differences observed between Vero-grown viruses and their 
B95a-derived progeny.
Virus Fitness Plaque
morphology
Antigenic
profile
HN F
JL-2 +1 ✓ 5 ✓ 205 (R->H) 230 (S-»G)
JL-5 -/+3 S4
UrPTl + s
Ur PT3 +
Enders + ✓ 92 (V—»G)
Rubini + ✓ ✓ 392 (C—»R)
Pol5/t +
Table 7.2: Summary of the differences observed between Vero-grown viruses and their 
HeLa-derived progeny.
Virus Fitness Plaque
morphology
Antigenic
profile
HN F
JL-2 -/+
JL-5 -/+ ✓
UrPTl -/+ ✓ 526 (K—»T)
Ur PT3 -/+ ✓ 255 (M->L)
Enders -/+ ✓ ✓ 347 (Y-»N)
Rubini -/+
Pol5/t -/+
1 +, Increase in virus fitness without prior adaptation period.
2 ✓ , Difference in phenotype detected.
3 -/+, Increase in virus fitness after a period o f  adaptation.
4 S, Silent change detected
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In addition to Vero cells, two other cell lines have been identified as possible alternatives 
for the analysis of mumps infection in vitro, B95a and HeLa cells. The data suggest that, 
although the HN protein is important for virus attachment and entry to the cell, the 
observed phenotypic changes are not likely to correspond to the observed genotypic 
changes in the HN. The observed genotypic changes in the HN are likely to be 
coincidental. This is based on observations that, in the majority of cases, a difference in 
plaque morphology or antigenicity coincides with a difference in the molecular structure of 
the HN protein but no correlation is observed between those properties. For approximately 
half of the B95a and HeLa-derived viruses, no phenotypic or genotypic change was 
observed beyond an increase in viral fitness, again suggesting no correlation between 
phenotypic and genotypic changes as far as tested. After one or several passages of a virus 
under different environmental conditions the virus population may consist of a different 
proportion of variant to parent and hence the virus population may show an altered 
genotype and may also show altered phenotypic characteristics. This concept has 
previously been observed for MuV growth in Vero and CEF cells (Afzal et al., 1998; Yates 
et al., 1996) and has now been observed for some MuVs after growth in B95a, HeLa and 
MRC-5 cells.
7.2 EFFECT of HOST CELL PASSAGE on MuV PHENOTYPE and GENOTYPE
Viral fitness is defined as the ability of a virus to produce infectious progeny and was 
measured using the TCID50 assay. HA and NA assays were performed to detected any 
virus activity not detected by the TCID50 assay. In addition to replicating viruses, non­
replicating viruses also contain HA and NA activity, hence these assays were not used to 
determine the infectivity of the MuVs. After passage in B95a cells, MuVs significantly 
increased in fitness without an apparent adaptation period, with the exception of one 
variant of the Jeryl Lynn vaccine (JL-5). After passage in HeLa cells, MuVs significantly 
increased in fitness following an apparent adaptation period. Adaptation to a cell line is
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usually indicative of a difference in virus genotype because it is likely that a virus, which 
has increased its fitness for a particular cell substrate after a period of adaptation, will be a 
variant of the original Vero-derived parent (Section 1.12). It was thus anticipated that 
B95a-derived viruses would potentially be identical in genotype to the Vero-grown parent, 
with the exception of JL-5, whilst HeLa-derived viruses would much more likely be 
variants of their respective Vero-grown parent. However, where genotypic and other 
phenotypic differences were expected they were not identified in all cases and vice-versa.
In addition to increased fitness some, but not all, of the progeny viruses after passage in 
B95a or HeLa cells had an altered phenotype and genotype. Four progeny viruses had 
altered plaque morphologies, and three of these coincided with a change in antigenic 
profile; the exception was Ur PT3 (Tables 7.1 A and B). Three further viruses had changes 
in antigenic profile which did not coincide with a difference in plaque morphology (Tables 
7.1 A and B). Six viruses had amino acid changes in their HN protein and each one 
coincided with altered plaque morphology and/or antigenicity. Only one virus had a 
change in the F protein. Seven of the virus progeny from passage in B95a or HeLa cells 
did not contain a phenotype or amino acid change, although two silent changes were 
detected. This was not unexpected for the B95a-derived viruses (except for JL-5) because 
there was no apparent period of adaptation but was unexpected for the HeLa-derived 
viruses because there was a clear period of adaptation.
These results imply that the role of the HN protein in cell tropism is ambiguous for the cell 
lines used in this study because sequence changes were not identified in all cases of 
adaptation, change in antigenicity or change in plaque morphology. For example, JL-5 
provided the most dramatic evidence for adaptation of all the viruses during its growth in 
B95a cells, where infectivity was barely detectable for the first two passages but then 
increased significantly. Curiously, this dramatic adaptation event did not coincide with a
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sequence difference in the HN or F proteins or any other phenotypic difference. 
Presumably other viral proteins are involved in host cell tropism.
Where differences in antigenicity were detected (in some viruses after passage in B95a or 
HeLa cells), they were anticipated to be due to substitutions within the HN protein 
sequence because the MAbs were raised against this protein and this was generally the 
case, with one exception (JL-5 passaged in HeLa cells). The substituted amino acid 
residues in the HN protein responsible for monoclonal antibody escape in the progeny 
viruses are:
• 205 (JL-2), 92 (Enders) and 392 (Rubini) after passage in B95a cells.
• 526 (Ur PT1) and 347 (Enders) after passage in HeLa cells.
No amino acid difference was detected which could explain the difference in antigenicity 
between JL-5 and its progeny after passage in HeLa cells; the resistance was likely due to 
breakthrough virus. There was no clear correlation between escape from neutralisation and 
a particular MAb or between escape from neutralisation by a specific MAb and substituted 
amino acid residues in the HN protein.
Differences in plaque morphology identified between parental Vero-grown viruses and 
their progeny also coincided with substitutions in the HN protein (Tables 7.1 A and B). 
However, no correlation was observed between the genotypic and phenotypic changes, 
therefore, the HN protein is not implicated as the cause of these phenotypic changes. The 
alterations in plaque morphology are likely due to differences between host cell factors 
present in the cell line used in growth of the virus and present in the cell line used for 
assaying the viruses (Vero cells).
The relative positions of the amino acid residues implicated in monoclonal antibody escape 
within the three-dimensional structure of the HN protein are unknown, as this has not been 
determined. However, using computer predictions kindly performed by Dr. Mark Forster, 
NIBSC, it was possible to predict the secondary structure of the HN protein, based on the
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published sequence of the HN protein of JL-2 and using a computer program developed by 
the Protein Bioinformatics Group at the University of Warwick; the results are presented in 
Figure 7.1. The computer predictions are based on careful cross validation of related 
protein chains.
The predicted structure of the HN protein, presented in Figure 7.1, shows an initial random 
coil region of 5 amino acids at the N-terminal end of the protein, followed by a 4 amino 
acid region of strand. Following the strand region is another region of random coil, then 
an a-helical structure including residues 26 to 60, presumed to be the transmembrane 
domain. Alpha helices were also predicted between amino acid residues 71 to 118, 
presumed to include both heptad repeat regions. There are many predicted regions of 
'strand', indicative of p-pleated sheets, and often two strands are separated by a short region 
of random coil, suggesting the (3 pleated sheets run in opposite direction to one another.
The mutations observed in this study (Tables 7.1 A and B) are randomly located in different 
regions of the HN protein (Figure 7.1). Amino acids at position 205, 347 and 392 are 
located in regions of random coil, amino acid at position 92 is in an a-helix region and 
amino acids at positions 255 and 526 are located in strand regions. No differences in the 
were observed when the computer predictions were performed using the mutated 
sequences, suggesting the mutations had no effect on the structure of the HN protein.
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Figure 7.1: The predicted structure of the HN protein. The degree of confidence was 
determined through comparison of known related sequences. C = random coil, E = 
strand and H = helix.
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Data for predicting whether amino acids are buried or exposed within the HN protein was 
determined using an alternate programme (Rost et al., 1995), data not shown. This 
programme predicts accessibility of amino acids by comparison of each amino acid in the 
protein sequence with the Dictionary of Secondary Structure of Proteins (DSSP). The 
results of this programme indicate that only two of the amino acids identified above are 
exposed (residues 205 and 347) and that all the other amino acids (92, 255, 392, 526) are 
buried within the HN protein (data not shown).
The two amino acids identified as being exposed (residues 205 and 347) are not implicated 
in the MAb resistance observed because resistance to the same MAbs in JL-5, Ur PT1 and 
Enders did not coincide with these mutations. It is possible that amino acids at positions 
205 and 347 were partially responsible for the changes in plaque morphology observed in 
JL-2 and Enders.
A molecular difference within the HN protein of Ur PT3 after passage in MRC-5 cells was 
identified at amino acid residue 431 with no apparent effect on virus plaque morphology or 
antigenicity. This difference coincided with the apparent adaptation of this virus to MRC- 
5 cells. Using the program developed by Rost et al (1995), this amino acid is predicted to 
be buried within the HN protein, and therefore, is not implicated in the apparent adaptation 
to MRC-5 cells (data not shown).
MuV growth in BCL, CEE and MRC-5 (except for Ur PT3) cells resulted in no growth of 
virus. Virus activity detected by the TCID50 assay was likely remaining input virus. 
Evidence of true replication could have been obtained by performing western blotting to 
assay for the viral proteins involved in replication. The low levels of infectious progeny 
could be due to several factors, including the inability of MuV to attach to the cell, to enter 
the cell and/or to replicate within the different environment. Also, for infectious virus to 
be produced, the mature F protein requires cleavage by an appropriate protease. Therefore, 
the distribution of protease in the host is also a critical factor in determining virus tropism.
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Growth of MuVs in the presence of external trypsin was not attempted in this study but 
could have aided virus growth.
It appears that the two Urabe viruses were less affected by passage than the other viruses. 
They maintain a good titre in B95a cells with no changes in plaque morphology, 
antigenicity or protein sequence and in HeLa cells the required adaptation period for Ur 
PT1 and Ur PT3 was minimal compared with the other strains. Takeda et al (1998) 
showed that Vero-grown measles virus (MV) lost its ability to replicate and induce 
syncytia in B95a cells, and they implicated the P and L proteins. It appears that a similar 
effect has happened with the Urabe viruses because Vero-grown Ur PT1 and Ur PT3 
caused less cell fusion in B95a cells in contrast to the other MuVs investigated. However, 
these two MuVs did replicate and produce infectious progeny upon infection of B95a cells. 
Unfortunately, no other virus proteins of MuVs were analysed in this study.
Host cell tropism and cell to cell spread of paramyxoviruses has been investigated in detail 
recently with different studies implicating different viral proteins as being responsible. A 
study by Yates (1995) implicated two amino acids in the adaptation of the Urabe strain of 
MuV to Vero or CEF cells, at positions 335 and 464 within the HN protein (section 1.12); 
the sequences of the other viral genes were not analysed. These amino acids were 
conserved between parental Vero-adapted viruses and their progeny in this study either 
suggesting that they were not important for determining host cell range but possibly for 
other phenotypic characteristics or that no adaptation occurred in this study.
Passage of wild type measles virus (MV) in Vero cells results in virus progeny that is 
attenuated (Kobune et al., 1990), whilst the use of B95a cells isolates virus that closely 
resembles the wild type in that it remains infectious for humans. Takeda et al (1998) 
analysed and compared the genome sequences, glycoprotein structure and function, and 
gene expression and replication of a wild type MV isolated in B95a cells and its Vero- 
adapted counterpart upon growth in B95a cells. Genome differences were detected in the
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H, P and L proteins. Further examination of the H proteins from the B95a or Vero-derived 
viruses showed that they were equally able to support fusion and it was concluded that the 
amino acid changes appeared to be co-incidental. Gene expression and replication was 
investigated by blocking de novo protein synthesis, amplifying the mRNAs obtained from 
primary transcription and confirming the specificity of each band by Southern blotting. 
The specific mRNA products after B95a infection with Vero-adapted virus were 
significantly less abundant than those from B95a-adapted virus; therefore, the genome 
replication of the Vero-adapted virus was significantly impaired in B95a cells compared 
with that of the B95a-adapted virus. The authors implicated the P and L proteins in this 
significantly impaired gene transcription and concluded that MV adaptation to growth in 
Vero cells results in transcriptional attenuation in B95a cells due to amino acid changes 
located in the polymerase and accessory proteins.
A study by Johnston et al (1999) also looked at host cell tropism of MV, this time by 
functionally analysing the syncytium-inducing ability of MV F and H proteins of vaccine 
and wild-type strains in different combinations in transfected Vero or HeLa cells. They 
concluded that the H and F proteins were necessary for MV host cell tropism but that other 
factors were also important. By mutational analysis, the M protein has also been shown to 
play an important role in MV spread (Cathomen et al., 1997), by interacting with the 
cytoplasmic tails of the F and H proteins, inhibiting cell-to-cell fusion and promoting the 
assembly of virus particles.
Virus glycoproteins are often implicated in host cell tropism because they attach the virus 
to the cell. However, because of the ubiquitous nature of the MuV cellular receptor, sialic- 
acid located on glycoproteins and glycolipids, in this study it is likely that the HN protein 
is not implicated in host cell tropism. This could have been verified with adsorption 
studies. Relating the genotypic and phenotypic characteristics of viruses studied for this 
thesis and comparing them to the other studies mentioned, it seems likely that the envelope
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glycoproteins, whilst highly implicated, do not solely determine MuV cell tropism or virus 
phenotype.
7.3 The HN PROTEIN
The HN protein is responsible for attaching the virus to the cellular receptor, a sialic-acid 
containing glycoprotein or glycolipid. It also interacts with the F protein to allow virus 
fusion with the host cell membrane. Data determined in this study suggests that molecular 
differences identified in the HN protein of the MuVs after passage in different host cells 
are coincidental and are not involved in determination of virus phenotype.
Unlike Ur PT3, Ur PT1 grown on HeLa cells, cannot haemagglutinate horse erythrocytes 
and these viruses differ by only one amino acid (89) in their HN protein. The region 
within the HN protein responsible for attachment to erythrocytes is unknown but 
potentially this amino acid forms part of the receptor-binding site. Using the program 
developed by Rost et al (1995) for predicting secondary structure and accessibility, this 
residue is located within an a-helical region but is buried within the helix and is therefore 
not implicated in this event (data not shown). It is unknown how this difference in the 
haemagglutinating ability occurs.
For influenza virus, neuraminidase activity is partly responsible for aiding in the budding 
of progeny viruses by preventing them reabsorbing to the infected cell and in the removal 
of sialic acid to prevent self-aggregation of virus particles (Palese et al., 1974). It is 
assumed that the MuV neuraminidase has a similar role. Of the parental Vero-grown 
viruses, only Enders and Rubini possessed detectable neuraminidase activity. Amino acids 
within the HN protein of Enders and Rubini, which were identical to each other but 
different to the HN protein of the other MuVs, were residues 106 and 266. It is probable 
that one or both of these amino acids form part of the neuraminidase active site. Active 
sites for neuraminidase have been proposed previously to be located between amino acids
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93 and 110 (Wang et al., 1999) and between 241 to 246 (Jorgensen et al., 1987). Amino 
acid 106, Arg in Enders and Rubini and Gly in the other viruses, is within one of these 
proposed neuraminidase active sites, suggesting that it can affect the NA activity of MuVs 
and is within an HR region, an important region for HN function, possibly both for 
neuraminidase activities and for interaction with the F protein (Stone-Hulslander et al., 
1999). Amino acid 266, Ala in Enders and Rubini and Asp in the other viruses, except 
Pol5/t (Glu), possibly also affects the NA activity of mumps viruses, where an Ala 
increases activity and a Glu decreases activity compared to Asp (the neuraminidase 
activity of Pol5/t was lower than other viruses). Using structural prediction programmes 
developed by Rost et al (1995), residues 106 and 266, determined in this project as being 
important for neuraminidase activity, are predicted to be exposed within the HN protein, 
compatible with their involvement in the neuraminidase active site (data not shown). Sites 
proposed previously to form neuraminidase active sites (residues 93 to 110 and 241 to 246) 
are predicted to be buried; the first is within an a-helical region and the second within a 
strand region.
Previous observations have suggested that levels of neuraminidase can affect the rate of 
fusion (Merz et al., 1981) and hence the plaque morphology of a virus. MuV only 
produces low levels of neuraminidase and in this study, no correlation is observed between 
NA activity and fusion activity or plaque morphology.
Although results from this study do not solely implicate the HN protein in determining 
host cell tropism, studies on other viruses have suggested that envelope glycoproteins play 
an important role. Analysis of molecularly cloned isolates of HIV-1 with different tropism 
for immortalized CD4+ cell lines, has identified part of the V3 loop of one of the envelope 
glycoproteins, gpl20, as the major determinant of cell tropism (Chavda et al, 1994). 
Although having a different sequence, the V3 region of the viral envelope protein, SU, of 
feline immunodeficiency virus (FIV) is also implicated in host cell tropism, through
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characterisation of chimeric infectious molecular clones containing envelope gene 
sequences (Vahlenkamp et aL, 1999).
The envelope glycoprotein of the rhabdovirus infectious hematopoietic necrosis virus 
(IHNV) has also been implicated in playing an integral part in tissue tropism (Kim et aL, 
1994). Kim et al (1994) analysed the genomes of neutralisation resistant variants of IHNV 
that had been selected with a glycoprotein (G)-specific monoclonal antibody and compared 
the sequence with the parental strain. One of the variants was highly attenuated with 
markedly different tissue tropism and sequence analysis indicated that two changes 
detected in the G protein were responsible for the altered tissue tropism of the variants.
7.4 The F PROTEIN
The F protein is responsible for MuV fusion with cell membranes, during virus entry into 
the cell and during the creation of multinucleated cells or syncytia when an infected cell 
fuses with a non-infected cell. Cytopathic effect in an infected cell line is an indication of 
virus infectivity. Mumps viruses did not produce CPE in BCL, CEF or MRC-5 cells; even 
Ur PT3, the only MuV to adapt to MRC-5 cells, did not produce CPE. In contrast, in 
MuV-infected B95a and HeLa cells, CPE was observed. The CPE in MuV-infected B95a 
cells and HeLa cells differed between MuV strains, Ur PT1 and Ur PT3 causing less cell 
fusion than the other MuV strains; this did not seemingly affect the infectivity titres of 
theses two viruses in B95a or HeLa cells. The F proteins of the two Urabe viruses differ 
from all the other strains by seven amino acid substitutions at positions 5 (Pro —> Leu, in 
the Urabe viruses), 17 (Ser —> Val), 95 (Pro —> Ser), 195 (Ser —> Phe), 246 (Ala —» Thr), 
370 (Val —> Thr) and 389 (Ser —> Asn). The amino acid differences at positions 5 and 17 
are located within the variable signal sequence of the F protein, and changes in this region 
are not considered important for the decreased cell fusion observed. Amino acid 95 is 
located within the F2 subunit just prior to the cleavage site. Amino acid 195 is located on
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the C terminal side of HRA (Joshi et al., 1998), and amino acids 370 and 389 are located to 
the N terminal side of HRB and within a cysteine rich area. Amino acids 95, 195, 246, 370 
and 389, separately or together, probably affect the fusogenic properties of the MuV F 
protein. Mutational analysis of the RW F protein showed that replacement of Ser-195 by 
aromatic amino acids such as Trp or Phe, significantly reduced the fusion inducibility of an 
otherwise fusion competent F protein (Tanabayshi et al., 1994). If this observation holds 
true for other strains of MuV, it could account for the reduced cell fusion caused by Ur 
PT1 and Ur PT3. The reduced ability to induce syncytium formation could also be due to 
differences in the P and L proteins, as discussed previously (Takeda et al., 1998).
For some paramyxoviruses, including MuV, the F protein also requires the presence of the 
HN protein for efficient fusion. The HN protein contains two HR domains, between amino 
acids 93 and 125, which are thought to form a-helical structures (Figure 7.1), could 
possibly interact with the HR domains of the F protein (Stone-Hulslander et al., 1999). 
Mutations in these HN HR domains adversely affected fusion promotion. The HN proteins 
of Ur PT1 and Ur PT3 contain mutations in the second HR domain when compared to the 
other MuVs. Mutations were observed at amino acid positions 121 to 123, NRN —> GKK. 
It is possible that these mutations adversely affect the fusion capability by an altered 
interaction between the HN and F proteins of the two viruses. However, Pol5/t also had 
mutations at the same site, NRN —> SKK, but its fusion ability was not adversely affected. 
Therefore, if these residues in the HN protein are important for fusion activity, the double 
K residue potentially is not implicated in adverse affects on fusion whilst residue 121 
could be, where a Gly reduces fusion ability. Residue 121 is located in an area of random 
coil (Figure 7.1) and is predicted to be exposed (Rost et a l, 1995), implying that it could 
interact with the F protein.
The F genes of the seven MuV strains under study were sequenced and a high conservation 
level was observed except for within the signal peptide. The signal peptide contains a
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sequence which not only directs and anchors the F protein in the RER membrane and 
hence the cell membrane but also provides the means for ribosome attachment to the 
mRNA. It is not presumed to have a direct role in fusion. Only one amino acid difference 
was identified between a parental Vero-adapted virus and its progeny. This was in the F 
protein of JL-2 (amino acid residue 230) after passage in B95a cells. The role of the 
mutation is unknown but it is not implicated in the smaller plaque morphology of JL-2 
because the amino acid difference only occurred after passage five whereas smaller 
plaques were observed after the first passage. The data suggest that the F protein does not 
have a main role in host cell tropism.
7.5 FUTURE STUDIES
In this study it would have been useful to passage MuV in Vero cells alongside passage in 
the other cell lines to investigate whether the parental Vero-adapted viruses would have 
increased in fitness in parallel with virus passaged in B95a and HeLa cells. In the future, it 
would be of interest to analyse the sequence of the P, L, M and NP genes of the B95a, 
HeLa and MRC-5 adapted viruses to investigate whether other amino acid differences 
could account for the host cell adaptation. It would also be of interest to grow the variants 
of the Jeryl Lynn and Urabe vaccines and of Enders and Rubini in B95a and HeLa cells in 
competition assays to determine if one virus population would outgrow the other and to 
calculate the level at which variants arise, by quantitative PCR. The isolation and growth 
of clinically derived wild type virus in B95a cells and in HeLa cells could be an important 
investigation to determine if virus progeny resembles the wild type or if  variants arise, as 
observed for isolation and passage in Vero cells, and to determine if  virus progeny retains 
its infectivity for humans.
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7.6 CONCLUSIONS
•  Mumps viruses passaged in B95a or HeLa cells were of greater fitness, as determined 
by an increase in infectivity, measured using the TCID50 assay, than the parental Vero- 
adapted viruses.
•  Changes in virus phenotype were identified after passage of MuVs in B95a and HeLa 
cells; the HN glycoprotein is not implicated in these events.
• Neither the HN nor F glycoproteins are implicated in the apparent adaptation of JL-5 to 
B95a cells or of all MuVs to HeLa cells.
• Amino acids 106 and 266 within the HN protein possibly affect the neuraminidase 
activity of MuVs and were predicted to be exposed on the surface of the HN protein.
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APPENDIX I
THE STANDARD GENETIC CODE
u u u Phe UCU Ser UAU Tyr UGU Cys
u u c Phe UCC Ser UAC Tyr , UGC Cys
UUA Leu UCA Ser UAA stop UGA stop
UUG Leu UCG Ser UAG stop UGG Tip
CUU Leu e c u Pro CAU His CGU Arg
c u e Leu CCC Pro CAC His CGC Arg
CUA Leu CCA Pro CAA Gin CGA Arg
CUG Leu CCG Pro CAG Gin CGG Arg
AUU lie ACU Thr AAU Asn AGU Ser
AUC He ACC Thr AAC Asn AGC Ser
AUA lie ACA Thr AAA Lys AGA Arg
AUG Met ACG Thr AAG Lys AGG Arg
GUU Val GCU Ala GAU Asp GGU Gly
GUC Val GCC Ala GAC Asp GGC Gly
GUA Val GCA Ala GAA Glu GGA Gly
GUG Val GCG Ala GAG Glu GGG Gly
SYMBOLS FOR AMINO ACIDS:
SYMBOL ABBREVIATION FULL NAME
A Ala Alanine
C Cys Cysteine
D Asp Aspartic acid
E Glu Glutamic acid
F Phe Phenylalanine
G Gly Glycine
H His Histidine
I Ile Isoleucine
K Lys Lysine
L Leu Leucine
M Met Methionine
N Asn Asparagine
P Pro Proline
Q Gin Glutamine
R Arg Arginine
S Ser Serine
T Thr Threonine
V Val Valine
W Trp Tryptophan
Y Tyr Tyrosine
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APPENDIX H
The nucleotide sequence determined of the HN gene of seven mumps viruses used in this 
project.
1 50
JL-2 
JL-5 
Ur PT1 
u r  P T 3  
Enders 
Rubini 
Pol5/t 
Consensus AAAGAAAAAA GCAAGCCAGA ACAAACTTAG GATCACAACA CAACACAGAA
51 100
J I i - 2  --------------------  --------------------  --------------------  --------------------  --------------------
J L - 5 --------------------
Ur PT1 CCCC------ C---- T --TC--T--- -G--CGA--G------------
Ur PT3 CCCC------ C---- T --TC--T--- -G- -CGA- - G ------------
Enders ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------
Pol5/t CCCC------ --C-------- ---C-------- G ------------
Consensus TATTAGCTGC TATCACAACT GTGTTCCGGC CACTAAGAAA ATGGAGCCCT
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
101
----------    C-------------------------
----------- T ---------  ----------  ---------- ----------
-A---- C-- --C------A -----------   T
-A---- C-- --C------A -----------   T
150
 T-C-- - -C A  -------------------   G---- C-
CGAAACTATT CATAATGTCG GACAATGCCA CCTTTGCACC TGGACCTGTT
151 200
JL-2 ----------
JL-5 ----------
Ur PT1 A-C-------- -A-AC--------- G ----------  C-------------
Ur PT3 A-C-------- -A-AC--------- G----------  C-------------
Enders ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------
Pol5/t A-C--------  AC----- ----------------  C-------------
Consensus GTTAATGCGG CTGGTAAGAA GACATTCCGA ACCTGTTTCC GAATATTGGT
201 250
JL-2   A ---------------- ----------  ----------
JL-5   -----A----T----------------------- ----------
Ur PT1 A--G------------------ ---------- A ---------- ------------
Ur PT3 A--G------------------ ---------- A ----------  --------
Enders   C---------------- ----------
Rubini   C---------------- ----------
Pol5/t A ------- G ------------ ----------  ----------  ----------
Consensus CCTATCTGTA CAAGCTGTTA CCCTTATATT GGTTATTGTC ACTTTAGGTG
JL-2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
251 300
G-G
G-G
 G-G-- ----------  ----------  ----------  ----------
AGCTTATTAG GATGATCAAT GATCAAGGCT TGAGCAATCA GTTGTCTTCA
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APPENDIX II continued:
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL - 5 
Ur PT1 
Ur PT3 
Enders • 
Rubini 
Pol5/t 
Consensus
JL-2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
301 350
-----------------  -----------------  -----------------G-------------------------------
 G-------  G------ A- ------------  ----------
 G-------  G----- A-- ----------- -.......---
----------  ----------  ---------- G-----------------------
----------  ----------  ---------- G--------------A-------
ATTACAGACA AGATAAGAGA ATCAGCTGCT ATGATTGCAT CTGCTGTGGG
351 400
-----------------   A ---------------- ----------  ----------
----------        - -T-------
-----------------   -C-------- ------------ -----------------
 G ------   -C-------- ------------ ----------
AGTAATGAAT CAAGTTATTC
-C--------
ATGGAGTAAC GGTATCCTTA CCCCTACAAA
401 450
------- T--
-----A ----
-----A ----
TTGAGGGAAA CCAAAATCAA
--G-------
--G-------
- -G-------
TTATTATC CA
------- T--
----C-----
CACTTGCCAC
------T---
------T---
AATCTGCACA
451
--- T -----
500
GG--A---A-
GG--A---A-
-G--A---A-
AACAGAAACC AAGTCTCAAA
-C--------
CTGCTCTACA AACATCCCCT TAGTTAATGA
501 550
-------- G-
-------- G-
-------A- -
-------A- -
------- A- -
T---------
CCTTAGGTTT
-------- G-
ATAAATGGAA TCAATAAGTT CATCATTGAA GATTATGCAA
551
-- C------
-- C------ -------- T-
600
--------- C
-- C ----------
-T--------  ----------  ----------  ----------  ----------
CCCATGATTT CTCCTATCGGC CATCCACTCA ACATGCCTAG CTTTATCCCA
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APPENDIX II continued:
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
PolS/t 
Consensus
601
----------    G------ -------- -------
-------- T- -----------     C
-------- T -------------------------------------------- C
650
-------- T -------------------------------------------- C----
ACTGCAACCT CACCCAATGG TTGCACAAGA ATTCCATCCT TTTCTTTAGG
651 700
-------- T ------------ ----------  ----------  ----------
---------------------------- C--------- --------------------------------------------------
--------------  C------------- ----------  ----------
--------------  C-------------G -----------------------
TAAGACACAC TGGTGTTACA CACATAATGT AATTAATGCC AACTGCAAGG
7 0 1  7 5  0
 GC ----------  ----------  ---------- T----------
-----------  C------ ----------- ------------T-C--------
---------- G--T----------  A ------ A-  G---
---------- G- -T----------  A ------ A-  G---
-------------------  C---------- -------------------- -----------------  -----------------
------------------- C------ ------ ------- ----------------------
---------- G- -C---------    G- -T
ATCATACTTC ATCGAACCAA TATGTTTCCA TGGGGATTCT CGTTCAAACC
751 800
-----------------------  T--------------- ---------------- ------------ --------------------
GCGTCAGGGT ATCCCATGTT CAAAACCCTA AAAATCCAAT ATCTCAGTGA
801 850
-T -----     A-
-T ----------      A-
TGGCCTGAAT CGGAAAAGCT
--------- T
GCTCAATTGC
---------- ------ A ----
AACAGTCCCT GATGGTTGCG
851 900
------C---
------C---
----------C--------------
  - C ------ G  A 1 T -- — — —T — — —
CAATGTACTG TTACGTTTCA ACTCAACTTG AAACCGACGA CTATGCGGGG
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APPENDIX II continued:
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL - 2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
901
----------      --G-------  ----------
----------    T---------------- ----------
-----       T G-
-----       T  G-
950
----------  ----------  ---------- C T  ----------G-
TCCAGCCCAC CTACCCAGAA ACTTACCCTG TTATTCTATA ATGACACCAT
951 1000 
--A-------   -G---------- A--------------
A
A
CACAGAAAGG ACAATATCTC CATCTGGTCT TGAAGGGAAT TGGGCTACTT
1001 1050
TGGTGCCAGG AGTGGGGAGT GGAATATATT TCGAAAATAA GTTGATCTTT
1051 1100
----------- c-
--------------------------     C --T -----
CCTGCATATG GGGGTGTCTT GCCCAATAGT ACACTAGGAG TTAAATCAGC
1101 1150
T
T
AAGAGAATTT TTCCGGCCCG TTAATCCATA TAATCCATGT TCAGGACCAC
1151
V ■
-------------------------- c --------
AACAAGAGTT AGATCAGCGT GCTTTGAGAT CATATTTCCC AAGTTACTTC
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APPENDIX II continued:
1 2 0 1  1250
JL-2 --------- -------------  ----------  ----------  ----------
JL-5  C ------------   T------------
Ur PT1  A ----A---------- T ------------ ----------
Ur PT3  A ----A---------- T ------------ ----------
Enders ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------
Pol5/t  A ----A------ A -------- T -------------  G ------
Consensus TCTAGTCGAA GGGTACAGAG TGCATTTCTG GTCTGTGCCT GGAATCAGAT
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
1251 1300
____________      T-
CCTAGTTACA AATTGCGAGC TAGTTGTCCC CTCAAACAAT CAGACACTGA
1301 1350
----------      G-------------
----------      -C-------- ------------
G
G
TGGGTGCAGA AGGAAGAGTT TTATTGATCA ATAATCGACT ATTATATTAT
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
1351 1400
-A -C-
-A -C
 A  -C--T----------------- ----------  ----------
CAGAGGAGTA CTAGCTGGTG GCCGTATGAA CTCCTCTATG AGATATCATT
JL-2 
JL - 5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
1401 1450
AC
CACATTTACA AACTCTGGTC AATCATCTGT GAATATGTCC TGGATACCTA
1451 1500
JL-2 ----------
JL-5 ----------
Ur PT1 ..........
Ur PT3 ----------
Enders ----------
Rubini ----------
Pol5/t --------
Consensus TATATTCATT CACTCGTCCT GGTTCGGGCA ACTGCAGTGG TGAAAATGTA
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APPENDIX II continued:
1501 1550
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5-----------------T — ------------ ----------
^  — — — — — — — — ■  ■  ■  ■  ■  3^ — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
— — — — — — — — — C*T ■ ■ ■ ■ ■ ^ 3 — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
Enders   A------------  ----------  ----------
Rubini ----------  ----------  ----------  ----------  ----------
P q  ^  ^  ^  ^  — — — — — — — — — c t  — — — — — G *■ ■ — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
Consensus TGCCCAACAG TCTGTGTATC AGGAGTTTAT CTTGATCCCT GGCCATTAAC
1551 1600
JL-2 ----------  --T-------  ----------  ----------  ----------
JL - 5----------------- A -----------  ----------
Ur PT1  T-------------   C- ------------ -------- C-
Ur PT3  T--------------- C- ------------ -------- C-
Enders ----------  ----------  ----------  ----------  ----------
Rubini      T ------------ ----------
Pol5/t  T--------------- ----------  ----------  ----------
Consensus TCCATACAGC CACCAATCAG GCATTAACAG AAATTTCTAT TTCACAGGTG
1601 1650
JL - 2 ----------  ----------  ----------
JL-5       A- - ----------
Enders ----------  ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------  ----------
Consensus CACTGCTAAA TTCAAGCACA ACCAGGGTGA ATCCTACCCT TTATGTCTCT
1651 1700
JL - 2 ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
Enders ----------  ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------  ----------
Consensus GCCCTTAATA ATCTTAAAGT ACTAGCCCCA TATGGTACTC AAGGATTGTT
1701 1750
JL-2  G ------ ------------ ----------
JL-5  T ------      C ------ C----
Ur PT1  G--------------- ----------  ----------  - -T-------
Ur PT3  G--------------- ----------  ----------  - -T-------
Enders  A ------ ------------ ----------  ----------  ----------
Rubini  A ------ ------------ ----------  ----------  ----------
Consensus TGCCTCATAC ACCACAACCA CCTGCTTTCA AGATACCGGT GACGCTAGTG
1751 1800
JL - 2 ----------  ----------  ---------- ------- '
JL-5     G------------------- G----
Ur PT1  T............................. -C-- -----------
Ur PT3  T    C- - ----------
Enders ----------  ----------  ----------  ----------  ----------
Rubini ----------  ----------  ----------  ----------  ----------
Consensus TGTATTGTGT CTATATTATG GAACTAGCAT CGAATATTGT TGGAGAATTC
228
APPENDIX II continued:
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
JL-2 
JL-5 
Ur PT1 
Ur PT3 
Enders 
Rubini 
Pol5/t 
Consensus
1801 1850
CAAATTCTAC CTGTGCTAGC CAGATTGACC ATCACTTGAG TTGTAGTGAA
1851 1899
 T       ---------------
  C- -  T - -----------
■ “ — — TG “ — — cjj * • CC! ■■■■■■ ■ ■ ■ ■ ■ CT — — — _ _ _ — — — — — — — — —
■  “  — — c c  ■  ■  ■  *  ■  — — — — — c t * “ _  — — — — — — — — — — — — — — —
— — 2^ — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
TGTAGCAGGA AGCTTTATGG GCGTGTCTCA TTTCTTATCG ATTATTAAG
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APPENDIX m
The nucleotide sequence of the F gene of the MuVs. The start codon at position 64-66 is 
underlined, as is the stop codon at position 1678-1680. The nucleotide sequence includes a 
consensus sequence and the sequences of the SBL-1 (Elango et al., 1989), RW (Waxham 
et al., 1995) and UrAm9 (Cusi et al., 1995) strains of MuV.
1 50
JL-5 ----------  ---------- A  G  ------------ ----------
UrPTl   C--T- ---- -G ------------- ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ---------- A ---------- ------------ ----------
SBL-1------------------  ----------  ----------  ----------  ----------
U r A M 9  — — — — T — — — — — — — G _  — — — C  — — — — — — — C  — — — — — — — — — —
Consensus AAGCCTAGAA GGATATCCTA CTTCTCAACT TTCCAACTTT GAAAATAGAA
51 100
JL-2---------  '-------  A ------ ------------
JL-5    C-     A -----
UrPTl —T—  — —-------— — ----- TT — — — — C--- — — —A A ----— — — G
UrPT3-------- -T--------   TT-----C------- A-A -------- G
ENDERS  C-------------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
P q 15 / 1 — T* — — — — — — — — — — — — — — — — — — — — — — — — — — — — ^  — — — — — — — — — — — — — — —
SBL-1 ----------  ----------  ----------  ----------  ----------
Ur Am 9--------—T--------   TT---— C------- A-A -------- G
Consensus TAGATCAGTA ATCATGAAGG CTTTTCCAGT TATTTGCTTG GGCTTTGCAA
JL- 2
JL- 5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
101 150
---------- T G  ------ ----- ------------ ----------
TCTTTTCATC CTCTATATGT GTGAATATCA ATATCTTGCA GCAAATTGGA
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
20 0151
-A-
-A-
T------------  A
- -T----------  A ---------------    T-
--T----------  A --------------- ----------  ----------
TACATCAAGC AACAGGTCAG GCAACTAAGC TATTACTCAC AAAGTTCAAG
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Appendix III continued:
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
2 0 1
----------  --A--------     --
-------A-- ----------      -T
------- A -----------------------------------------T
250
 A- - ----------  ----------  ----------  ----------
 A- - ----------  ----------  ----------  -T--------
CTCCTACGTA GTGGTCAAGC TTTTACCGAA TATCCAACCC ACTGATAACA
251 300
---------------------------------       C-
--------------- c ---------------------- -------------------  -------------------  -------------------
GCTGTGAATT TAAGAGTGTA ACTCAATACA ATAAGACCTT GAGTAATTTG
301 350
----------------------------------------------        T-
--------------------------------        T--
--------------------------------        T--
-------------------------     A ----------
-------------------------     A ----------
---------- -------- Q—  ----------  ----------  -T--------
 ----------------------     A-G-- ------
CTTCTTCCAA TTGCAGAAAA CATAAACAAT ATTGCATCGC CCTCACCTGG 
351 400
- G ------ A --------- T------- T-
- G ------ A --------- T------- T-
------------ A --------------- ----------  ----------
------------ A --------------- ----------  ----------
GTCAAGACGT CATAAACGGT TTGCTGGCAT TGCCATTGGC ATTGCTGCGC
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Appendix III continued:
401 450
JL-2   G--- -- ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl     A -  ----------
UrPT3     A -- ----------
ENDERS   G--- -- ----------  ----------
RUBINI   G--------------  ----------  ----------
Pol5/t     A -- ----------
SBL-1------------------  ----------  ----------  ----------  ----------
RW ----------  ----------  --G------------------- ----------
UrAm9     A -- ----------
Consensus TCGGTGTTGC GACCGCAGCA CAAGTGACTG CCGCTGTCTC ATTAGTTCAA
451 500
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl     G ----- - A- -
UrPT3     G ----- - A- -
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
SBL-1 ----------  ----------  ----------  ----------  ----------
RW     G -----------  -----
UrAm9  -»-------------    G ----------  A--
Consensus GCACAGACAA ATGCACGTGC AATAGCAGCG ATGAAAAATT CAATACAGGC
501 550
JL-2       G ------------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl  A ----------------------   T------
UrPT3   A ----------------------   T ------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
P0l5/t  C------ ------------ ----------  ---T------------------
SBL-1 ----------  ----------  ----------  ----------  ----------
RW   A ------ ------------ ----------  ----------
UrAm9  A --------------------    T ----
Consensus AACTAATCGG GCAGTCTTCG AAGTGAAGGA AGGCACCCAA CAGTTAGCTA
551 600
JL-2      ~
JL-5 ----------  ----------  ----------  ----------  --G-------
UrPTl     C -  ----------
UrPT3     C -  ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t     C -- ----------
SBL-1 ----------  ----------  ----------  ----------  ----------
RW     C -  ----------
UrAM9     C -  ----------
Consensus TAGCGGTACA AGCAATACAA GACCATATCA ATACTATTAT GAACACCCAA
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Appendix III continued:
601 650
JL-2-------------------  ----------  ----------  ---------- -------- T--
JL - 5       A --- ------
UrPTl ----------  ----------  ----------  ---------- ----- T-T---
UrPT3 ----------  ----------  ----------  ---------- ----- T-T---
ENDERS------ ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t------ ----------  ----------  ----------  ---------- ----- T -----
SBL-1------------------  ----------  ----------  ----------  ----------
RW ----------  ----------  ----------  ---------- ------- A ---
UrAm9 ----------  ----------  ----------  ---------- ----- T -----
Consensus TTGAACAATA TGTCTTGTCA GATCCTTGAT AACCAGCTTG CAACCTCCCT
651 700
JL-2       C----- ------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl ----------  ----------  ----------  ----------  ----------
UrPT3 ----------  ----------  ----------  ----------  ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t         C--
S B L -1 --------------- --------------------  -------------------- ----------------------- -----------------------  --------------------
RW ----------  ----------  ----------  ----------  ----------
UrAm9 ----------  ----------  ----------  ----------  ----------
Consensus AGGATTATAC CTAACAGAAT TAACAACAGT GTTTCAGCCA CAATTAATTA
701 750
JL - 2     C -- ----------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl  G--------------- ----------  ----------  ----------
UrPT3  G--------------- ----------  ----------  ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t------ ----------  ----------  ----------  ----------  ----------
SBL-1------------------  ----------  ---------- ------------ ----------
RW  G--------------- ----------  ----------  ----------
UrAm9 ----------  ----------  ----------  ----------  ----------
Consensus ATCCAGCATT GTCACCGATT AGTATACAAG CCTTGAGGTC TTTGCTTGGA
751 800
JL-2  A------------  ----------  ----------  ----------
JL - 5 ----------  ----------  ----------  ----------  ----------
UrPTl ----------  ---------- C------------   C--A-
UrPT3 ----------  ---------- C------------   C--A-
ENDERS  A-     C------------
RUBINI  A-     C------------
Pol5/t       C--G------------
SBL-1 ----------  ----------  ----------  ----------  ----------
RW       G------------
UrAm9 ----------  ---------- C---------------------------- C A-
Consensus AGTATGACGC CTGCAGTGGT TCAAGCAACA TTATCTACTT CAATTTCTGC
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801 850
JL-2 ----------  ----------  ----------
JL-5  G-----------  ------- --------------- ----------
UrPTl         .---T ----
UrPT3        T ..... ......-
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t       T A ---------
SBL-1------------------  ----------  ----------
RW        T ------------
UrAm9       T ------------
Consensus TGCTGAAATA CTAAGTGCCG GTCTAATGGA GGGTCAGATA GTTTCTGTTC
851 900
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ---------- ---- ------------------- ---------
UrPTl       T--- ------ T -----
UrPT3       T--- ------ T -----
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t     C ------- T----------- T-----
RW     C ------- T-----------
UrAm9        T--- ------ T--C--
Consensus TGCTAGATGA GATGCAGATG ATAGTTAAGA TAAACATTCC AACCATTGTC
901 950
JL-2         -A--T--C--
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl ----------  ----------  ----------  ----------  ----------
UrPT3 ----------  ----------  ----------  ----------  ----------
ENDERS ----------  ----------  ----------  ---------- ----- T-----
RUBINI ----------  ----------  ----------  ---------- ----- T-----
Pol5/t       A- ----------
SBL-1------------------  ----------  ----------  ---------- ----- T-----
RW ----------  ----------  ----------  ----------  ----------
UrAm9 ----------  ---------- ---- ------- ------------ ----------
Consensus ACACAATCAA ATGCATTGGT GATTGACTTC TACTCAATTT CGAGCTTTAT
951 1000
JL-2     r-----------
JL- 5 ----------  ----------  ----------  ----------
ENDERS ---------- ------------ ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ---------- ------------
Pol5/t------ ----------  ---------- ------------ ----------  - “A -------
SBL-1------------------  ----------  ----------  ----------  ----------
RW ----------  ----------  ----------  ---------- C-A--------
UrAm9  G ----------------------   A ------
Consensus TAATAATCAA GAATCCATAA TTCAATTGCC AGACAGGATC TTGGAGATCG
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1001 1050
JL-2       C -----------T
JL-5  C--------------- ----------  ----------  ----------
UrPTl   A ------- A------------  ----------
UrPT3   A ------- A------------  ----------
ENDERS -A--------  ----------  ----------  ----------  ----------
RUBINI -A--------  ----------  ----------  ----------  ----------
Pol5/t   A ----A--A- ----------  ----------
SBL-1 -A-------- ------------ ----------  ----------  ----------
RW ---------- ----- A  -------- A------------  ----------
UrAm9   A ------- A------------  ----------
Consensus GGAATGAACA ATGGCGCTAT CCAGCTAAGA ATTGTAAGTT GACAAGACAC
1051 1100
JL-2 --------- - —    - -
JL-5  G------------- ----------  ----------  ----------
UrPTl  C----------------------------      T-
UrPT3         T---
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI---------------------------------         G -----
Pol5/t     --- -------T......T----
SBL-1------------------  ----------  ----------  ----------  ----------
RW         T---
UrAm9      *- T ------ T----
Consensus CACATATTCT GCCAATACAA TGAGGCAGAG AGGCTGAGCC TAGAAACAAA
1101 1150
JL-2          -
JL - 5 -------- —  -------- —  -----
UrPTl ----------  ----------  -A--------  ----------  - -C-------
UrPT3 ----------  ----------  -A--------  ----------  - -C-------
ENDERS ----------  ----------  ----------  ---------- T----------
RUBINI ----------  ----------  ----------  ---------- T ----------
Pol5/t------ ----------  ----------  -A  T--- --C-------
SBL-1------------------  ----------  ----------  ---------- T ----------
RW   T ----- -A-----------  - -C-------
UrAm9 ----------  ----------  -A-------- ------------ --C-------
Consensus ACTATGCCTT GCAGGCAATA TTAGTGCCTG TGTGTTCTCA CCTATAGCAG
1151 1200
JL-2  C-------------------  G------------ ----------
JL - 5 ----------  ----------  ----------  ----------
UrPTl ----------  ---------- ACG-------- ------------ ----------
UrPT3 ----------  ---------- ACG-------- ------------ ----------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t     A- ----------  ----------
SBL-1 ----------  ----------  ----------  ----------  ----------
RW ----------  ----------  ----------  ----------  ----------
UrAin9 ----------  ---------- ACG-------- ------------ ----------
Consensus GGAGTTATAT GAGGCGATTT GTAGCACTGG ATGGAACAAT TGTTGCAAAC
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1201 1250
JL - 2 ----------  ----------
JL-5 --C--G-------  A ------- T ------ ------------ ----------
UrPTl     A- ----------  ----------
UrPT3     A- ----------  ----------
ENDERS------ ----------  ----------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t  A ---------  A --------------- ----------  ----------
SBL-1------------------  ----------  ----------  ----------  ----------
RW ----------  ----------  ----------  ----------  ----------
UrAmS ---------C -----------  --------- A------------  ----------
Consensus TGTCGAAGTG TAACGTGTCT ATGCAAGAGT CCATCTTATC CTATATACCA
1251 1300
JL-2 ----------  ----------  ----------  ----------  ----------
JL-5-------------------  ----------  ---------- ------- A  ----------
UrPTl ----------  ----------  ----------  ----------  ----------
UrPT3       CG-------------
ENDERS       CG-- ----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t        CG-- ----------
SBL-1------------------  ----------  ----------  ----------  ----------
RW       CA-------------
UrAm9       CG-------------
Consensus ACCTGACCAT CATGCAGTCA CGACCATTGA TCTAACGTCA TGTCAAACAT
1301 1350
JL-2       A --- ------
JL-5---------        ---T------
UrPTl  A-   T----------------  T---------------
UrPT3  A-   T -----------------  T---------------
ENDERS ----------  ----------  ----------  ----------  ----------
RUBINI------         T------
SBL-1------------------  ----------  ----------  ----------  --------
UrAmS  A - - ----- T--------------------  T---------------
Consensus TGTCCCTGGA CGGACTGGAT TTCAGCATTG TCTCGCTAAG CAACATCACT
1351 1400
JL-2       G --------
JL-5         C-----
UrPTl ----------  -C C- - ----------  ----------  ----------
UrPT3 ----------  -C C- - ----------  ----------  ----------
ENDERS ----------  ----------  ----------  ---------- C----------
RUBINI ----------  ----------  ----------  ----------  ----------
Pol5/t-----------------  -C C-- ----------  ----------  -C--------
SBL-1 ----------  ----------  ----------  ---------- ------------
RW ----------  -C C- - ----------  - - A ------- ------------
UrAm9 ----------  -C C-- ----------  ----------  ----------
Consensus TACGCTGAGA ATCTTACTAT TTCATTGTCT CAGACAATCA ATACTCAACC
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JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
1401 1450
----------        - -T-------
------C-------------A---------- - ----------  ----------
------C-------------A------------ ------ ----- ------------
------C-------------A------------  ----------  ----------
------C----------- A - ---------A--------- ----- ------------
------C-------------A------------  ----------  ----------
CATTGATATA TCAACTGAGC TGAGTAAGGT TAATGCATCC CTCCAAAATG
1451 1500
JL-2
JL b ----- A - --- G
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus CCGTTAAATA CATAAAAGAG AGCAACCATC AACTCCAATC TGTTAGTGTA
1501 1550
JL-2
JL - 5 G ---------  ------- ----G------
UrPTl -AC - -C------------ ------T--
UrPT3 -AC- -C------------ ------T- -
ENDERS
RUBINI
SBL-1
RW -A- --C-- - -T-------- ------------
UrAm9 -AC- -C-- ................... T- -
Consensus AGTTCTAAAA TCGGAGCTAT AATTGTAGCA GCCTTAGTTT TGAGCATCCT
JL-2
JL-5
UrPTl
UrPT3
ENDERS
RUBINI
Pol5/t
SBL-1
RW
UrAm9
Consensus
1551 1600
---A----------------------------         A ---
---A-------   ---     A --
---------     T ------------ ----------
 A ----------------------------       A ---
---A----------------------------       A ---
GTCGATTATC ATTTCGCTAT TGTTTTGCTG CTGGGCTTAC ATTGCGACTA
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1601 1650
— JL - 2 ----------  ----------  ----------  ----------  ----------
JL-5 ----------  ----------  ----------  ----------  ----------
UrPTl ---------- ------------  ----------  ---------- T -----------
UrPT3 ----------  ----------  ----------  ---------- T -----------
ENDERS ---------- ------------  ----------  ----------  ----------
RUBINI ---------- ------------  ----------  ----------  ----------
Pol5/t -------T-- --------------------------     T---
SBL-1 ----------  ----------  ----------  ----------  ----------
RW          G
UrAm9 ----------  ----------  ----------  ---------- T -----------
Consensus AAGAAATCAG AAGAATCAAC TTCAAAACAA AT CATAT CAA CACAATATCA
1651 1700
JL - 2 ---------- ------------------------ ---------- -------- A —
JL-5 ----------  ----------  ----------  -C G  ----------
|  * ^  — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — Ç J C  — — — — — — — — — — — — — —
 ^ — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — — —
ENDERS -------- G ---------  ----------  ----------  ----------
RUBINI ----------  ----------  ----------  ----------  ----------
SBL-1------------------  ----------  ----------  ----------  ----------
j X m  9  — — — — — — — — — — — — — — — — — — — — ^  — — — — — — — — — — C ! C  — — — C  ■  — — — — — — — — — —
Consensus AGTAGTGTCG ATGATCTCAT CAGGTACTAA TTTTAAATTG GTGATTCGTC
1 7 0 1
t iii—2  A    G--------—
J L -5   T T -----------------------  -
U r PT1 --------- T —G — — -----------  —
U r PT3 --------- T —G — — ---------------------  —
ENDERS  A -----------------------  -
RUBINI  A ----------------------- —
Pol5/t — — — — —T — C — — — - --------  —
S B L -1  — — —-------- G - ------- — — — — — — — —
RW --------- T - CG - --------------------- —
UrAm9 --------- T - G—  ---------------------  —
C o n s e n s u s  CTGCAATTAG AAAAGATTTA G
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